Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 89
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Novel risk loci for COVID-19 hospitalization among admixed American populations

  • Diz-de Almeida, Silvia|||0000-0003-2813-8928
  • Cruz, Raquel|||0000-0002-6964-8898
  • Luchessi, Andre D.
  • Lorenzo-Salazar, José M.
  • López de Heredia, Miguel|||0000-0003-2826-9565
  • Quintela, Inés|||0000-0002-0239-7975
  • González-Montelongo, Rafaela
  • Nogueira Silbiger, Vivian|||0000-0002-9252-0278
  • Sevilla Porras, Marta
  • Tenorio Castaño, Jair Antonio|||0000-0002-5308-2316
  • Nevado, Julián|||0000-0001-5611-2659
  • Aguado, José María|||0000-0002-9520-8255
  • Aguilar, Carlos
  • Aguilera-Albesa, Sergio|||0000-0003-3540-1448
  • Almadana, Virginia
  • Almoguera, Berta|||0000-0002-5599-2954
  • Alvarez, Nuria
  • Andreu-Bernabeu, Álvaro
  • Arana-Arri, Eunate|||0000-0001-9759-333X
  • Arango, Celso|||0000-0003-3382-4754
  • Arranz, María Jesús|||0000-0002-6757-9198
  • Artiga, Maria-Jesus
  • Baptista-Rosas, Raúl C.|||0000-0002-0273-4740
  • Barreda Sánchez, María
  • Belhassen-Garcia, Moncef
  • Bezerra, Joao F.
  • Bezerra, Marcos AC.
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Brion, María|||0000-0001-7463-2148
  • Brugada, Ramon|||0000-0001-6607-3032
  • Bustos, Matilde
  • Calderón, Enrique J.|||0000-0002-3166-5086
  • Carbonell, Cristina|||0000-0002-6271-5111
  • Castaño, Luis|||0000-0003-0437-9401
  • Castelao, Jose E.
  • Conde-Vicente, Rosa
  • Cordero-Lorenzana, M. Lourdes
  • Cortes-Sanchez, Jose L.
  • Corton, Marta|||0000-0003-0087-1626
  • Darnaude, M. Teresa
  • De Martino-Rodríguez, Alba|||0000-0002-2436-9852
  • Campo Pérez, Víctor del|||0000-0002-9424-9653
  • Diaz de Bustamante, Aranzazu
  • Domínguez-Garrido, Elena|||0000-0002-2066-0511
  • Eirós, Rocío
  • Fariñas, M. Carmen
  • Fernandez-Nestosa, María J.|||0000-0001-7764-7791
  • Fernández-Robelo, Uxía
  • Fernández-Rodríguez, Amanda|||0000-0002-5110-2213
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Gago-Dominguez, Manuela
  • Gil-Fournier, Belén
  • Gómez-Arrue, Javier
  • González Álvarez, Beatriz
  • González Bernaldo de Quirós, Fernan
  • González-Neira, Anna
  • González-Peñas, Javier|||0000-0002-3850-3012
  • Gutiérrez-Bautista, Juan F.|||0000-0003-1374-0756
  • Herrero, María José
  • Herrero-Gonzalez, Antonio
  • Jimenez-Sousa, María A.
  • Lattig, María Claudia|||0000-0003-2113-9266
  • Liger Borja, Anabel
  • Lopez-Rodriguez, Rosario
  • Mancebo, Esther
  • Martín-López, Caridad
  • Martín, Vicente|||0000-0003-0552-2804
  • Martinez-Nieto, Oscar
  • Martinez-Lopez, Iciar
  • Martinez-Resendez, Michel F.
  • Martinez-Perez, Angel|||0000-0002-5934-1454
  • Mazzeu, Juliana F.
  • Merayo Macías, Eleuterio
  • Minguez, Pablo|||0000-0003-4099-9421
  • Moreno Cuerda, Victor
  • Oliveira, Silviene F.|||0000-0002-7741-0257
  • Ortega-Paino, Eva
  • Parellada, Mara|||0000-0001-7977-3601
  • Paz-Artal, Estela|||0000-0002-0646-2375
  • Santos, Ney PC.
  • Pérez-Matute, Patricia
  • Perez, Patricia
  • Pérez-Tomás, M. Elena|||0000-0002-5429-3414
  • Perucho, Teresa
  • Pinsach-Abuin, Mellina
  • Pita, Guillermo|||0000-0003-2393-0510
  • Pompa-Mera, Ericka N.
  • Porras-Hurtado, Gloria L.
  • Pujol, Aurora|||0000-0002-9606-0600
  • Ramiro-León, Soraya
  • Resino, Salvador|||0000-0001-8783-0450
  • Fernandes, Marianne R.
  • Rodríguez-Ruiz, Emilio
  • Rodriguez-Artalejo, Fernando
  • Rodriguez-Garcia, José A.
  • Ruiz-Cabello, Francisco
  • Ruiz-Hornillos, Javier
  • Ryan, Pablo|||0000-0002-4212-7419
  • Soria Fernández, José Manuel|||0000-0002-6226-4293
  • Souto, Juan Carlos|||0000-0003-2092-5142
  • Tamayo, Eduardo
  • Tamayo-Velasco, Alvaro
  • Taracido-Fernandez, Juan Carlos
  • Teper, AlejandroHospital de Niños Ricardo Gutierrez (Buenos Aires, Argentina)
  • Torres-Tobar, Lilian
  • Urioste, Miguel|||0000-0001-7583-7305
  • Valencia-Ramos, Juan
  • Yáñez, Zuleima
  • Zarate, Ruth N.
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Sánchez, Pascual
  • Real, Luis M.|||0000-0003-4932-7429
  • Guillén-Navarro, Encarna|||0000-0002-2915-7381
  • Ayuso, Carmen|||0000-0002-9606-6957
  • Parra, Esteban J.|||0000-0002-2057-8577
  • Riancho, José A.|||0000-0003-0691-8755
  • Rojas-Martinez, Augusto|||0000-0003-3765-6778
  • Flores, Carlos|||0000-0001-5352-069X
  • Lapunzina, Pablo|||0000-0002-6324-4825
  • Carracedo, Ángel|||0000-0003-1085-8986
The genetic basis of severe COVID-19 has been thoroughly studied, and many genetic risk factors shared between populations have been identified. However, reduced sample sizes from non-European groups have limited the discovery of population-specific common risk loci. In this second study nested in the SCOURGE consortium, we conducted a genome-wide association study (GWAS) for COVID-19 hospitalization in admixed Americans, comprising a total of 4702 hospitalized cases recruited by SCOURGE and seven other participating studies in the COVID-19 Host Genetic Initiative. We identified four genome-wide significant associations, two of which constitute novel loci and were first discovered in Latin American populations (BAZ2B and DDIAS). A trans-ethnic meta-analysis revealed another novel cross-population risk locus in CREBBP. Finally, we assessed the performance of a cross-ancestry polygenic risk score in the SCOURGE admixed American cohort. This study constitutes the largest GWAS for COVID-19 hospitalization in admixed Latin Americans conducted to date. This allowed to reveal novel risk loci and emphasize the need of considering the diversity of populations in genomic research.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies, A Multi-Centre Study

  • Sancho-Saldaña, Agustín
  • Gil Sánchez, Anna|||0000-0002-0738-5578
  • González-Mingot, Cristina|||0000-0002-6387-8764
  • Peralta, Silvia
  • Solana, Maria José
  • Torres, Pascual|||0000-0001-7903-3478
  • Juanes, Alba
  • Quibus, Laura
  • Ruiz, Emilio
  • Sanpedro, Eduardo
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • García Rubio, Sebatián
  • Baron, Beatriz Pardiñas|||0000-0002-3041-9238
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Sotoca Fernández, Javier|||0000-0003-3400-1434
  • González-Suárez, Inés|||0000-0002-9897-0771
  • Eichau Madueño, Sara
  • Prieto, Jose Maria|||0000-0002-8170-0724
  • Blasco Quilez, Maria Rosario|||0000-0003-2719-4629
  • Sabín-Muñoz, Julia|||0000-0001-5745-7544
  • Sánchez López, Antonio José|||0000-0001-7168-6175
  • Llorens Calatayud, Gloria
  • Calles, Carmen
  • Perez-Sempere, Angel|||0000-0002-0195-2834
  • Garces, Moises|||0000-0002-1756-5492
  • Carmona, Olga|||0000-0002-5957-0046
  • Moral, Ester
  • Hervás, José Vicente
  • Blanco Morgado, Yolanda|||0000-0002-1834-0498
  • Sola-Valls, Nuria
  • Téllez Lara, Nieves|||0000-0001-8787-2239
  • Forero, Lucía|||0000-0003-0256-6748
  • Brieva Ruiz, Luis|||0000-0002-5871-6189
Background: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients enrolled in the EMCOVID database. The DMTs were used to manage MS by reducing relapses, lesion accumulation, and disability progression. However, concerns arose regarding the susceptibility of pwMS to COVID-19 due to potential interactions between SARS-CoV-2 and the immune system, as well as the immunomodulatory effects of DMTs. Methods: This prospective observational study utilized data from a Multiple Sclerosis and COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data, SARS-CoV-2 serology, and symptoms of COVID-19 were extracted for pwMS receiving any type of DMT. The relationship between demographics, MS phenotype, DMTs, and COVID-19 was evaluated. The evolution of SARS-CoV-2 antibodies over a 6-month period was also assessed. Results: The study included 709 pwMS, with 376 patients providing samples at the 6-month follow-up visit. The seroprevalence of SARS-CoV-2 antibodies was higher among pwMS than the general population, with Interferon treatment being significantly associated with greater seroprevalence (16.9% vs. 8.4%; p 0.003). However, no other specific DMT showed a significant association with antibody presence. A total of 32 patients (8.5%) tested positive for IgG, IgM, or IgA antibodies against SARS-CoV-2 at baseline, but then tested negative at 6 months. Most of the pwMS in the cohort were asymptomatic for COVID-19 and, even among symptomatic cases, the prognosis was generally favourable. Conclusion: pwMS undergoing DMTs exhibited a higher seroprevalence of COVID-19 than the general population. Interferon treatment was associated with a higher seroprevalence, suggesting a more robust humoral response. This study provides valuable insights into the seroprevalence and persistence of SARS-CoV-2 antibodies in pwMS and contributes to our understanding of the impact of COVID-19 amongst this population.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

New statistical model for misreported data with application to current public health challenges

  • Moriña, David|||0000-0001-5949-7443
  • Fernández-Fontelo, Amanda|||0000-0002-0822-6915
  • Cabaña, Alejandra|||0000-0002-1289-967X
  • Puig, Pedro|||0000-0002-6607-9642
The main goal of this work is to present a new model able to deal with potentially misreported continuous time series. The proposed model is able to handle the autocorrelation structure in continuous time series data, which might be partially or totally underreported or overreported. Its performance is illustrated through a comprehensive simulation study considering several autocorrelation structures and three real data applications on human papillomavirus incidence in Girona (Catalonia, Spain) and Covid-19 incidence in two regions with very different circumstances: the early days of the epidemic in the Chinese region of Heilongjiang and the most current data from Catalonia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

On a new SEIRDE o I o epidemic model eventually initiated from outside with delayed re-susceptibility and vaccination and treatment feedback controls

  • De la Sen, Manuel|||0000-0001-9320-9433
  • Ibeas, Asier|||0000-0001-5094-3152
  • Garrido, Aitor J.|||0000-0002-3016-4976
This paper studies a new extended SEIR (susceptible-exposed-infectious recovered) epidemic model which incorporates the contribution of infective contagions to the resident population from infective exposed (Eo) and infectious (Io) outsiders as well as eventual delayed re-susceptibility by partial loss of immunity. It is referred to as a SEIRDEoIo since the dead individuals caused by the disease are defined as a new subpopulation. The potential contribution of the disease propagation of non-resident external infected travellers is considered as well as a re-susceptibility which increases the susceptible numbers and a parallel loss of immunity caused by a potential delayed re-infection. The model is also studied under eventual vaccination and treatment controls each one of them including two additive terms including proportional feedback of the susceptible and infectious, respectively, as well as control actions being independent of the population numbers. The disease-free and endemic equilibrium points are characterized, as well as their dependence on the control gains, and their stability properties are also studied. It is found that they are unique and only one of the two is a global attractor depending on the model parameter values. Typically, the value of the basic reproduction number is crucial to characterize the stability or, alternatively, that of the coefficient transmission rate provided that the remaining parameters are prefixed. The controls are also useful to increase the admissible minimum threshold of the infection force compatible with the stability of the disease-free equilibrium point. Simulation results are given, some of them related to parameterizations of usefulness related to the recent COVID-19, while others to a varicella case study.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Metabolomic Biomarkers of Pulmonary Fibrosis in COVID-19 Patients One Year After Hospital Discharge

  • Botello-Marabotto, Marina Dolores
  • Tarraso, Julia
  • Mulet, Alba
  • Presa-Fernandez, Lucia
  • Fernandez-Fabrellas, Estrella
  • Rodriguez Portal, Jose A.
  • Ros, Jose A.
  • Lozano-Vicente, Desire
  • Signes-Costa, Jaime
  • Bernardos Bau, Andrea|||0000-0002-3842-5771
  • Martínez-Bisbal, M.Carmen|||0000-0002-8526-4413
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Coronavirus disease 2019 (COVID-19) global pandemic has affected more than 600 million people up to date. The symptomatology and severity of COVID-19 are very broad, and there are still concerns about the long-term sequelae that it can have on discharged patients. The development of pulmonary fibrotic sequelae after this infection is especially worrying. Our aim was to determine if there was a metabolomic signature that could predict the development of pulmonary fibrotic sequelae. It is a multicenter prospective observation subcohort based on the COVID-FIBROTIC study. A metabolomic analysis was performed by nuclear magnetic resonance (NMR) on serum samples from patients admitted with bilateral COVID-19 pneumonia collected 2 months after hospital discharge. One year after admission, clinical, functional and radiological data were collected from these same patients. Finally, 109 patients (mean age 57.68 [DS14.03], 65.13% male) were available. Fibrotic sequelae 1 year after COVID-19 disease were found in 33% of them. Based on the NMR analysis of the serum samples, it was possible to distinguish with 80.82% of sensitivity, 72.22% of specificity and 0.83 of an area under the curve (AUC) value which patients would have radiological signs of pulmonary fibrotic pattern 1 year after sample collection. According to the metabolites participating in the discriminative model and the univariate statistics, glucose, valine, and fatty acids (& boxH;CH-CH2-CH & boxH;) were suggested as potential biomarkers of the development of pulmonary fibrotic sequelae after COVID-19., This work was supported by project PID2021-126304OB-C41 funded by MCIN/AEI/10.13039/501100011033/and by European Regional Development Fund - A way of doing Europe and Generalitat Valenciana (project CIPROM/2021/007) and CIBER (CB07/01/2012). There has also been the support of Institute of Health Carlos III (COV20/01209, Ministry of Science and Innovation of Spain) and grants from the Valencian Society of Pulmonology (FNCV Grant 2022 IP: Lucia Fernandez Presa; FNCV Grant Coordinated Research Project 2022 IP: Jaime Signes-Costa), U26 NMR: Biomedical Applications II platform from Nanbiosis (Research Infrastructures & Services of CIBER-BBN) and Marina Botello - Marabotto PhD grant (FPU 2020) from Spanish' government.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

CRISPR-Cas12a-Based Detection of SARS-CoV-2 Harboring the E484K Mutation

  • Marqués, María-Carmen
  • Ruiz, Raúl
  • Montagud-Martínez, Roser
  • Márquez-Costa, Rosa
  • Albert, Sandra
  • Domingo-Calap, Pilar
  • Rodrigo Tarrega, Guillermo
[EN] The novel respiratory virus SARS-CoV-2 is rapidly evolving across the world with the potential of increasing its transmission and the induced disease. Here, we applied the CRISPR-Cas12a system to detect, without the need of sequencing, SARS-CoV-2 genomes harboring the E484K mutation, first identified in the Beta variant and catalogued as an escape mutation. The E484K mutation creates a canonical protospacer adjacent motif for Cas12a recognition in the resulting DNA amplicon, which was exploited to obtain a differential readout. We analyzed a series of fecal samples from hospitalized patients in Valencia (Spain), finding one infection with SARS-CoV-2 harboring the E484K mutation, which was then confirmed by sequencing. Overall, these results suggest that CRISPR diagnostics can be a useful tool in epidemiology to monitor the spread of escape mutations., We thank M. Carmen Montaner, Javier Peman, Miguel Salavert, and Alba Ruiz from the Hospital Universitario y Politecnico La Fe for their support in the collection of the fecal samples. This work was supported by the Fondo Supera COVID-19 from CRUE and Banco Santander (Grant COV-CRISPIS, BOE-A-2020-7995, to GR), the CSIC PTI Salud Global (Grant SGL2021-03-040, to GR, and Grants 202020E292 and SGL2103034, to PDC) through the European Union-Next Generation EU, the Fondo COVID-19 from the Instituto de Salud Carlos III (Grant COV20/00210, to PDC), and the Generalitat Valenciana (Grant SEJI/2020/011, to GR). PDC was supported by the Ramon y Cajal program (RYC2019-028015-I) and RMC by a predoctoral fellowship (PRE2019-088531), both from the Spanish Ministerio de Ciencia e Innovacion.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Is the long-term mortality similar in COVID-19 and community-acquired pneumonia?

  • Méndez, Raúl
  • González-Jiménez, Paula
  • Latorre, Ana
  • Mengot, Noé
  • Zalacain, Rafael
  • Ruiz, Luis A.
  • Serrano, Leyre
  • España, Pedro P.
  • Uranga, Ane
  • Cillóniz, Catia
  • Torres, Antoni
  • Menéndez, Rosario
  • Hervás-Marín, David|||0000-0003-0635-4961
[EN] There are no data on the association of type of pneumonia and long-term mortality by the type of pneumonia (COVID-19 or community-acquired pneumonia [CAP]) on long-term mortality after an adjustment for potential confounding variables. We aimed to assess the type of pneumonia and risk factors for long-term mortality in patients who were hospitalized in conventional ward and later discharged., This study received support by a non-conditional grant from Gebro Pharma Laboratories, which did not participate in the design, data collection, statistical analysis or writing of the article. El Instituto de Salud Carlos III (ISCIII) through Project [PI17/01421] and Project [COV20/00385] (co-funded by the European Regional Development Fund/European Social Fund. Investing in your future ). Sociedad Española de Neumología y Cirugía Torácica (SEPAR): 1078/2020. Sociedad Española de Neumología y Cirugía Torácica (SEPAR): Convocatoria extraordinaria PII Infecciones Respiratorias 2011. RaM is the recipient of a Juan Rodés grant, supported by the Instituto de Salud Carlos III (ISCIII [JR21/00051]). PG-J is the recipient of a postresident research grant supported by the Health Research Institute La Fe (2019-053-1). CC received a grant from the Fondo de Investigación Sanitaria (PI19/00207), Instituto de Salud Carlos III, co-funded by the European Union.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

A Multifunctionalized Potyvirus-Derived Nanoparticle That Targets and Internalizes into Cancer Cells

  • Truchado, Daniel A.
  • Rincón, Sara
  • Zurita, Lucia
  • Tomé-Amat, Jaime
  • Lorz, Corina
  • Ponz, Fernando
  • Juárez Molina, María
[EN] Plant viral nanoparticles (VNPs) are attractive to nanomedicine researchers because of their safety, ease of production, resistance, and straightforward functionalization. In this paper, we developed and successfully purified a VNP derived from turnip mosaic virus (TuMV), a well-known plant pathogen, that exhibits a high affinity for immunoglobulins G (IgG) thanks to its functionalization with the Z domain of staphylococcal Protein A via gene fusion. We selected cetuximab as a model IgG to demonstrate the versatility of this novel TuMV VNP by developing a fluorescent nanoplatform to mark tumoral cells from the Cal33 line of a tongue squamous cell carcinoma. Using confocal microscopy, we observed that fluorescent VNP-cetuximab bound selectively to Cal33 and was internalized, revealing the potential of this nanotool in cancer research., This work was conceived as transversal to efforts experimentally aimed to TuMV nanobiotechnological functionalizations. Consequently, it has benefited from different grants obtained throughout the years. These are P2018/BAA-4574, COV20/00114, and PanGreen-CM from the Comunidad de Madrid; RTA2015-00017-00-00 from INIA; and ARIMNet-2 618127, an ERANet project. DAT was supported by a Margarita Salas postdoctoral grant funded by the Spanish Ministry of Universities and UCM (CT31/21). SR was funded by a contract under grant P2018/BAA-4574 from the Comunidad de Madrid. The CBGP was granted Severo Ochoa Distinctions of Excellence by the Spanish Ministry of Science and Innovation (SEV- 2016-0672 and CEX2020-000999-S).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

P systems in the time of COVID-19

  • Baquero, Fernando
  • Llorens, Carlos
  • Campos Frances, Marcelino
  • Sempere Luna, José María|||0000-0003-2393-9224
[EN] In this paper, we present LOIMOS, which is an epidemiological scenario simulator developed in the context of the fight against the pandemic caused by coronavirus SARS-CoV-2 on a global scale. LOIMOS has been fully developed under the paradigm of membrane computing using transition P systems with communication rules, active membranes and a stochastic simulator engine. In this paper we detail the main components of the system and we report some examples of epidemiological scenarios evaluated with LOIMOS., This work has been developed with the financial support of the Ministerio de Ciencia e Innovacion and Instituto de Salud Carlos III, Grant COV20_00067, and the European Union's Horizon 2020 research and innovation programme under Grant agreement no. 952215 corresponding to the TAILOR project.
Repositori Institucional UIB
Publicación Artículo científico (JournalArticle)

GDF15 and ACE2 stratify COVID-19 patients according to severity while ACE2 mutations increase infection susceptibility

  • Barcelo, Carles
  • Gonzalez-Freire, Marta
  • Torrens-Mas, Margalida
  • Perelló-Reus, Catalina M
  • Trias-Ferrer, Neus
  • Ibargüen-González, Lesly
  • Crespí, Catalina
  • Galmes-Panades, Aina Maria
  • Navas-Enamorado, Cayetano
  • Sanchez-Polo, Andres
  • Piérola-Lopetegui, Javier
  • Masmiquel, Luis
  • Socias Crespi, Lorenzo
[eng] Coronavirus disease 19 (COVID-19) is a persistent global pandemic with a very heterogeneous disease presentation ranging from a mild disease to dismal prognosis. Early detection of sensitivity and severity of COVID-19 is essential for the development of new treatments. In the present study, we measured the levels of circulating growth differentiation factor 15 (GDF15) and angiotensin-converting enzyme 2 (ACE2) in plasma of severity-stratified COVID-19 patients and uninfected control patients and characterized the <em>in vitro</em> effects and cohort frequency of ACE2 SNPs. Our results show that while circulating GDF15 and ACE2 stratify COVID-19 patients according to disease severity, ACE2 missense SNPs constitute a risk factor linked to infection susceptibility.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

  • Chocarro de Erauso, Luisa
  • Blanco, Ester
  • Fernández-Rubio, Leticia
  • Garnica, Maider
  • Zuazo Ibarra, Miren
  • García Granda, María Jesús
  • Bocanegra Gondán, Ana Isabel
  • Echaide Górriz, Míriam
  • Johnston, Colette
  • Edwards, Carolyn J.
  • Legg, James
  • Pierce, Andrew J.
  • Arasanz Esteban, Hugo
  • Fernández Hinojal, Gonzalo
  • Vera García, Ruth
  • Ausín, Karina
  • Santamaría Martínez, Enrique
  • Fernández Irigoyen, Joaquín
  • Kochan, Grazyna
  • Escors Murugarren, David
Many cancer patients do not benefit from PD-L1/PD-1 blockade immunotherapies. PD-1 and LAG-3 co-upregulation in T-cells is one of the major mechanisms of resistance by establishing a highly dysfunctional state in T-cells. To identify shared features associated to PD-1/LAG-3 dysfunctionality in human cancers and T-cells, multiomic expression profiles were obtained for all TCGA cancers immune infiltrates. A PD-1/LAG-3 dysfunctional signature was found which regulated immune, metabolic, genetic, and epigenetic pathways, but especially a reinforced negative regulation of the TCR signalosome. These results were validated in T-cell lines with constitutively active PD-1, LAG-3 pathways and their combination. A differential analysis of the proteome of PD-1/LAG-3 T-cells showed a specific enrichment in ubiquitin ligases participating in E3 ubiquitination pathways. PD-1/LAG-3 co-blockade inhibited CBL-B expression, while the use of a bispecific drug in clinical development also repressed C-CBL expression, which reverted T-cell dysfunctionality in lung cancer patients resistant to PD-L1/PD-1 blockade. The combination of CBL-B-specific small molecule inhibitors with anti-PD-1/anti-LAG-3 immunotherapies demonstrated notable therapeutic efficacy in models of lung cancer refractory to immunotherapies, overcoming PD-1/LAG-3 mediated resistance. © The Author(s) 2024., This research was supported by: The Spanish Association against Cancer (AECC), PROYE16001ESCO; Instituto de Salud Carlos III (ISCIII)-FEDER Project grants FIS PI20/00010, FIS PI23/00196, COV20/00237, and TRANSPOCART ICI19/00069; Biomedicine Project Grant from the Department of Health of the Government of Navarre-FEDER funds (BMED 050-2019, 51-2021, 036-2023); Strategic projects from the Department of Industry, Government of Navarre (AGATA, Ref. 0011-1411-2020-000013; LINTERNA, Ref. 0011-1411-2020-000033; DESCARTHES, 0011-1411-2019-000058); European Union Horizon 2020 ISOLDA project, under grant agreement ID: 848166. LC is financed byInstituto de Salud Carlos III (ISCIII), co-financed by FEDER funds, "ContratosPFIS: contratos predoctorales de formación en investigación en salud" (FI21/00080); ME is financed by the Navarrabiomed-Fundación Miguel Servetpredoctoral contract.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Metabolic dyshomeostasis induced by SARS-CoV-2 structural proteins reveals immunological insights into viral olfactory interactions

  • Lachén Montes, Mercedes
  • Mendizuri, Naroa
  • Ausín, Karina
  • Echaide Górriz, Míriam
  • Blanco, Ester
  • Chocarro de Erauso, Luisa
  • Toro, María de
  • Escors Murugarren, David
  • Fernández Irigoyen, Joaquín
  • Kochan, Grazyna
  • Santamaría Martínez, Enrique
One of the most common symptoms in COVID-19 is a sudden loss of smell. SARS-CoV-2 has been detected in the olfactory bulb (OB) from animal models and sporadically in COVID-19 patients. To decipher the specific role over the SARS-CoV-2 proteome at olfactory level, we characterized the in-depth molecular imbalance induced by the expression of GFP-tagged SARS-CoV-2 structural proteins (M, N, E, S) on mouse OB cells. Transcriptomic and proteomic trajectories uncovered a widespread metabolic remodeling commonly converging in extracellular matrix organization, lipid metabolism and signaling by receptor tyrosine kinases. The molecular singularities and specific interactome expression modules were also characterized for each viral structural factor. The intracellular molecular imbalance induced by each SARS-CoV-2 structural protein was accompanied by differential activation dynamics in survival and immunological routes in parallel with a differentiated secretion profile of chemokines in OB cells. Machine learning through a proteotranscriptomic data integration uncovered TGF-beta signaling as a confluent activation node by the SARS-CoV-2 structural proteome. Taken together, these data provide important avenues for understanding the multifunctional immunomodulatory properties of SARS-CoV-2 M, N, S and E proteins beyond their intrinsic role in virion formation, deciphering mechanistic clues to the olfactory inflammation observed in COVID-19 patients., This work was funded by grants from the Spanish Ministry of Science, Innovation and Universities (Ref. PID2019-110356RB-I00/AEI/10.13039/501100011033) to JF-I. and ES), the Department of Economic and Business Development from Government of Navarra (Ref. 0011-1411-2020-000028 to ES), the Instituto de Salud Carlos III (ISCIII)-FEDER project grants (Ref. FIS PI17/02119, FIS PI20/00010; COV20-00237 to DE), the Department of Health of the Government of Navarre (Ref: BMED 050-2019 to DE) and the European Project Horizon 2020 (ref: ID: 848166; Improved vaccination for older adults-ISOLDA to DE).
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

A blood microRNA classifier for the prediction of ICU mortality in COVID-19 patients: a multicenter validation study

  • de Gonzalo Calvo, David
  • Molinero, Marta
  • Benítez, Iván D.
  • Perez Pons, Manel
  • García Mateo, Nadia
  • Ortega, Alicia
  • Postigo, Tamara
  • García Hidalgo, María C.
  • Belmonte, Thalía
  • Rodríguez Muñoz, Carlos
  • González, Jessica
  • Torres, Gerard
  • Gort Paniello, Clara
  • Moncusí Moix, Anna
  • Estella García, Ángel
  • Tamayo Lomas, Luis
  • Martínez de la Gándara, Amalia
  • Socias, Lorenzo
  • Peñasco, Yhivian
  • de la Torre, María del Carmen
  • Bustamante Munguira, Elena
  • Gallego Curto, Elena
  • Martínez Varela, Ignacio
  • Martín Delgado, María Cruz
  • Vidal Cortés, Pablo
  • López Messa, Juan
  • Pérez García, Felipe
  • Caballero, Jesús
  • Añón, José Manuel
  • Loza Vázquez, Ana
  • Carbonell, Nieves
  • Marin Corral, Judith
  • Jorge García, Ruth Noemí
  • Barberà, Carmen
  • Ceccato, Adrián
  • Fernández Barat, Laia
  • Ferrer, Ricard
  • García Gasulla, Dario
  • Lorente Balanza, Jose Ángel
  • Menéndez, Rosario
  • Motos, Ana
  • Peñuelas, Oscar
  • Riera, Jordi
  • Bermejo Martin, Jesús F.
  • Torres, Antoni
  • Barbé, Ferrán
Background: The identification of critically ill COVID-19 patients at risk of fatal outcomes remains a challenge. Here, we first validated candidate microRNAs (miRNAs) as biomarkers for clinical decision-making in critically ill patients. Second, we constructed a blood miRNA classifier for the early prediction of adverse outcomes in the ICU. Methods: This was a multicenter, observational and retrospective/prospective study including 503 critically ill patients admitted to the ICU from 19 hospitals. qPCR assays were performed in plasma samples collected within the first 48 h upon admission. A 16-miRNA panel was designed based on recently published data from our group. Results: Nine miRNAs were validated as biomarkers of all-cause in-ICU mortality in the independent cohort of critically ill patients (FDR < 0.05). Cox regression analysis revealed that low expression levels of eight miRNAs were associated with a higher risk of death (HR from 1.56 to 2.61). LASSO regression for variable selection was used to construct a miRNA classifier. A 4-blood miRNA signature composed of miR-16-5p, miR-192-5p, miR-323a-3p and miR-451a predicts the risk of all-cause in-ICU mortality (HR 2.5). Kaplan‒Meier analysis confirmed these findings. The miRNA signature provides a significant increase in the prognostic capacity of conventional scores, APACHE-II (C-index 0.71, DeLong test p-value 0.055) and SOFA (C-index 0.67, DeLong test p-value 0.001), and a risk model based on clinical predictors (C-index 0.74, DeLong test-p-value 0.035). For 28-day and 90-day mortality, the classifier also improved the prognostic value of APACHE-II, SOFA and the clinical model. The association between the classifier and mortality persisted even after multivariable adjustment. The functional analysis reported biological pathways involved in SARS-CoV infection and inflammatory, fibrotic and transcriptional pathways. Conclusions: A blood miRNA classifier improves the early prediction of fatal outcomes in critically ill COVID-19 patients., 11 páginas
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Specific Activation of T Cells by an ACE2-Based CAR-Like Receptor upon Recognition of SARS-CoV-2 Spike Protein

  • González García, Pablo
  • Muñoz Miranda, Juan Pedro
  • Fernández Cisnal, R.
  • Olvera Collantes, Lucía
  • Moares Fernández, Noelia del Carmen
  • Gabucio López, Antonio
  • Fernández Ponce, Cecilia Matilde
  • García Cózar, Francisco José
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of the Coronavirus Disease 2019 (COVID-19) pandemic, which is still a health issue worldwide mostly due to a high rate of contagiousness conferred by the high-affinity binding between cell viral receptors, Angiotensin-Converting Enzyme 2 (ACE2) and SARS-CoV-2 Spike protein. Therapies have been developed that rely on the use of antibodies or the induction of their production (vaccination), but despite vaccination being still largely protective, the efficacy of antibody-based therapies wanes with the advent of new viral variants. Chimeric Antigen Receptor (CAR) therapy has shown promise for tumors and has also been proposed for COVID-19 treatment, but as recognition of CARs still relies on antibody-derived sequences, they will still be hampered by the high evasion capacity of the virus. In this manuscript, we show the results from CAR-like constructs with a recognition domain based on the ACE2 viral receptor, whose ability to bind the virus will not wane, as Spike/ACE2 interaction is pivotal for viral entry. Moreover, we have developed a CAR construct based on an affinity-optimized ACE2 and showed that both wild-type and affinity-optimized ACE2 CARs drive activation of a T cell line in response to SARS-CoV-2 Spike protein expressed on a pulmonary cell line. Our work sets the stage for the development of CAR-like constructs against infectious agents that would not be affected by viral escape mutations and could be developed as soon as the receptor is identified., 2020 Emergency Call for Research Projects about the SARSCoV- 2 virus and the COVID-19 disease of the Institute of Health ‘Carlos III’, Ministerio de Ciencia e Innovación, Spain, grant number COV20/00173; PAIDI 2020 Consejería de Universidades, Investigación y Tecnología, grant number P20-01293; Consejería de Salud y Familias, Junta de Andalucia, Spain, grant number PECART-0096-2020.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Hyperspectral image processing for the identification and quantification of lentiviral particles in fluid samples

  • Gómez‑González, Emilio
  • Fernández‑Muñoz, Beatriz
  • Barriga‑Rivera, Alejandro
  • Navas‑García, José Manuel
  • Fernández‑Lizaranzu, Isabel
  • Munoz‑González, Francisco Javier
  • Parrilla‑Giráldez, Rubén
  • Requena‑Lancharro, Desiree
  • Guerrero‑Claro, Manuel
  • Gil‑Gamboa, Pedro
  • Rosell‑Valle, Crsitina
  • Gómez‑González, Carmen
  • Mayorga‑Buiza, Maria José
  • Martín‑López, María
  • Muñoz, Olga
  • Gómez Martín, Juan Carlos
  • Relimpio López, María Isabel
  • Aceituno‑Castro, Jesús
  • Perales‑Esteve, Manuel A.
  • Puppo‑Moreno, Antonio
  • García Cózar, Francisco José
  • Olvera Collantes, Lucía
  • de los Santos‑Trigo, Silvia
  • Gómez, Emilia
  • Sánchez Pernaute, Rosario
  • Padillo‑Ruiz, Javier
  • Márquez‑Rivas, Javier
Optical spectroscopic techniques have been commonly used to detect the presence of biofilm-forming pathogens (bacteria and fungi) in the agro-food industry. Recently, near-infrared (NIR) spectroscopy revealed that it is also possible to detect the presence of viruses in animal and vegetal tissues. Here we report a platform based on visible and NIR (VNIR) hyperspectral imaging for non-contact, reagent free detection and quantification of laboratory-engineered viral particles in fluid samples (liquid droplets and dry residue) using both partial least square-discriminant analysis and artificial feed-forward neural networks. The detection was successfully achieved in preparations of phosphate buffered solution and artificial saliva, with an equivalent pixel volume of 4 nL and lowest concentration of 800 TU.mu L-1. This method constitutes an innovative approach that could be potentially used at point of care for rapid mass screening of viral infectious diseases and monitoring of the SARS-CoV- 2 pandemic., This research was funded by grants number COV20-00080 and COV20-00173 of the 2020 Emergency Call for Research Projects about the SARS-CoV-2 virus and the COVID-19 disease of the Institute of Health 'Carlos III', Spanish Ministry of Science and Innovation, and by grant number EQC2019-006240-P of the 2019 Call for Acquisition of Scientific Equipment, FEDER Program, Spanish Ministry of Science and Innovation. This work has been supported by the European Commission through the JRC HUMAINT project. ABR was supported by grant number RTI2018-094465-J funded by the Spanish National Agency of Research. The authors would like to gratefully acknowledge the assistance of the members of the EOD-CBRN Group of the Spanish National Police, whose identities cannot be disclosed, and who are represented here by JMNG. Authors thank continuous support from their institutions.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Optical imaging spectroscopy for rapid, primary screening of SARS-CoV-2: a proof of concept

  • Gómez‑González, Emilio
  • Barriga‑Rivera, Alejandro
  • Fernández‑Muñoz, Beatriz
  • Navas‑García, José Manuel
  • Fernández‑Lizaranzu, Isabel
  • Munoz‑González, Francisco Javier
  • Parrilla‑Giráldez, Rubén
  • Requena‑Lancharro, Desiree
  • Gil‑Gamboa, Pedro
  • Rosell‑Valle, Crsitina
  • Gómez‑González, Carmen
  • Mayorga‑Buiza, Maria José
  • Martín‑López, María
  • Muñoz, Olga
  • Gómez Martín, Juan Carlos
  • Relimpio López, María Isabel
  • Aceituno‑Castro, Jesús
  • Perales‑Esteve, Manuel A.
  • Puppo‑Moreno, Antonio
  • García Cózar, Francisco José
  • Olvera Collantes, Lucía
  • Gómez‑Díaz, Raquel
  • de los Santos‑Trigo, Silvia
  • Huguet‑Carrasco, Montserrat
  • Rey, Manuel
  • Gómez, Emilia
  • Sánchez Pernaute, Rosario
  • Padillo‑Ruiz, Javier
  • Márquez‑Rivas, Javier
Effective testing is essential to control the coronavirus disease 2019 (COVID-19) transmission. Here we report a-proof-of-concept study on hyperspectral image analysis in the visible and near-infrared range for primary screening at the point-of-care of SARS-CoV-2. We apply spectral feature descriptors, partial least square-discriminant analysis, and artificial intelligence to extract information from optical diffuse reflectance measurements from 5 mu L fluid samples at pixel, droplet, and patient levels. We discern preparations of engineered lentiviral particles pseudotyped with the spike protein of the SARS-CoV-2 from those with the G protein of the vesicular stomatitis virus in saline solution and artificial saliva. We report a quantitative analysis of 72 samples of nasopharyngeal exudate in a range of SARS-CoV-2 viral loads, and a descriptive study of another 32 fresh human saliva samples. Sensitivity for classification of exudates was 100% with peak specificity of 87.5% for discernment from PCR-negative but symptomatic cases. Proposed technology is reagent-free, fast, and scalable, and could substantially reduce the number of molecular tests currently required for COVID-19 mass screening strategies even in resource-limited settings., The authors would like to gratefully acknowledge the assistance of the members of the Explosive Ordnance Disposal-Chemical, Biological, Radiological & Nuclear (EOD-CBRN) Group of the Spanish National Police, whose identities cannot be disclosed, and who are represented here by JMNG. The authors also thank Manuel Guerrero-Claro for his technical assistance with the implementation of the neural networks, and the companies CAMBRICO BIOTECH (Sevilla, Spain), CER "Dr. Gregorio Medina Blanco" (Espartinas, Sevilla, Spain) and SAMU (Sevilla, Spain) for their collaboration in the collection of human samples. This research was funded by Grants Number COV20-00080 and COV20-00173 of the 2020 Emergency Call for Research Projects about the SARS-CoV-2 virus and the COVID-19 disease of the Institute of Health 'Carlos III', Spanish Ministry of Science and Innovation, and by Grant Number EQC2019-006240-P funded by MICIN/AEI/10.13039/501100011033 and by "ERDF A way of making Europe". ABR was supported by Grant Number RTI2018-094465-J-I00 funded by MICIN/AEI/10.13039/501100011033 and by "ERDF A way of making Europe". This work has been supported by the European Commission through the Joint Research Center (JRC) HUMAINT project.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 Infection and C-Section: A Prospective Observational Study

  • Morán Antolín, Eva
  • Broullon Molanes, José Román
  • de la Cruz Conty, María Luisa
  • Encinas Pardilla, María Begoña
  • Guadix Martín, María del Pilar
  • Sainz Bueno, José Antonio
  • Forcén Acebal, Laura
  • Pintado Recarte, Pilar
  • Álvarez Bartolomé, Ana
  • Martínez Cendán, Juan Pedro
  • Martínez-Pérez, Oscar
  • Spanish Obstetric Emergency Group (S.O.E.G.)
Pregnant women are particularly vulnerable to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. In addition to unfavorable perinatal outcomes, there has been an increase in obstetric interventions. With this study, we aimed to clarify the reasons, using Robson's classification model, and risk factors for cesarean section (C-section) in SARS-CoV-2-infected mothers and their perinatal results. This was a prospective observational study that was carried out in 79 hospitals (Spanish Obstetric Emergency Group) with a cohort of 1704 SARS-CoV-2 PCR-positive pregnant women that were registered consecutively between 26 February and 5 November 2020. The data from 1248 pregnant women who delivered vaginally (vaginal + operative vaginal) was compared with those from 456 (26.8%) who underwent a C-section. C-section patients were older with higher rates of comorbidities, in vitro fertilization and multiple pregnancies (p < 0.05) compared with women who delivered vaginally. Moreover, C-section risk was associated with the presence of pneumonia (p < 0.001) and 41.1% of C-sections in patients with pneumonia were preterm (Robson's 10th category). However, delivery care was similar between asymptomatic and mild-moderate symptomatic patients (p = 0.228) and their predisposing factors to C-section were the presence of uterine scarring (due to a previous C-section) and the induction of labor or programmed C-section for unspecified obstetric reasons. On the other hand, higher rates of hemorrhagic events, hypertensive disorders and thrombotic events were observed in the C-section group (p < 0.001 for all three outcomes), as well as for ICU admission. These findings suggest that this type of delivery was associated with the mother's clinical conditions that required a rapid and early termination of pregnancy., This project was supported by public funds that were obtained in competitive calls: Grant COV20/00021 (EUR 43,000 from the Instituto de Salud Carlos III-Spanish Ministry of Health) and co-financed with Fondo Europeo de Desarrollo Regional (FEDER) funds.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

  • González, Jessica
  • Batlle, Jordi
  • Benítez, Iván D.
  • Torres, Gerard
  • Santisteve, Sally
  • Targa, Adriano D.S.
  • Gort Paniello, Clara
  • Moncusí Moix, Anna
  • Aguilà, Maria
  • Seck, Fatty
  • Ceccato, Adrián
  • Ferrer, Ricard
  • Motos, Anna
  • Riera, Jordi
  • Fernández, Laia
  • Menéndez, Rosario
  • Lorente, José A.
  • Peñuelas, Oscar
  • García Gasulla, Dario
  • Peñasco, Yhivian
  • Ricart, Pilar
  • Abril Palomares, Elena
  • Aguilera, Luciano
  • Rodríguez, Alejandro
  • Boado Varela, Maria Victoria
  • Beteré, Belén
  • Pozo-Laderas, Juan Carlos
  • Solé Violán, Jordi
  • Salvador-Adell, Inmaculada
  • Andrea Novo, Mariana
  • Barberán, José
  • Amaya Villar, Rosario
  • Garnacho-Montero, José
  • Gómez, José M.
  • Blandino Ortiz, Aaron
  • Tamayo Lomas, Luis
  • Úbeda, Alejandro
  • Catalán‑González, Mercedes
  • Sánchez Miralles, Ángel
  • Gumucio-Sanguino, Víctor D.
  • Bustamante Munguira, Elena
  • Valdivia, Luis Jorge
  • Caballero, Jesús
  • Gallego, Elena
  • Rodríguez, Covadonga
  • Castellanos Ortega, Álvaro
  • Trenado, Josep
  • Marin Corral, Judith
  • Albaiceta, Guillermo M.
  • de la Torre, María del Carmen
  • Loza Vázquez, Ana
  • Vidal, Pablo
  • Añón, José Manuel
  • Carbajales Pérez, Cristina
  • Sagredo, Víctor
  • Carbonell, Nieves
  • Socias, Lorenzo
  • Barberà, Carme
  • Estella García, Ángel
  • Díaz, Emili
  • de Gonzalo Calvo, David
  • Torres, Antoni
  • Barbé, Ferrán
  • Cabello, M. A.
  • Alcaraz-Serrano, V.
  • Aldecoa, C.
  • Alegre, C.
  • Calderón, Á. A.
  • Álvarez, S.
  • Bardi, T.
  • Segade, P. B.
  • Barroso, M.
  • García, J.Á.B
  • Bermejo, J.
  • Bigas, J.
  • Blancas, R.
  • Cortés, M. L. B.
  • Saera, M.B.
  • Bofill, N.
  • Vieiro, M.T.B.
  • Bueno, L.
  • Bustamante Munguira, Juan
  • Martínez, C. B. D.
  • Hermoso, D. C.
  • Fernández, S.C.
  • Cano, I.
  • Canseco, J.
  • Fernández, P. C.
  • García, L. C.
  • Carvalho, S.
  • Castellà, M.
  • Castellví, A.
  • Castro, P.
  • Centelles-Serrano, M.J.
  • Ávila, R.C.
  • Cillóniz, C.
  • Clar, L.
  • Climent, C.
  • Codina, J.
  • Conde, P.
  • Contreras, S.
  • Parra, R.D.F.
  • Sánchez, R.D.P.
  • Mendoza, D.D.
  • Díaz, Y.
  • Vilas, M.D.R.
  • Moreno, C.D.
  • Dot, I.
  • Giraudo, P.E.
  • Arijón, I.E.
  • Monjo, T.F.
  • Fernández, J.
  • Ferrando, C.
  • Figueras, A.
  • Gomà, G.
  • Casal, V.G.
  • Gómez, S.
  • Gonzalez, C.G.
  • Gordo, F.
  • Gracia, M.P.
  • Fernández, M.J.G.
  • Herraiz, A.
  • Herrán-Monge, R.
  • Ibarz, M.
  • Iglesias, S.
  • Mantellini, C. L.
  • Naya, G. M.
  • Barcos, I. M.
  • Marcos, P.
  • Peis, E. M.
  • Cuadrado, M. M.
  • Delgado, M. C. M.
  • Vicente, P. M.
  • Martínez, P. M.
  • Fernández, C.E.M.
  • Juan, M. D. M.
  • Palacios, B.M.
  • Jiménez, J. F. M.
  • Masclans, J. R.
  • Maseda, E.
  • Fernández, E. M. M.
  • Banderas, P. M.
  • Mínguez, O.
  • Miralbés, M.
  • Monclou, J.
  • Montejo-González, J. C.
  • Montserrat, N.
  • Aznar, M. M.
  • Morales, D.
  • Cano, S.G.M.
  • Rodríguez, D. M.
  • Muñoz-Bermúdez, R.
  • Nicolás, J.M.
  • Bou, R.N.
  • Salinas, R.N.
  • Ocón, M.
  • Ortega, A.
  • Ossa, S.
  • Pagliarani, P.
  • Parrilla, F.
  • Pedregosa-Díaz, J.
  • Bastida, L. P.
  • Pérez, P.
  • Pérez-García, F.
  • Planelles, G. P.
  • Rubio, E. P.
  • Laguna, D.P.
  • Prados, J.
  • Pujol, A.
  • Coll, N. R.
  • Sánchez-Girón, G.R.
  • Roche-Campo, F.
  • Rodríguez, L.
  • Castro, F. R. D.
  • Rodríguez, S.
  • Ruiz, C. R.
  • Rubio, J.
  • Pensado, M. S.
  • Serra, L.
  • Serra-Fortuny, M.
  • Lázaro, A. S.
  • Servià, L.
  • Soliva, L.
  • Speziale, C.
  • Tormos, A.
  • Torres, M.
  • Tranque-Liberal, C.
  • Trefler, S.
  • Trujillano, J.
  • Vaca, R.
  • Val, E.
  • Ruiz, L. V.
  • Vallverdú, M.
  • Martín-Montalvo, M. V. D. H.
  • Adrio, S.V.
  • Vázquez, N.
  • Vengoechea, J.
  • Vilà-Vilardel, C.
  • Vilanova, J.
  • Warrington, T.V.
  • Yang, H.
  • Yang, M.
  • Zapatero, A.
Introduction: Critical COVID-19 survivors have a high risk of respiratory sequelae. Therefore, we aimed to identify key factors associated with altered lung function and CT scan abnormalities at a follow-up visit in a cohort of critical COVID-19 survivors. Methods: Multicenter ambispective observational study in 52 Spanish intensive care units. Up to 1327 PCR-confirmed critical COVID-19 patients had sociodemographic, anthropometric, comorbidity and lifestyle characteristics collected at hospital admission; clinical and biological parameters throughout hospital stay; and, lung function and CT scan at a follow-up visit. Results: The median [p25–p75] time from discharge to follow-up was 3.57 [2.77–4.92] months. Median age was 60 [53–67] years, 27.8% women. The mean (SD) percentage of predicted diffusing lung capacity for carbon monoxide (DLCO) at follow-up was 72.02 (18.33)% predicted, with 66% of patients having DLCO < 80% and 24% having DLCO < 60%. CT scan showed persistent pulmonary infiltrates, fibrotic lesions, and emphysema in 33%, 25% and 6% of patients, respectively. Key variables associated with DLCO < 60% were chronic lung disease (CLD) (OR: 1.86 (1.18–2.92)), duration of invasive mechanical ventilation (IMV) (OR: 1.56 (1.37–1.77)), age (OR [per-1-SD] (95%CI): 1.39 (1.18–1.63)), urea (OR: 1.16 (0.97–1.39)) and estimated glomerular filtration rate at ICU admission (OR: 0.88 (0.73–1.06)). Bacterial pneumonia (1.62 (1.11–2.35)) and duration of ventilation (NIMV (1.23 (1.06–1.42), IMV (1.21 (1.01–1.45)) and prone positioning (1.17 (0.98–1.39)) were associated with fibrotic lesions. Conclusion: Age and CLD, reflecting patients’ baseline vulnerability, and markers of COVID-19 severity, such as duration of IMV and renal failure, were key factors associated with impaired DLCO and CT abnormalities.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Immunoassay for SARS-CoV-2 Humoral Response Monitorization: A Study of the Antibody Response in COVID-19 Patients with Different Clinical Profiles during the First and Second Waves in Cadiz, Spain

  • Olvera Collantes, Lucía
  • Moares Fernández, Noelia del Carmen
  • Fernández Cisnal, R.
  • Muñoz Miranda, Juan Pedro
  • González García, Pablo
  • Gabucio López, Antonio
  • Freyre Carrillo, Carolina
  • Jordan-Chaves, Juan de Dios
  • Trujillo-Soto, Teresa
  • Rodriguez-Martinez, María P.
  • Martin-Rubio, Maria I.
  • Escuer, Eva
  • Rodríguez Iglesias, Manuel Antonio
  • Fernández Ponce, Cecilia Matilde
  • García Cózar, Francisco José
There is still a long way ahead regarding the COVID-19 pandemic, since emerging waves remain a daunting challenge to the healthcare system. For this reason, the development of new preventive tools and therapeutic strategies to deal with the disease have been necessary, among which serological assays have played a key role in the control of COVID-19 outbreaks and vaccine development. Here, we have developed and evaluated an immunoassay capable of simultaneously detecting multiple IgG antibodies against different SARS-CoV-2 antigens through the use of Bio- PlexTM technology. Additionally, we have analyzed the antibody response in COVID-19 patients with different clinical profiles in Cadiz, Spain. The multiplex immunoassay presented is a high-throughput and robust immune response monitoring tool capable of concurrently detecting anti-S1, anti-NC and anti-RBD IgG antibodies in serum with a very high sensitivity (94.34–97.96%) and specificity (91.84–100%). Therefore, the immunoassay proposed herein may be a useful monitoring tool for individual humoral immunity against SARS-CoV-2, as well as for epidemiological surveillance. In addition, we show the values of antibodies against multiple SARS-CoV-2 antigens and their correlation with the different clinical profiles of unvaccinated COVID-19 patients in Cadiz, Spain, during the first and second waves of the pandemic., Project grant number COV20-00173 of the 2020 Emergency Call for Research Projects about the SARS-CoV-2 virus and the COVID-19 disease of the Institute of Health “Carlos III” from the Spanish Ministry of Science and Innovation; Project grant number PECART-0096-2020, Consejería de Salud y Familias, Junta de Andalucía, Spain.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Determination of the characteristic inactivation fluence for SARS-CoV-2 under UV-C radiation considering light absorption in culture media

  • Brun Torres, Alejandro
  • Vázquez, Daniel
  • Moreno, Sandra
  • Fernández-Balbuena, A.A.
  • Alda, Javier
The optical absorption coefficient of culture media is critical for the survival analysis of pathogens under optical irradiation. The quality of the results obtained from experiments relies on the optical analysis of the spatial distribution of fluence which also depends on the geometry of the sample. In this contribution, we consider both the geometrical shape and the culture medium's absorption coefficient to evaluate how the spatial distribution of optical radiation affects pathogens/viruses. In this work, we exposed SARS-CoV-2 to UV-C radiation ([Formula: see text] = 254 nm) and we calculated-considering the influence of the optical absorption of the culture medium-a characteristic inactivation fluence of [Formula: see text] = 4.7 J/m2, or an equivalent 10% survival (D90 dose) of 10.8 J/m2. Experimentally, we diluted the virus into sessile drops of Dulbecco's Modified Eagle Medium to evaluate pathogen activity after controlled doses of UV irradiation. To validate the optical absorption mode, we carried out an additional experiment where we varied droplet size. Our model-including optical absorption and geometrical considerations-provides robust results among a variety of experimental situations, and represents our experimental conditions more accurately. These results will help to evaluate the capability of UV disinfecting strategies applied to a variety of everyday situations, including the case of micro-droplets generated by respiratory functions., This work has been partially supported by funding contracts with Luminalia Ingeniería S.L., and TK Elevator Manufacturing Spain, and by a grant from the Comunidad de Madrid with reference COV20-01244-CM. This publication was also supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement 871029. The authors are especially grateful to Luis Prada and Luis Estrada for their contribution to clarify some important issues of the UV sources, to Dr. Alexander Cuadrado for his encouragement in pursuing these results, and to Dr. Irene Alda for her careful reading and language review of this manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Relevance of oxidative stress in inhibition of eIF2 alpha phosphorylation and stress granules formation during Usutu virus infection

  • Blázquez, Ana B.
  • Martín-Acebes, M. A.
  • Poderoso, Teresa
  • Saiz Calahorra, Juan Carlos
20 Pág., Usutu virus (USUV) is an African mosquito-borne flavivirus closely related to West Nile, Japanese encephalitis, Zika, and dengue viruses. USUV emerged in 1996 in Europe, where quickly spread across the continent causing a considerable number of bird deaths and varied neurological disorders in humans, including encephalitis, meningoencephalitis, or facial paralysis, thus warning about USUV as a potential health threat. USUV replication takes place on the endoplasmic reticulum (ER) of infected cells, inducing ER stress and resulting in the activation of stress-related cellular pathways collectively known as the integrated stress response (ISR). The alpha subunit of the eukaryotic initiation factor eIF2 (eIF2α), the core factor in this pathway, is phosphorylated by stress activated kinases: protein kinase R (PKR), PKR-like endoplasmic reticulum kinase (PERK), heme-regulated inhibitor kinase (HRI), and general control non-repressed 2 kinase (GCN2). Its phosphorylation results, among others, in the downstream inhibition of translation with accumulation of discrete foci in the cytoplasm termed stress granules (SGs). Our results indicated that USUV infection evades cellular stress response impairing eIF2α phosphorylation and SGs assembly induced by treatment with the HRI activator ArsNa. This protective effect was related with oxidative stress responses in USUV-infected cells. Overall, these results provide new insights into the complex connections between the stress response and flavivirus infection in order to maintain an adequate cellular environment for viral replication., This work was supported by grants RTA2015-009 (J-C. S.) and E-RTA20017-003-C02 (J-C. S.) from INIA, PID2019-105117RR-C21(HOSTMEVIR) (J-C. S.) from the Spanish Ministerio de Ciencia e Innovación, (J-C. S.) from Instituto de Salud Carlos III, and S2018/BAA-4370 (PLATESA-2) (J-C. S.) from the Comunidad Autónoma de Madrid., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance

  • Jiménez-Cabello, L.
  • Utrilla-Trigo, S.
  • Barreiro-Piñeiro, Natalia
  • Pose-Boirazian, Tomás
  • Martínez-Costas, José Manuel
  • Marín-López, A.
  • Ortego, Javier
27 Pág. Centro de Investigación en Sanidad Animal (CISA), Bluetongue virus (BTV) and African horse sickness virus (AHSV) are widespread arboviruses that cause important economic losses in the livestock and equine industries, respectively. In addition to these, another arthropod-transmitted orbivirus known as epizootic hemorrhagic disease virus (EHDV) entails a major threat as there is a conducive landscape that nurtures its emergence in non-endemic countries. To date, only vaccinations with live attenuated or inactivated vaccines permit the control of these three viral diseases, although important drawbacks, e.g., low safety profile and effectiveness, and lack of DIVA (differentiation of infected from vaccinated animals) properties, constrain their usage as prophylactic measures. Moreover, a substantial number of serotypes of BTV, AHSV and EHDV have been described, with poor induction of cross-protective immune responses among serotypes. In the context of next-generation vaccine development, antigen delivery systems based on nano- or microparticles have gathered significant attention during the last few decades. A diversity of technologies, such as virus-like particles or self-assembled protein complexes, have been implemented for vaccine design against these viruses. In this work, we offer a comprehensive review of the nano- and microparticulated vaccine candidates against these three relevant orbiviruses. Additionally, we also review an innovative technology for antigen delivery based on the avian reovirus nonstructural protein muNS and we explore the prospective functionality of the nonstructural protein NS1 nanotubules as a BTV-based delivery platform., This research was funded by grants PID2020-112992RR-I00 and PID2019-105308RB-I00 from the Spanish Ministry of Science, / from ISCIII and DEVASARMIC from Santander-CRUE. The Xunta de Galicia (ED431B 2018/04, Centro singular de investigación de Galicia accreditation 2016–2019) and the European Union (European Regional Development Fund - ERDF) are gratefully acknowledged. S.U-T. was a recipient of a predoctoral fellowship from the Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Centro de Investigación en Sanidad Animal (program FPI-SGIT-2018)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Tools for the targeted genetic modification of poxvirus genomes

  • Matía, Alejandro
  • Lorenzo, María M.
  • Blasco, Rafael
8 Pág., The potential of viruses as biotechnology platforms is becoming more appealing due to technological advances in synthetic biology techniques and to the increasing accessibility of means to manipulate virus genomes. Among viral systems, poxviruses, and their prototype member Vaccinia Virus, are one of the outstanding choices for different biotechnological and medical applications based on heterologous gene expression, recombinant vaccines or oncolytic viruses. The refinement of genetic engineering methods on Vaccinia Virus over the last decades have contributed to facilitate the manipulation of the genomes of poxviruses, and may aid in the improvement of virus variants designed for different goals through reverse genetic approaches. Targeted genetic changes are usually performed by homologous recombination with the viral genome. In addition to the classic approach, recent methodological advances that may assist new strategies for the mutation or edition of poxvirus genomes are reviewed., This work was supported by grant RTA2017-0066 from Ministerio de Ciencia e Innovación and grant COV20-0901 from Instituto de Salud Carlos III, Spain. A.M. was recipient of a predoctoral contract from Subprograma Estatal de Formación, Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+I, Spain. Funding sources had no involvement in study design; in the collection, analysis and interpretation of data; in the writing of the report or in the decision to submit the article for publication., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Use of exosomes as vectors to carry advanced therapies

  • Sancho-Albero, María
  • Medel-Martínez, Ana
  • Martín-Duque, Pilar
Exosomes are microvesicles of nanometric size involved in the communication between cells and tissues. Inside their bilipidic membrane they carry nucleic acids such as cargos (DNA, miRNA, etc.). Some of the advantages that make exosomes very attractive therapeutic vehicles are (i) their tropism through different tissues, (ii) the ability to pass biological barriers and (iii) the protection of the encapsulated material from the immune system and degradation. Viruses are some of the most widely employed gene therapy vehicles; however, they are still facing many problems, such as inefficient tropism to damaged areas and their elimination by the immune system. One of the functions attributed to exosomes is the elimination of substances that could be harmful to the cell, including viruses. Recently it has been investigated whether complete viruses or part of them could be encapsulated in exosomes, for a new viral-exosome gene therapy approach. Moreover, nanotechnology is another type of advanced therapy (together with gene and cell therapies) that can be used, among other utilities, to transfer genetic material. Recently the field of encapsulation of nanomaterials in exosomes, with or without gene transfer, is increasing. In this review we will summarize all of those studies. This journal is
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Coagulation Parameters: An Efficient Measure for Predicting the Prognosis and Clinical Management of Patients with COVID-19

  • Quintana-Diaz, M.
  • Andres-Esteban, E.M.
  • Ramirez-Cervantes, K.L.
  • Olivan-Blazquez, B.
  • Juarez-Vela, R.
  • Gea-Caballero, V.
Background. COVID-19 is an ongoing global pandemic. Since the detection of the first cases of coronavirus disease 2019 (COVID-19) in Wuhan, China, the current pandemic has affected more than 25.3 million people worldwide. The aim of this study was to evaluate the relationship between coagulation abnormalities and prognosis in a cohort of patients with COVID-19. Methods. We performed a retrospective cohort study of 3581 patients admitted to Hospital La Paz (Madrid, Spain) due to respiratory infection by severe acute respiratory syndrome coronavirus from the beginning of the current pandemic to 15 July 2020. Results. Of the 3581 study patients, 48.94% were men, and 19.80% were healthcare workers. The median age was 62 years. Compared with the survivors, the non-survivors had lower prothrombin activity (82.5 (Interquartile range-IQR, 67-95) vs. 95.25 (IQR, 87-104) for non-survivors and survivors, respectively; p < 0.001), higher fibrinogen levels (748.5-IQR, 557-960) vs. 572.75 (IQR, 417-758; p < 0.001), and notably higher D-dimer levels (2329-IQR, 1086.12-5670.40) vs. 635.5 (IQR, 325.5-1194.8); p < 0.001). Conclusions. The evaluation of coagulation parameters could be an efficient measure for predicting the prognosis and improving the clinical management of patients with COVID-19.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Pulmonary long-term consequences of COVID-19 infections after hospital discharge

  • Blanco, J.R.
  • Cobos-Ceballos, M.J.
  • Navarro, F.
  • Sanjoaquin, I.
  • Arnaiz de las Revillas, F.
  • Bernal, E.
  • Buzon-Martin, L.
  • Viribay, M.
  • Romero, L.
  • Espejo-Pérez, S.
  • Valencia, B.
  • Ibañez, D.
  • Ferrer-Pargada, D.
  • Malia, D.
  • Gutierrez-Herrero, F.G.
  • Olalla, J.
  • Jurado-Gamez, B.
  • Ugedo, J.
Objectives: COVID-19 survivors are reporting residual abnormalities after discharge from the hospital. Limited information is available about this stage of recovery or the lingering effects of the virus on pulmonary function and inflammation. The aim of this study was to describe lung function and to identify biomarkers in serum and induced sputum samples from patients recovering from COVID-19 hospitalisation. Methods: Patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by a real-time PCR (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were recruited for this study. Each hospital screened their lists of discharged patients at least 45 days after symptom onset. SARS-CoV-2-infected patients were divided into mild/moderate and severe disease groups according to the severity of their symptoms during hospitalisation. Patients’ epidemiological and medical histories, comorbidities, chronic treatments, and laboratory parameters were evaluated. Pulmonary function tests, the standardised 6-minute walk test (6 MWT) and chest computed tomography (CT) were also performed. The levels of proteases, their inhibitors, and shed receptors were measured in serum and induced sputum samples. Results: A total of 100 patients with respiratory function tests were included in this study. The median number of days after the onset of symptoms was 104 (IQR 89.25, 126.75). COVID-19 was severe in 47% (47/100) of patients. CT was normal in 48% (48/100) of patients. Lung function was normal (FEV1 ≥80%, FVC ≥80%, FEV1/FVC ≥0.7, and diffusing capacity for carbon monoxide [DLCO] ≥80%) in 92% (92/100), 94% (94/100), 100% (100/100) and 48% (48/100) of patients, respectively. Multivariate analysis showed that a DLCO <80% (OR 5.92; 95%CI 2.28-15.37; p <0.0001) and a lower serum LDH level (OR 0.98; 95%CI 0.97-0.99) were associated with the severe disease group of SARS-CoV-2 during hospital stay. Conclusions: A diffusion deficit (DLCO <80%) was still present after hospital discharge and was associated with the most severe SARS-CoV-2 cases.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Humoral responses to SARS-CoV-2 by healthy and sick dogs during the COVID-19 pandemic in Spain

  • Perisé-Barrios, A.J.
  • Tomeo-Martín, B.D.
  • Gómez-Ochoa, P.
  • Delgado-Bonet, P.
  • Plaza, P.
  • Palau-Concejo, P.
  • González, J.
  • Ortiz-Díez, G.
  • Meléndez-Lazo, A.
  • Gentil, M.
  • García-Castro, J.
  • Barbero-Fernández, A.
COVID-19 is a zoonotic disease caused by SARS-CoV-2. Infections of animals with SARS-CoV-2 have recently been reported, and an increase of severe lung pathologies in domestic dogs has also been detected by veterinarians in Spain. Therefore, further descriptions of the pathological processes in those animals that show symptoms similar to those described in humans affected by COVID-19 would be highly valuable. The potential for companion animals to contribute to the continued transmission and community spread of this known human-to-human disease is an urgent issue to be considered. Forty animals with pulmonary pathologies were studied by chest X-ray, ultrasound analysis, and computed tomography. Nasopharyngeal and rectal swabs were analyzed to detect canine pathogens, including SARS-CoV-2. An additional twenty healthy dogs living in SARS-CoV-2-positive households were included. Immunoglobulin detection by several immunoassays was performed. Our findings show that sick dogs presented severe alveolar or interstitial patterns with pulmonary opacity, parenchymal abnormalities, and bilateral lesions. The forty sick dogs were negative for SARS-CoV-2 but Mycoplasma spp. was detected in 26 of 33 dogs. Five healthy and one pathological dog presented IgG against SARS-CoV-2. Here we report that despite detecting dogs with a-SARS-CoV-2 IgG, we never obtained a positive RT-qPCR for SARS-SoV-2, not even in dogs with severe pulmonary disease; suggesting that even in the case of canine infection, transmission would be unlikely. Moreover, dogs living in COVID-19-positive households could have been more highly exposed to infection with SARS-CoV-2.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2

  • Santiago, Llipsy
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • González-Ramírez, Andrés M.
  • Macías-León, Javier
  • Moreo, Eduardo
  • Redrado, Sergio
  • García-García, Ana
  • Taleb, Víctor
  • Lira-Navarrete, Erandi
  • Hurtado-Guerrero, Ramón
  • Aguilo, Nacho
  • del Mar Encabo-Berzosa, Maria
  • Hidalgo, Sandra
  • Galvez, Eva M.
  • Ramirez-Labrada, Ariel
  • de Miguel, Diego
  • Benito, Rafael
  • Miranda, Patricia
  • Fernández, Antonio
  • Domingo, José M.
  • Serrano, Laura
  • Yuste, Cristina
  • Villanueva-Saz, Sergio
  • Paño-Pardo, José R.
  • Pardo, Julián
Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few days after infection. Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at very different concentrations which correlated with previous disease severity and gender. Anti-RBD IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN) against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from 168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2 infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Sars-cov-2 seroprevalence in household domestic ferrets (Mustela putorius furo)

  • Giner, Jacobo
  • Villanueva-Saz, Sergio
  • Tobajas, Ana Pilar
  • Pérez, María Dolores
  • González, Ana
  • Verde, Maite
  • Yzuel, Andrés
  • García-García, Ana
  • Taleb, Víctor
  • Lira-Navarrete, Erandi
  • Hurtado-Guerrero, Ramón
  • Pardo, Julián
  • Santiago, Llipsy
  • Paño, José Ramón
  • Ruíz, Héctor
  • Lacasta, Delia
  • Fernández, Antonio
Animal infections with SARS-CoV-2 have been reported in different countries and several animal species have been proven to be susceptible to infection with SARS-CoV-2 both naturally and by experimental infection. Moreover, infections under natural conditions in more than 20 mink farms have been reported where humans could have been the source of infection for minks. However, little information is available about the susceptibility of pet animals under natural conditions and currently there is no SARS-CoV-2 epidemiological assessment occurrence in household ferrets. In this study, the presence of SARS-CoV-2 antibodies was evaluated in serum samples obtained from 127 household ferrets (Mustela putorius furo) in the Province of Valencia (Spain). Two ferrets tested positive to SARS-CoV-2 (1.57%) by in-house enzyme-linked immunosorbent assay based on receptor binding domain (RBD) of Spike antigen. Furthermore, anti- RBD SARS-CoV-2 antibodies persisted at detectable levels in a seropositive SARS-CoV-2 domestic ferret beyond 129 days since the first time antibodies were detected. This study reports for the first time the evidence of household pet ferrets exposure to SARS-CoV-2 in Spain to date.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Geographic factors associated with poorer outcomes in patients diagnosed with covid-19 in primary health care

  • Magallón-Botaya, R.
  • Oliván-Blázquez, B.
  • Ramírez-Cervantes, K.L.
  • Méndez-López-de-La-manzanara, F.
  • Aguilar-Palacio, I.
  • Casajuana-Closas, M.
  • Andrés-Esteban, E.
Background: The prognosis of older age COVID-19 patients with comorbidities is associated with a more severe course and higher fatality rates but no analysis has yet included factors related to the geographical area/municipality in which the affected patients live, so the objective of this study was to analyse the prognosis of patients with COVID-19 in terms of sex, age, comorbidi-ties, and geographic variables. Methods: A retrospective cohort of 6286 patients diagnosed with COVID-19 was analysed, considering demographic data, previous comorbidities and geographic variables. The main study variables were hospital admission, intensive care unit (ICU) admission and death due to worsening symptoms; and the secondary variables were sex, age, comorbidities and geographic variables (size of the area of residence, distance to the hospital and the driving time to the hospital). A comparison analysis and a multivariate Cox model were performed. Results: The multivariate Cox model showed that women had a better prognosis in any type of analysed prog-nosis. Most of the comorbidities studied were related to a poorer prognosis except for dementia, which is related to lower admissions and higher mortality. Suburban areas were associated with greater mortality and with less hospital or ICU admission. Distance to the hospital was also associated with hospital admission. Conclusions: Factors such as type of municipality and distance to hospital act as social health determinants. This fact must be taken account in order to stablish specifics prevention measures and treatment protocols.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 outbreak on a Spanish mink farm: epidemiological, molecular, and pathological studies

  • Badiola, J. J.
  • Otero, A.
  • Sevilla, E.
  • Marín, B.
  • García Martínez, M.
  • Betancor, M.
  • Sola, D.
  • Pérez Lázaro, S.
  • Lozada, J.
  • Velez, C.
  • Chiner-Oms, Á.
  • Comas, I.
  • Cancino-Muñoz, I.
  • Monleón, E
  • Monzón, M.
  • Acín, C.
  • Bolea, R.
  • Moreno, B.
Farmed minks have been reported to be highly susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and may represent a risk to humans. In this study, we describe the first outbreak of SARS-CoV-2 occurred on a mink farm in Spain, between June and July 2020, involving 92,700 animals. The outbreak started shortly after some farm workers became seropositive for SARS-CoV-2. Minks showed no clinical signs compatible with SARS-CoV-2 infection throughout the outbreak. Samples from 98 minks were collected for histopathological, serological, and molecular studies. Twenty out of 98 (20.4%) minks were positive by RT-qPCR and 82 out 92 (89%) seroconverted. This finding may reflect a rapid spread of the virus at the farm with most of the animals overcoming the infection. Additionally, SARS-CoV-2 was detected by RT-qPCR in 30% of brain samples from positive minks. Sequencing analysis showed that the mink sequences were not closely related with the other mink SARS-CoV-2 sequences available, and that this mink outbreak has its probable origin in one of the genetic variants that were prevalent in Spain during the first COVID-19 epidemic wave. Histological studies revealed bronchointerstitial pneumonia in some animals. Immunostaining of viral nucleocapsid was also observed in nasal turbinate tissue. Farmed minks could therefore constitute an important SARS-CoV-2 reservoir, contributing to virus spread among minks and humans. Consequently, continuous surveillance of mink farms is needed.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

No evidence of SARS-CoV-2 infection in wild mink (Mustela lutreola and neogale vison) from northern Spain during the first two years of pandemic

  • Villanueva Saz, S.
  • Giner, J.
  • Palomar, A. M.
  • Gómez, M. A.
  • Põdra, M.
  • Aranda, M. C.
  • Jiménez, M. A.
  • Lizarraga, P.
  • Hernández, R.
  • Portillo, A.
  • Oteo, J. A.
  • Ruíz-Arrondo, I.
  • Pérez, M. D.
  • Tobajas, A. P.
  • Verde, M.
  • Lacasta, D.
  • Marteles, D.
  • Hurtado-Guerrero, R.
  • Santiago, L.
  • Ruiz, H.
  • Fernández, A.
The impact of the SARS-CoV-2 pandemic on wildlife is largely unevaluated, and extended surveillance of animal species is needed to reach a consensus on the role of animals in the emergence and maintenance of SARS-CoV-2. This infection has been detected in farmed and domestic animals and wild animals, mainly in captivity. The interactions or shared resources with wildlife could represent a potential transmission pathway for the SARS-CoV-2 spill over to other wild species and could lead to health consequences or the establishment of new reservoirs in susceptible hosts. This study evaluated the presence of SARS-CoV-2 in European mink (Mustela lutreola) and American mink (Neogale vison) in Spain by enzyme-linked immunosorbent assay (ELISA) using the receptor binding domain (RBD) of Spike antigen in serum samples and/or by RT-qPCR assays in oropharyngeal and rectal swabs. From January 2020 to February 2022, a total of 162 animals (127 European mink and 35 American mink) with no evidence of SARS-CoV-2 infection were included in the study. Antibodies against the SARS-CoV-2 were not found in the serum samples analysed (n = 126), nor was the virus amplified by RT-qPCR (n = 160 swabs). Our results suggest that the potential role of wild mink and the European mink bred in captivity and released to the wild as dispersers of SARS-CoV-2 is so far low. However, wildlife surveillance for early detection of human and animal risks should be continued. In this sense, epidemiological monitoring measures, including serology and molecular analysis, are necessary.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

  • Zabana, Yamile
  • Marín-Jiménez, Ignacio
  • Rodríguez-Lago, Iago
  • Vera, Isabel
  • Martín-Arranz, María Dolores
  • Guerra, Iván
  • Gisbert, Javier P.
  • Mesonero, Francisco
  • Benítez, Olga
  • Taxonera, Carlos
  • Ponferrada-Díaz, Ángel
  • Piqueras, Marta
  • Lucendo, Alfredo J.
  • Caballol, Berta
  • Mañosa, Míriam
  • Martínez-Montiel, Pilar
  • Bosca-Watts, Maia
  • Gordillo, Jordi
  • Bujanda, Luis
  • Manceñido, Noemí
  • Martínez-Pérez, Teresa
  • López, Alicia
  • Rodríguez-Gutiérrez, Cristina
  • García-López, Santiago
  • Vega, Pablo
  • Rivero, Montserrat
  • Melcarne, Luigi
  • Calvo, Maria
  • Iborra, Marisa
  • Barreiro de-Acosta, Manuel
  • Sicilia, Beatriz
  • Barrio, Jesús
  • Pérez, José Lázaro
  • Busquets, David
  • Pérez-Martínez, Isabel
  • Navarro-Llavat, Mercè
  • Hernández, Vicent
  • Argüelles-Arias, Federico
  • Ramírez Esteso, Fernando
  • Meijide, Susana
  • Ramos, Laura
  • Gomollón, Fernando
  • Muñoz, Fernando
  • Suris, Gerard
  • de Zarate, Jone Ortiz
  • Huguet, José María
  • Llaó, Jordina
  • García-Sepulcre, Mariana Fe
  • Sierra, Mónica
  • Durà, Miguel
  • Estrecha, Sandra
  • Fuentes Coronel, Ana
  • Hinojosa, Esther
  • Olivan, Lorenzo
  • Iglesias, Eva
  • Gutiérrez, Ana
  • Varela, Pilar
  • Rull, Núria
  • Gilabert, Pau
  • Hernández-Camba, Alejandro
  • Brotons, Alicia
  • Ginard, Daniel
  • Sesé, Eva
  • Carpio, Daniel
  • Aceituno, Montserrat
  • Cabriada, José Luis
  • González-Lama, Yago
  • Jiménez, Laura
  • Chaparro, María
  • López-San Román, Antonio
  • Alba, Cristina
  • Plaza-Santos, Rocío
  • Mena, Raquel
  • Tamarit-Sebastián, Sonsoles
  • Ricart, Elena
  • Calafat, Margalida
  • Olivares, Sonsoles
  • Navarro, Pablo
  • Bertoletti, Federico
  • Alonso-Galán, Horacio
  • Pajares, Ramón
  • Olcina, Pablo
  • Manzano, Pamela
  • Domènech, Eugeni
  • Esteve, Maria
We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March–July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged ≥ 60 years (OR 7.1, 95% CI: 1.8–27 and 4.5, 95% CI: 1.3–15.9), while having ≥2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3–11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Relationship between initial symptoms and the prognosis, sex, and demographic area of patients with COVID-19

  • Oliván-Blázquez, Bárbara
  • Bartolomé-Moreno, Cruz
  • Gericó-Aseguinolaza, Junkal
  • Méndez-López, Fátima
  • Lerma-Irureta, David
  • Lamiquiz-Moneo, Itziar
  • Fernández-Martínez, Selene
  • Magallón-Botaya, Rosa
A method of determining the initial symptoms and main prognostic identifiers for COVID-19 can be a key tool for physicians, especially primary care physicians. Therefore, the objective of this study was to examine the prognosis of patients with COVID-19 from two different demographic regions according to baseline and main symptoms, age, and sex.MethodsAll individuals selected from both urban and rural health centers were over 18 years of age, had COVID-19 before 2 March 2021, and were followed up with a primary care physician. All patients included in this study were recruited in terms of sex, age at the time of infection, type of contact, baseline symptoms, primary and secondary symptomatology, emergency assistance, hospitalization, intensive care unit (ICU) admission, and death.ResultsA total of 219 and 214 subjects were recruited from rural and urban health centers, respectively. Subjects with COVID-19 from rural areas were significantly older in age, with a higher proportion of men, and had significantly lower baseline and main symptoms than those from urban areas. In addition, the presence of both fever and dyspnea as the initial or main symptom is significantly associated with emergency assistance, hospitalization, and death, regardless of sex, age, and demographic area. This type of illness was reported to be significantly less frequent in the rural population than in the urban population.ConclusionThe presence of both fever and dyspnea as both initial and main symptoms is a poor prognostic factor for COVID-19, regardless of age, sex, and demographic areas. In addition, women reported lower levels of fever and dyspnea, requiring minimal emergency assistance and fewer hospitalization, and a lower rate of mortality than men. During a COVID-19 infection follow-up, subjects in rural areas seem to have less access to medical care than those in urban areas.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Serum lipid mediator profiles in COVID-19 patients and lung disease severity: a pilot study

  • Irún, Pilar
  • Gracia, Rafael
  • Piazuelo, Elena
  • Pardo, Julián
  • Morte, Elena
  • Paño, José Ramon
  • Boza, Julio
  • Carrera-Lasfuentes, Patricia
  • Higuera, Gustavo A.
  • Lanas, Ángel
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is highly heterogeneous, ranging from asymptomatic to severe and fatal cases. COVID-19 has been characterized by an increase of serum pro-inflammatory cytokine levels which seems to be associated with fatal cases. By contrast, the role of pro-resolving lipid mediators (SPMs), involved in the attenuation of inflammatory responses, has been scarcely investigated, so further studies are needed to understand SPMs metabolism in COVID-19 and other infectious diseases. Our aim was to analyse the lipid mediator metabolome, quantifying pro- and anti-inflammatory serum bioactive lipids by LC–MS/MS in 7 non-infected subjects and 24 COVID-19 patients divided into mild, moderate, and severe groups according to the pulmonary involvement, to better understand the disease outcome and the severity of the pulmonary manifestations. Statistical analysis was performed with the R programming language (R Foundation for Statistical Computing, Vienna, Austria). All COVID-19 patients had increased levels of Prostaglandin E2. Severe patients showed a significant increase versus controls, mild- and moderate-affected patients, expressed as median (interquartile range), in resolvin E1 [112.6 (502.7) vs 0.0 (0.0) pg/ml in the other groups], as well as in maresin 2 [14.5 (7.0) vs 8.1 (4.2), 5.5 (4.3), and 3.0 (4.0) pg/ml, respectively]. Moreover, 14-hydroxy docosahexaenoic acid (14-HDHA) levels were also increased in severe vs control and mild-affected patients [24.7 (38.2) vs 2.4 (2.2) and 3.7 (6.4) ng/mL, respectively]. Resolvin D5 was also significantly elevated in both moderate [15.0 (22.4) pg/ml] and severe patients [24.0 (24.1) pg/ml] versus controls [0.0 (0.0) pg/ml]. These results were confirmed by sparse partial least squares discriminant analysis which highlighted the contribution of these mediators to the separation between each of the groups. In conclusion, the potent inflammatory response to SARS-CoV-2 infection involves not only pro- but also anti-inflammatory lipid mediators that can be quantified in easily accessible serum samples, suggesting the need to perform future research on their generation pathways that will help us to discover new therapeutic targets.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Elevated levels of serum CDCP1 in individuals recovering from severe COVID-19 disease

  • Blanco, Jose Ramón
  • Cobos-Ceballos, María Jesús
  • Navarro, Francisco
  • Sanjoaquin, Isabel
  • Armiñanzas, Carlos
  • Bernal, Enrique
  • Buzon-Martin, Luis
  • Viribay, Miguel
  • Pérez-Martínez, Laura
  • Espejo-Pérez, Simona
  • Valencia, Borja
  • Guzman-Aguilar, Jesus
  • Ruiz-Cubillan, Juan-Jose
  • Alcalde, Consuelo
  • Gutierrez-Herrero, Fernando Gustavo
  • Olalla, Julian
  • Andres-Esteban, Eva-Maria
  • Jurado-Gamez, Bernabe
  • Ugedo, Javier
Background: COVID-19 survivors report residual lung abnormalities after discharge from the hospital. The aim of this study was to identify biomarkers in serum and induced sputum samples from patients after hospitalization for COVID-19. Methods: Patients admitted to hospitals in Spain with laboratory-confirmed COVID-19 were recruited for this study. SARS-CoV-2-infected patients were divided into groups with mild/moderate and severe disease according to the severity of their symptoms during hospitalization. Levels of 92 biomarkers were measured in serum and induced sputum samples. Results: A total of 108 patients (46.2% severe cases) were included in this study. The median number of days after the onset of symptoms was 104. A significant difference was observed in diffusing capacity for carbon monoxide (DLCO), an indicator of lung function, whereby DLCO <80% was significantly lower in severe cases (p <0.001). Differences in inflammatory biomarkers were observed between patients with mild/moderate and severe disease. For some biomarkers, correlations in serum and induced sputum levels were detected. Independent predictors of severe disease were DLCO <80% and the serum CDCP1 value. Conclusions: Higher levels of CDCP1 remain after hospital discharge and are associated with the severity of COVID-19. The possible prognostic implications warrant further investigation.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Enhancing SARS-CoV-2 Surveillance through Regular Genomic Sequencing in Spain: The RELECOV Network

  • Vázquez-Morón, Sonia
  • Iglesias-Caballero, María
  • Lepe, José
  • Garcia, Federico
  • Melón, Santiago
  • Marimon, José
  • García de Viedma, Darío
  • Folgueira, Maria
  • Galán, Juan
  • López-Causapé, Carla
  • Benito-Ruesca, Rafael
  • Alcoba-Florez, Julia
  • Gonzalez Candelas, Fernando
  • Toro, María
  • Fajardo, Miguel
  • Ezpeleta, Carmen
  • Lázaro, Fernando
  • Pérez Castro, Sonia
  • Cuesta, Isabel
  • Zaballos, Angel
  • Pozo, Francisco
  • Casas, Inmaculada
  • on behalf of RELECOV Network Members
Millions of SARS-CoV-2 whole genome sequences have been generated to date. However, good quality data and adequate surveillance systems are required to contribute to meaningful surveillance in public health. In this context, the network of Spanish laboratories for coronavirus (RELECOV) was created with the main goal of promoting actions to speed up the detection, analyses, and evaluation of SARS-CoV-2 at a national level, partially structured and financed by an ECDC-HERA-Incubator action (ECDC/GRANT/2021/024). A SARS-CoV-2 sequencing quality control assessment (QCA) was developed to evaluate the network’s technical capacity. QCA full panel results showed a lower hit rate for lineage assignment compared to that obtained for variants. Genomic data comprising 48,578 viral genomes were studied and evaluated to monitor SARS-CoV-2. The developed network actions showed a 36% increase in sharing viral sequences. In addition, analysis of lineage/sublineage-defining mutations to track the virus showed characteristic mutation profiles for the Delta and Omicron variants. Further, phylogenetic analyses strongly correlated with different variant clusters, obtaining a robust reference tree. The RELECOV network has made it possible to improve and enhance the genomic surveillance of SARS-CoV-2 in Spain. It has provided and evaluated genomic tools for viral genome monitoring and characterization that make it possible to increase knowledge efficiently and quickly, promoting the genomic surveillance of SARS-CoV-2 in Spain.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

  • Sancho-Saldaña, Agustín
  • Gil-Sánchez, Anna
  • González-Mingot, Cristina
  • Peralta, Silvia
  • Solana, Maria Jose
  • Torres, Pascual
  • Juanes, Alba
  • Quibus, Laura
  • Ruiz, Emilio
  • Sanpedro, Eduardo
  • Quirant-Sánchez, Bibiana
  • Martínez-Cáceres, Eva
  • Ramo Tello, Cristina
  • Presas-Rodríguez, Silvia
  • García Rubio, Sebatián
  • Pardiñas Baron, Beatriz
  • Ramió-Torrentà, Lluís
  • Sotoca, Javier
  • González-Suárez, Inés
  • Eichau, Sara
  • Prieto-González, José M.
  • Blasco Quilez, Maria Rosario
  • Sabín-Muñoz, Julia
  • Sánchez-López, Antonio José
  • Llorens Calatayud, Gloria
  • Calles, Carmen
  • Sempere, Ángel Pérez
  • Garcés, Moises
  • Carmona, Olga
  • Moral, Ester
  • Hervás, José Vicente
  • Blanco, Yolanda
  • Sola-Valls, Nuria
  • Tellez Lara, Nieves
  • Forero, Lucía
  • Brieva, Luis
Background: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients enrolled in the EMCOVID database. The DMTs were used to manage MS by reducing relapses, lesion accumulation, and disability progression. However, concerns arose regarding the susceptibility of pwMS to COVID-19 due to potential interactions between SARS-CoV-2 and the immune system, as well as the immunomodulatory effects of DMTs. Methods: This prospective observational study utilized data from a Multiple Sclerosis and COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data, SARS-CoV-2 serology, and symptoms of COVID-19 were extracted for pwMS receiving any type of DMT. The relationship between demographics, MS phenotype, DMTs, and COVID-19 was evaluated. The evolution of SARS-CoV-2 antibodies over a 6-month period was also assessed. Results: The study included 709 pwMS, with 376 patients providing samples at the 6-month follow-up visit. The seroprevalence of SARS-CoV-2 antibodies was higher among pwMS than the general population, with Interferon treatment being significantly associated with greater seroprevalence (16.9% vs. 8.4%; p 0.003). However, no other specific DMT showed a significant association with antibody presence. A total of 32 patients (8.5%) tested positive for IgG, IgM, or IgA antibodies against SARS-CoV-2 at baseline, but then tested negative at 6 months. Most of the pwMS in the cohort were asymptomatic for COVID-19 and, even among symptomatic cases, the prognosis was generally favourable. Conclusion: pwMS undergoing DMTs exhibited a higher seroprevalence of COVID-19 than the general population. Interferon treatment was associated with a higher seroprevalence, suggesting a more robust humoral response. This study provides valuable insights into the seroprevalence and persistence of SARS-CoV-2 antibodies in pwMS and contributes to our understanding of the impact of COVID-19 amongst this population.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Identification of FasL as a crucial host factor driving COVID-19 pathology and lethality

  • Albert, Marie-Christine
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • De Miguel, Diego
  • Peña, Natacha
  • Montinaro, Antonella
  • Varanda, Ana Beatriz
  • Theobald, Sebastian J.
  • Areso, Itziar
  • Saggau, Julia
  • Koch, Manuel
  • Liccardi, Gianmaria
  • Peltzer, Nieves
  • Rybniker, Jan
  • Hurtado-Guerrero, Ramón
  • Merino, Pedro
  • Monzón, Marta
  • Badiola, Juan J.
  • Reindl-Schwaighofer, Roman
  • Sanz-Pamplona, Rebeca
  • Cebollada-Solanas, Alberto
  • Megyesfalvi, Zsolt
  • Dome, Balazs
  • Secrier, Maria
  • Hartmann, Boris
  • Bergmann, Michael
  • Pardo, Julián
  • Walczak, Henning
The dysregulated immune response and inflammation resulting in severe COVID-19 are still incompletely understood. Having recently determined that aberrant death-ligand-induced cell death can cause lethal inflammation, we hypothesized that this process might also cause or contribute to inflammatory disease and lung failure following SARS-CoV-2 infection. To test this hypothesis, we developed a novel mouse-adapted SARS-CoV-2 model (MA20) that recapitulates key pathological features of COVID-19. Concomitantly with occurrence of cell death and inflammation, FasL expression was significantly increased on inflammatory monocytic macrophages and NK cells in the lungs of MA20-infected mice. Importantly, therapeutic FasL inhibition markedly increased survival of both, young and old MA20-infected mice coincident with substantially reduced cell death and inflammation in their lungs. Intriguingly, FasL was also increased in the bronchoalveolar lavage fluid of critically-ill COVID-19 patients. Together, these results identify FasL as a crucial host factor driving the immuno-pathology that underlies COVID-19 severity and lethality, and imply that patients with severe COVID-19 may significantly benefit from therapeutic inhibition of FasL.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Outcomes of hospitalized patients with COVID-19 according to level of frailty

  • Andrés-Esteban E.M.
  • Quintana-Diaz M.
  • Ramírez-Cervantes K.L.
  • Benayas-Peña I.
  • Silva-Obregón A.
  • Magallón-Botaya R.
  • Santolalla-Arnedo I.
  • Juárez-Vela R.
  • Gea-Caballero V.
Background: The complications from coronavirus disease 2019 (COVID-19) have been the subject of study in diverse scientific reports. However, many aspects that influence the prognosis of the disease are still unknown, such as frailty, which inherently reduces resistance to disease and makes people more vulnerable. This study aimed to explore the complications of COVID-19 in patients admitted to a third-level hospital and to evaluate the relationship between these complications and frailty. Methods: An observational, descriptive, prospective study was performed in 2020. A sample of 254 patients from a database of 3, 112 patients admitted to a high-level hospital in Madrid, Spain was analyzed. To assess frailty (independent variable) the Clinical Frailty Scale (CFS) was used. The outcome variables were sociodemographic and clinical, which included complications, length of stay, intensive care unit (ICU) admission and prognosis. Results: A total of 13.39% of the patients were pre-frail and 17.32% were frail. Frail individuals had a shorter hospital stay, less ICU admission, higher mortality and delirium, with statistical significance. Conclusion: Frailty assessment is a crucial approach in patients with COVID-19, given a higher mortality rate has been demonstrated amongst frail patients. The CFS could be a predictor of mortality in COVID-19.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Absence of SARS-CoV-2 Antibodies in Natural Environment Exposure in Sheep in Close Contact with Humans

  • Villanueva-Saz, Sergio
  • Giner, Jacobo
  • Fernández, Antonio
  • Lacasta, Delia
  • Ortín, Aurora
  • Ramos, Juan José
  • Ferrer, Luis Miguel
  • Ruiz de Arcaute, Marta
  • Tobajas, Ana Pilar
  • Pérez, María Dolores
  • Verde, Maite
  • Marteles, Diana
  • Hurtado-Guerrero, Ramón
  • Pardo, Julián
  • Santiago, Llipsy
  • González-Ramírez, Andrés Manuel
  • Macías-León, Javier
  • García-García, Ana
  • Taleb, Víctor
  • Lira-Navarrete, Erandi
  • Paño-Pardo, José Ramón
  • Ruíz, Héctor
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the zoonotic causative agent of coronavirus disease 2019 (COVID-19) that has caused a pandemic situation with millions of infected humans worldwide. Among domestic animals, there have been limited studies regarding the transmissibility and exposure to the infection in natural conditions. Some animals are exposed andor susceptible to SARS-CoV-2 infection, such as cats, ferrets and dogs. By contrast, there is no information about the susceptibility of ruminants to SARS-CoV-2. This study tested the antibody response in 90 ovine pre-pandemic serum samples and 336 sheep serum samples from the pandemic period (June 2020 to March 2021). In both cases, the animals were in close contact with a veterinary student community composed of more than 700 members. None of the serum samples analyzed was seroreactive based on an enzyme-linked immunosorbent assay (ELISA) using the receptor-binding domain (RBD) of the spike antigen. In this sense, no statistical difference was observed compared to the pre-pandemic sheep. Our results suggest that it seems unlikely that sheep could play a relevant role in the epidemiology of SARS-CoV-2 infection. This is the first study to report the absence of evidence of sheep exposure to SARS-CoV-2 in natural conditions.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Serological evidence of SARS-CoV-2 and co-infections in stray cats in Spain

  • Villanueva-Saz, S.
  • Giner, J.
  • Tobajas, A.P.
  • Pérez, M.D.
  • González-Ramírez, A.M.
  • Macías-León, J.
  • González, A.
  • Verde, M.
  • Yzuel, A.
  • Hurtado-Guerrero, R.
  • Pardo, J.
  • Santiago, L.
  • Paño-Pardo, J.R.
  • Ruíz, H.
  • Lacasta, D.M.
  • Sánchez, L.
  • Marteles, D.
  • Gracia, A.P.
  • Fernández, A.
A new coronavirus known as SARS-CoV-2 emerged in Wuhan in 2019 and spread rapidly to the rest of the world causing the pandemic disease named coronavirus disease of 2019 (COVID-19). Little information is known about the impact this virus can cause upon domestic and stray animals. The potential impact of SARS-CoV-2 has become of great interest in cats due to transmission among domestic cats and the severe phenotypes described recently in a domestic cat. In this context, there is a public health warning that needs to be investigated in relation with the epidemiological role of this virus in stray cats. Consequently, in order to know the impact of the possible transmission chain, blood samples were obtained from 114 stray cats in the city of Zaragoza (Spain) and tested for SARS-CoV-2 and other selected pathogens susceptible to immunosuppression including Toxoplasma gondii, Leishmania infantum, feline leukaemia virus (FeLV) and feline immunodeficiency virus (FIV) from January to October 2020. Four cats (3.51%), based on enzyme-linked immunosorbent assay (ELISA) using the receptor binding domain (RBD) of Spike antigen, were seroreactive to SARS-CoV-2. T. gondii, L. infantum, FeLV and FIV seroprevalence was 12.28%, 16.67%, 4.39% and 19.30%, respectively. Among seropositive cats to SARS-CoV-2, three cats were also seropositive to other pathogens including antibodies detected against T. gondii and FIV (n = 1); T. gondii (n = 1); and FIV and L. infantum (n = 1). The subjects giving positive for SARS-CoV-2 were captured in urban areas of the city in different months: January 2020 (2/4), February 2020 (1/4) and July 2020 (1/4). This study revealed, for the first time, the exposure of stray cats to SARS-CoV-2 in Spain and the existence of concomitant infections with other pathogens including T. gondii, L. infantum and FIV, suggesting that immunosuppressed animals might be especially susceptible to SARS-CoV-2 infection.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Preserved efficacy of lyophilized SARS-CoV-2 mRNA vaccine incorporating novel ionizable lipids after one year at 25 °C

  • Mata, Elena
  • Broset, Esther
  • Matute, Carlos
  • Stoian, Andrei
  • Adame, Susana
  • Alejo, Teresa
  • López, Alexandre
  • Andrés, Beatriz
  • Heredero, Juan
  • de Miguel, Diego
  • Giménez-Warren, Javier
  • Lampaya, Verónica
  • Casabona, Diego
  • Calvo, Alba
  • Quincoces, Gema
  • Peñuelas, Iván
  • Gamazo, Carlos
  • Uranga, Iratxe
  • Peña, Natacha
  • Arias, Maykel
  • Pardo, Julián
  • Moreno, Bernardino
  • Badiola, Juan
  • Martínez-Oliván, Juan
  • Pérez-Herrán, Esther
mRNA vaccines have shown great efficacy against SARS-CoV-2, yet challenges remain in optimizing vaccine components to achieve enhanced immune response and vaccine stability. In this study, we developed CPVax-CoV, a new lyophilized mRNA vaccine that features novel thiolactone-based ionizable lipids and newly designed untranslated regions (UTRs) for enhanced expression. Incorporation of these optimized components into our vaccine candidate CPVax-CoV significantly improved immune responses in mice compared to commercially available mRNA vaccines. Moreover, lyophilized CPVax-CoV has proven to be thermostable, maintaining its biological activity for up to one year at 4 °C and 25 °C after lyophilization, overcoming the cold-chain limitations of current mRNA vaccines. This vaccine demonstrates protective efficacy against ancestral SARS-CoV-2 and the Omicron XBB variant, offering a scalable solution for global distribution and pandemic preparedness. These findings underscore the potential of this platform for future next-generation mRNA vaccine development.
e-cienciaDatos, Repositorio de Datos del Consorcio Madroño
Datos de investigación Set de datos (Dataset)

HEROES-SPA: Psychological support

  • Mediavilla Torres, Roberto
<p>HEROES is a longitudinal observational study that describes mental health outcomes among healthcare workers (HCWs) amidst the COVID-19 pandemic and explores their association with various exposures. The project involves over 20 countries worldwide, including Spain. The study protocol is available here: https://doi.org/10.1007%2Fs00127-021-02211-9.</p> <p>This dataset allows replication of the main models of the manuscript entitled "Use of psychological interventions among healthcare workers over the 2-year period following the COVID-19 pandemic: A longitudinal study", which has been accepted for publication in PlosONE (doi:10.1371/journal.pone.0292932). The information that it contains is in keeping with the European General Data Protection Regulation. The analytic code is also uploaded.</p>
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Impact of COVID-19 disease on placental histopathology. PLAXAVID study

  • Montáns Araújo, José
  • García Ruiz, Itziar
  • Garcia Aguilar, E.
  • Hidalgo Bermejo, F. J.
  • Suy Franch, Anna
  • Maiz, Nerea
COVID-19 disease; Placental histopathology, Malaltia COVID-19; Histopatologia placentària, Enfermedad COVID-19; Histopatología placentaria, Background: The impact of COVID-19 on pregnancy has been analyzed suggesting an increased risk of placental lesions that might lead to maternal and neonatal complications. However, the current published evidence is not conclusive because contradictory results. Methods: PLAXAVID is an observational, retrospective, histopathological, single-center study that aimed to evaluate the prevalence of vascular and inflammatory lesions in placental and umbilical cord samples of one hundred women infected by SARS-CoV-2 during pregnancy. Results: The histopathological analysis showed that in most of the placentas (77.8%) there were signs of maternal vascular malperfusion (MVM; primary endpoint). The most common MVM features were an accelerated villous maturation (37.4%), central villous infarcts (33.3%), and villous agglutination (46.5%). Fetal vascular malperfusion (FVM) was identified in 57.6% of samples, and the most frequent features were hyalinized avascular villi (38.4%), fetal vascular thrombi (20.2%) and umbilical cord at risk of partial obstruction (14.1%). Acute and chronic inflammatory pathology were noticed in 22.2% and 49.5% of placentas, respectively. No significant correlations were found between MVM presence and the time, duration, and severity of infection, nor with the duration of pregnancy. However, in critically ill patients, the pregnancy duration (p=0.008), newborn weight (p=0.003), and APGAR test scores (p<0.001) were significantly lower. The same trend was observed considering the presence of infection at the time of delivery and in preterm births. Conclusion: A very high percentage of placentas with vascular and/or inflammatory lesions was found in the analyzed cohort. Therefore, PLAXAVID study results supported that COVID-19 should be considered a risk factor during gestation and requires close monitoring of pregnancy., The study has been founded by ITF Research Pharma S.L.U. The Gesta-COVID19 was supported by a grant from Instituto de Salud Carlos III (ISCIII) (COV20/00188).
Docta Complutense
Datos de investigación Set de datos (Dataset)

RNA sequence of SARS-CoV-2

  • Alda, Irene
  • Quintana Benito, Jaime
  • Alda, Javier
RNA sequence of SARS-CoV-2 used for the computational analysis of the UV-inactivation process.
Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

A Multifunctionalized Potyvirus-Derived Nanoparticle That Targets and Internalizes into Cancer Cells

  • Truchado Martín, Daniel A.|||0000-0003-0448-0112
  • Juarez-Molina, María|||0009-0003-4649-1554
  • Rincon Crego, Sara
  • Zurita Crespo, Lucía|||0009-0008-3722-0855
  • Tomé Amat, Jaime María|||0000-0003-4442-3649
  • Lorz, Corina|||0000-0001-8214-9076
  • Ponz Ascaso, Fernando|||0000-0003-0344-4363
Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

A nanobiotechnological approach to control non-persistent aphid-transmitted plant viruses, based on functionalized virus-like particles

  • Moreno Lozano, Aránzazu|||0000-0003-1394-3123
  • Ferriol Safont, Inmaculada|||0000-0003-0111-7537
  • Zurita Crespo, Lucía|||0009-0008-3722-0855
  • Plaza Martín, María|||0000-0003-3937-9639
  • Galán Cubero, María Del Rocío|||0009-0005-8168-8090
  • Urbano Bernabé, Adriana|||0009-0003-0508-8216
  • Fereres Castiel, Alberto|||0000-0001-6012-3270
  • Ponz Ascaso, Fernando|||0000-0003-0344-4363
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gestation and COVID-19, clinical and microbiological observational study (Gesta-COVID19)

  • Suy, Anna|||0000-0003-2987-6105
  • Garcia-Ruiz, Itziar|||0000-0002-0717-7795
  • Carbonell-Socias, Melchor|||0000-0002-8165-6751
  • García Manau, Pablo|||0000-0002-2415-1626
  • Rodó, Carlota|||0000-0001-8801-5677
  • Maiz, Nerea|||0000-0001-8261-6383
  • Sulleiro, Elena|||0000-0002-9783-6060
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Fernández Hidalgo, Nuria|||0000-0002-2115-344X
  • Frick, Marie Antoinette|||0000-0002-2553-5090
  • Camba, Fatima
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Carreras Moratonas, Elena|||0000-0003-3471-7248
The Coronavirus Disease 2019 (COVID-19) is a novel disease which has been having a worldwide affect since December 2019. Evidence regarding the effects of SARS-CoV-2 during pregnancy is conflicting. The presence of SARS-CoV-2 has been demonstrated in biological samples during pregnancy (placenta, umbilical cord or amniotic fluid); however, maternal and fetal effects of the virus are not well known. Descriptive, multicentre, longitudinal, observational study in eight tertiary care hospitals throughout Spain, that are referral centres for pregnant women with COVID-19. All pregnant women with positive SARS-CoV-2 real-time reverse transcriptase polymerase chain reaction during their pregnancy or 14 days preconception and newborns born to mothers infected with SARS-CoV-2 will be included. They will continue to be followed up until 4 weeks after delivery. The aim of the study is to investigate both the effect of COVID-19 on the pregnancy, and the effect of the pregnancy status with the evolution of the SARS-CoV-2 disease. Other samples (faeces, urine, serum, amniotic fluid, cord and peripheral blood, placenta and breastmilk) will be collected in order to analyse whether or not there is a risk of vertical transmission and to describe the behaviour of the virus in other fluids. Neonates will be followed until 6 months after delivery to establish the rate of neonatal transmission. We aim to include 150 pregnant women and their babies. Ethics approval will be obtained from all the participating centres. There is little information known about COVID-19 and its unknown effects on pregnancy. This study will collect a large number of samples in pregnant women which will allow us to demonstrate the behaviour of the virus in pregnancy and postpartum in a representative cohort of the Spanish population.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mental health impact of the first wave of COVID-19 pandemic on Spanish healthcare workers, A large cross-sectional survey

  • Alonso, Jordi|||0000-0001-8627-9636
  • Vilagut, Gemma|||0000-0002-3714-226X
  • Mortier, Philippe|||0000-0003-2113-6241
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Alayo, Itxaso|||0000-0002-7333-3450
  • Aragón-Peña, Andrés
  • Aragonès, Enric|||0000-0002-5245-4667
  • Campos Martorell, Mireia
  • Cura González, Isabel del|||0000-0002-3931-5304
  • Emparanza, José I.
  • Espuga Jordana, Meritxell|||0000-0003-2723-2699
  • Forjaz, M. Joao
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Haro Abad, Josep Maria|||0000-0002-3984-277X
  • López Fresneña, Nieves
  • Salázar, Alma D. Martínez de
  • Molina, Juan D.|||0000-0001-8561-8130
  • Ortí-Lucas, Rafael M.|||0000-0003-2211-7413
  • Parellada, Mara|||0000-0001-7977-3601
  • Pelayo-Terán, José Maria|||0000-0001-9711-2874
  • Pérez-Zapata, Aurora
  • Pijoan, José I.
  • Plana, Nieves
  • Puig Reixach, Maria Teresa|||0000-0003-1402-7653
  • Rius i Gibert, Maria Cristina|||0000-0001-5189-6503
  • Rodríguez-Blázquez, Carmen
  • Sanz, Ferran|||0000-0002-7534-7661
  • Serra, Consol|||0000-0001-8337-8356
  • Kessler, Ronald|||0000-0003-4831-2305
  • Bruffaerts, Ronny|||0000-0002-0330-3694
  • Vieta, Eduard|||0000-0002-0548-0053
  • Pérez Solà, Víctor|||0000-0002-5825-2337
Los profesionales sanitarios son vulnerables al impacto negativo en salud mental de la pandemia COVID-19. Evaluamos la prevalencia de trastornos mentales y factores asociados durante la primera oleada de la pandemia en sanitarios españoles. Métodos: Se invitó a todos los trabajadores de 18 instituciones sanitarias espanolas (6 CCAA) a encuestas en línea evaluando características individuales, estado de infección y exposición a COVID-19 y salud mental (5 Mayo --- 7 Septiembre, 2020). Reportamos: probables trastornos mentales actuales (Trastorno depresivo mayor TDD [PHQ-8≥10], Trastorno de ansiedad generalizada TAG [GAD-7≥10], Ataques de pánico, Trastorno de estrés postraumático TEP [PCL-5≥7]; y Trastorno por uso de sustancias TUS [CAGE-AID≥2]. La interferencia funcional grave (Escala de Discapacidad de Sheehan) identificó los probables trastornos "discapacitantes". Resultados: Participaron 9.138 sanitarios. Prevalencia de cribado positivo: 28,1% TDD; 22,5% TAG, 24,0% Pánico; 22,2% PTE; y 6,2% TUS. En general, el 45,7% presentó algún trastorno mental actual y el 14,5% algún trastorno discapacitante. Los sanitarios con trastornos mentales previos tuvieron el doble de prevalencia que aquellos sin patología mental previa. Ajustando por todas las variables, el trastorno mental incapacitante se asoció positivamente con: trastornos previos(TUS: OR=5.74; 95%CI 2.53-13.03; Ánimo: OR=3.23; 95%CI:2.27-4.60; Ansiedad: OR=3,03; IC95%: 2,53-3,62); edad 18-29 a ̃nos (OR=1,36; IC 95%: 1,02-1,82); atender "siempre" a pacientesCOVID-19 (OR=5,19; IC 95%: 3,61-7,46), género femenino (OR=1,58; IC 95%: 1,27-1,96) y haber estado en cuarentena o aislado (OR=1,60; IC 95%: 1,31-1,95). Conclusiones: Uno de cada 7 sanitarios españoles presentaron un probable trastorno mental discapacitante durante la primera oleada de COVID-19. Aquéllos con trastornos mentales alguna vez antes de la pandemia, los que están expuestos con frecuencia a pacientes con COVID-19, los infectados o en cuarentena / aislados, las mujeres y las enfermeras auxiliares deben considerarse grupos que necesitan seguimiento y apoyo de su salud mental.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

On the use of entropy issues to evaluate and control the transients in some epidemic models

  • De la Sen, Manuel|||0000-0001-9320-9433
  • Nistal, Raul|||0000-0003-2196-1989
  • Ibeas, Asier|||0000-0001-5094-3152
  • Garrido, Aitor J.|||0000-0002-3016-4976
This paper studies the representation of a general epidemic model by means of a first-order differential equation with a time-varying log-normal type coefficient. Then the generalization of the first-order differential system to epidemic models with more subpopulations is focused on by introducing the inter-subpopulations dynamics couplings and the control interventions information through the mentioned time-varying coefficient which drives the basic differential equation model. It is considered a relevant tool the control intervention of the infection along its transient to fight more efficiently against a potential initial exploding transmission. The study is based on the fact that the disease-free and endemic equilibrium points and their stability properties depend on the concrete parameterization while they admit a certain design monitoring by the choice of the control and treatment gains and the use of feedback information in the corresponding control interventions. Therefore, special attention is paid to the evolution transients of the infection curve, rather than to the equilibrium points, in terms of the time instants of its first relative maximum towards its previous inflection time instant. Such relevant time instants are evaluated via the calculation of an "ad hoc" Shannon's entropy. Analytical and numerical examples are included in the study in order to evaluate the study and its conclusions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

On confinement and quarantine concerns on an seiar epidemic model with simulated parameterizations for the covid-19 pandemic

  • De la Sen, Manuel|||0000-0001-9320-9433
  • Ibeas, Asier|||0000-0001-5094-3152
  • Agarwal, Ravi P.|||0000-0003-0075-1704
This paper firstly studies an SIR (susceptible-infectious-recovered) epidemic model without demography and with no disease mortality under both total and under partial quarantine of the susceptible subpopulation or of both the susceptible and the infectious ones in order to satisfy the hospital availability requirements on bed disposal and other necessary treatment means for the seriously infectious subpopulations. The seriously infectious individuals are assumed to be a part of the total infectious being described by a time-varying proportional function. A time-varying upper-bound of those seriously infected individuals has to be satisfied as objective by either a total confinement or partial quarantine intervention of the susceptible subpopulation. Afterwards, a new extended SEIR (susceptible-exposed-infectious-recovered) epidemic model, which is referred to as an SEIAR (susceptible-exposed-symptomatic infectious-asymptomatic infectious-recovered) epidemic model with demography and disease mortality is given and focused on so as to extend the above developed ideas on the SIR model. A proportionally gain in the model parameterization is assumed to distribute the transition from the exposed to the infectious into the two infectious individuals (namely, symptomatic and asymptomatic individuals). Such a model is evaluated under total or partial quarantines of all or of some of the subpopulations which have the effect of decreasing the number of contagions. Simulated numerical examples are also discussed related to model parameterizations of usefulness related to the current COVID-19 pandemic outbreaks.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Supervision of the infection in an si (Si-rc) epidemic model by using a test loss function to update the vaccination and treatment controls

  • De la Sen, Manuel|||0000-0001-9320-9433
  • Ibeas, Asier|||0000-0001-5094-3152
  • Nistal, Raul|||0000-0003-2196-1989
  • Alonso-Quesada, Santiago|||0000-0002-4724-7583
  • Garrido, Aitor J|||0000-0002-3016-4976
This paper studies and proposes some supervisory techniques to update the vaccination and control gains through time in a modified SI (susceptible-infectious) epidemic model involving the susceptible and subpopulations. Since the presence of linear feedback controls are admitted, a compensatory recovered (or immune) extra subpopulation is added to the model under zero initial conditions to deal with the recovered subpopulations transferred from the vaccination and antiviral/antibiotic treatment on the susceptible and the infectious, respectively. Therefore, the modified model is referred to as an SI(RC) epidemic model since it integrates the susceptible, infectious and compensatory recovered subpopulations. The defined time-integral supervisory loss function can evaluate weighted losses involving, in general, both the susceptible and the infectious subpopulations. It is admitted, as a valid supervisory loss function, that which involves only either the infectious or the susceptible subpopulations. Its concrete definition involving only the infectious is related to the Shannon information entropy. The supervision problem is basically based on the implementation of a parallel control structure with different potential control gains to be judiciously selected and updated through time. A higher decision level structure of the supervisory scheme updates the appropriate active controller (i.e., that with the control gain values to be used along the next time window), as well as the switching time instants. In this way, the active controller is that which provides the best associated supervisory loss function along the next inter-switching time interval. Basically, a switching action from one active controller to another one is decided as a better value of the supervisory loss function is detected for distinct controller gain values to the current ones.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The four horsemen of a viral Apocalypse, The pathogenesis of SARS-CoV-2 infection (COVID-19)

  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Mur, Isabel|||0000-0001-7660-8483
  • Pomar, Virginia|||0000-0002-8473-5834
  • Corominas, Hèctor|||0000-0002-7738-6787
  • Casademont i Pou, Jordi|||0000-0002-8100-1827
  • Benito, Natividad|||0000-0001-6410-013X
The pathogenesis of coronavirus disease 2019 (COVID-19) may be envisaged as the dynamic interaction between four vicious feedback loops chained or happening at once. These are the viral loop, the hyperinflammatory loop, the non-canonical renin-angiotensin system (RAS) axis loop, and the hypercoagulation loop. Severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 lights the wick by infecting alveolar epithelial cells (AECs) and downregulating the angiotensin converting enzyme-2 (ACE2)/angiotensin (Ang-1-7)/Mas1R axis. The viral feedback loop includes evading the host's innate response, uncontrolled viral replication, and turning on a hyperactive adaptative immune response. The inflammatory loop is composed of the exuberant inflammatory response feeding back until exploding in an actual cytokine storm. Downregulation of the ACE2/Ang-(1-7)/Mas1R axis leaves the lung without a critical defense mechanism and turns the scale to the inflammatory side of the RAS. The coagulation loop is a hypercoagulable state caused by the interplay between inflammation and coagulation in an endless feedback loop. The result is a hyperinflammatory and hypercoagulable state producing acute immune-mediated lung injury and eventually, adult respiratory distress syndrome.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

  • Bastard, Paul|||0000-0002-5926-8437
  • Rosen, Lindsey|||0000-0001-5894-3878
  • Zhang, Qian|||0000-0002-9040-3289
  • Michailidis, Eleftherios|||0000-0002-9907-4346
  • Hoffmann, Hans-Heinrich|||0000-0003-0554-0244
  • Zhang, Yu|||0000-0002-0332-0013
  • Dorgham, Karim|||0000-0001-9539-3203
  • Philippot, Quentin
  • Rosain, Jérémie|||0000-0002-2822-161X
  • Béziat, Vivien|||0000-0002-4020-824X
  • Manry, Jeremy|||0000-0001-5998-2051
  • Shaw, Elana|||0000-0001-9265-8026
  • Haljasmägi, Liis|||0000-0001-7162-9808
  • Peterson, Pärt|||0000-0001-6755-791X
  • Lorenzo, Lazaro|||0000-0001-6648-8684
  • Bizien, Lucy|||0000-0001-9163-9122
  • Trouillet-Assant, Sophie|||0000-0001-6439-4705
  • Dobbs, Kerry|||0000-0002-3432-3137
  • Almeida de Jesus, Adriana
  • Belot, Alexandre|||0000-0003-4902-5332
  • Kallaste, Anne|||0000-0002-7492-667X
  • Catherinot, Emilie
  • Tandjaoui-Lambiotte redondo, Yacine|||0000-0003-1123-4788
  • Le Pen, Jérémie|||0000-0001-7025-9526
  • Kerner, Gaspard|||0000-0003-0146-9428
  • Bigio, Benedetta|||0000-0001-7291-5638
  • Seeleuthner, Yoann|||0000-0002-1878-8567
  • Yang, Rui|||0000-0003-4427-2158
  • Bolze, Alexandre|||0000-0001-7399-2766
  • Spaan, András|||0000-0001-5981-7259
  • Delmonte, Ottavia M.
  • Abers, Michael S.
  • Aiuti, Alessandro|||0000-0002-5398-1717
  • Casari, Giorgio|||0000-0002-0115-8980
  • Lampasona, Vito|||0000-0001-5162-8445
  • Piemonti, Lorenzo|||0000-0002-2172-2198
  • Ciceri, Fabio|||0000-0003-0873-0123
  • Bilguvar, Kaya|||0000-0002-7313-7652
  • Lifton, Richard P.
  • Vasse, Marc
  • Smadja, David M.
  • Migaud, Mélanie|||0000-0003-3062-1214
  • Hadjadj, Jérome|||0000-0002-2520-3272
  • Terrier, Benjamin|||0000-0001-6612-7336
  • Duffy, Darragh|||0000-0002-8875-2308
  • Quintana-Murci, Lluis|||0000-0003-2429-6320
  • van de Beek, Diederik|||0000-0002-4571-044X
  • Roussel, Lucie|||0000-0001-5355-702X
  • Vinh, Donald C.|||0000-0003-1347-7767
  • Tangye, Stuart|||0000-0002-5360-5180
  • Haerynck, Filomeen|||0000-0001-9161-7361
  • Dalmau, David|||0000-0003-1936-478X
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Brodin, Petter|||0000-0002-8103-0046
  • Nussenzweig, Michel|||0000-0003-0592-8564
  • Boisson-Dupuis, Stephanie|||0000-0002-7115-116X
  • Rodríguez-Gallego, Carlos|||0000-0002-4344-8644
  • Vogt, Guillaume
  • Mogensen, Trine Hyrup|||0000-0002-1853-9704
  • Oler, Andrew J.|||0000-0002-6310-0434
  • Gu, Jingwen
  • Burbelo, Peter D.|||0000-0003-1717-048X
  • Cohen, Jeffrey I.|||0000-0003-0238-7176
  • Biondi, Andrea
  • Bettini, Laura Rachele|||0000-0002-0280-1704
  • D'Angio, Mariella|||0000-0001-7889-8576
  • Bonfanti, Paolo|||0000-0001-7289-8823
  • Rossignol, Patrick
  • Mayaux, Julien
  • Rieux-Laucat, Frédéric|||0000-0001-7858-7866
  • Husebye, Eystein Sverre|||0000-0002-7886-2976
  • Fusco, Francesca
  • Ursini, Matilde Valeria
  • Imberti, Luisa|||0000-0002-2075-8391
  • Sottini, Alessandra
  • Paghera, Simone
  • Quiros-Roldan, Eugenia
  • Rossi, Camillo
  • Castagnoli, Riccardo|||0000-0003-0029-9383
  • Montagna, Daniela
  • Licari, Amelia|||0000-0002-1773-6482
  • Marseglia, Gian Luigi|||0000-0003-3662-0159
  • Duval, Xavier
  • Ghosn, Jade
  • Tsang, John S.|||0000-0003-3186-3047
  • Goldbach-Mansky, Raphaela|||0000-0001-7865-5769
  • Kisand, Kai|||0000-0002-5426-4648
  • Lionakis, Michail S.
  • Puel, Anne|||0000-0003-2603-0323
  • Zhang, Shein-Ying
  • Holland, Steven|||0000-0003-3207-5464
  • Gorochov, Guy|||0000-0003-2097-9677
  • Jouanguy, Emmanuelle|||0000-0002-7358-9157
  • Rice, Charles M.|||0000-0003-3087-8079
  • Cobat, Aurélie|||0000-0001-7209-6257
  • Notarangelo, Luigi|||0000-0002-8335-0262
  • Abel, Laurent|||0000-0001-7016-6493
  • Su, Helen C.|||0000-0002-5582-9110
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-w (IFN-w) (13 patients), against the 13 types of IFN-a (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

  • Zhang, Qian|||0000-0002-9040-3289
  • Bastard, Paul|||0000-0002-5926-8437
  • Liu, Zhiyong|||0000-0002-6930-5879
  • Le Pen, Jérémie|||0000-0001-7025-9526
  • Moncada-Velez, Marcela|||0000-0002-3073-5345
  • Chen, Jie|||0000-0002-5354-4170
  • Ogishi, Masato|||0000-0003-2421-7389
  • Sabli, Ira K. D.|||0000-0002-0170-2990
  • Hodeib, Stephanie|||0000-0002-5978-6189
  • Korol, Cecilia|||0000-0002-0023-8823
  • Rosain, Jérémie|||0000-0002-2822-161X
  • Bilguvar, Kaya|||0000-0002-7313-7652
  • Ye, Junqiang
  • Bolze, Alexandre|||0000-0001-7399-2766
  • Bigio, Benedetta|||0000-0001-7291-5638
  • Yang, Rui|||0000-0003-4427-2158
  • Arias, Andrés Augusto|||0000-0002-9478-8403
  • Zhou, Qinhua|||0000-0002-5112-3727
  • Zhang, Yu|||0000-0002-0332-0013
  • Onodi, Fanny
  • Korniotis, Sarantis
  • Karpf, Léa
  • Philippot, Quentin
  • Chbihi, Marwa|||0000-0002-2771-851X
  • Bonnet-Madin, Lucie|||0000-0002-9848-3287
  • Dorgham, Karim|||0000-0001-9539-3203
  • Smith, Nikaïa|||0000-0002-0202-612X
  • Schneider, William M.|||0000-0001-9407-6118
  • Razooky, Brandon S.|||0000-0002-5263-1512
  • Hoffmann, Hans-Heinrich|||0000-0003-0554-0244
  • Michailidis, Eleftherios|||0000-0002-9907-4346
  • Moens, Leen
  • Han, Ji Eun|||0000-0003-1112-9320
  • Lorenzo, Lazaro|||0000-0001-6648-8684
  • Bizien, Lucy|||0000-0001-9163-9122
  • Meade, Philip|||0000-0002-6754-7209
  • Neehus, Anna-Lena|||0000-0002-8573-6820
  • Ugurbil, Aileen Camille|||0000-0002-9450-3092
  • Corneau, Aurélien
  • Kerner, Gaspard|||0000-0003-0146-9428
  • Zhang, Peng|||0000-0002-6129-567X
  • Rapaport, Franck|||0000-0001-6553-2110
  • Seeleuthner, Yoann|||0000-0002-1878-8567
  • Manry, Jeremy|||0000-0001-5998-2051
  • Masson, cecile|||0000-0001-7870-7821
  • Schmitt, Yohann
  • Schlüter, Agatha|||0000-0001-6732-1528
  • Le Voyer, Tom|||0000-0002-7253-3135
  • Khan, Taushif|||0000-0002-7917-8965
  • Li, Juan|||0000-0002-1617-3294
  • Fellay, Jacques|||0000-0002-8240-939X
  • Roussel, Lucie|||0000-0001-5355-702X
  • Shahrooei, Mohammad
  • Alosaimi, Mohammed F.
  • Mansouri, Davood
  • Al-Saud, Haya
  • Al-Mulla, Fahd|||0000-0001-5409-3829
  • Almourfi, Feras|||0000-0002-5166-4662
  • Al-Muhsen, Saleh Zaid
  • Alsohime, Fahad|||0000-0002-4979-3895
  • Al Turki, Saeed|||0000-0001-7017-336X
  • Hasanato, Rana|||0000-0002-4697-2222
  • van de Beek, Diederik|||0000-0002-4571-044X
  • Biondi, Andrea
  • Bettini, Laura Rachele|||0000-0002-0280-1704
  • D'Angio, Mariella|||0000-0001-7889-8576
  • Bonfanti, Paolo|||0000-0001-7289-8823
  • Imberti, Luisa|||0000-0002-2075-8391
  • Sottini, Alessandra
  • Paghera, Simone
  • Quiros-Roldan, Eugenia
  • Rossi, Camillo
  • Oler, Andrew J.|||0000-0002-6310-0434
  • Tompkins, Miranda F.|||0000-0003-2941-7515
  • Alba, Camille|||0000-0002-0458-1629
  • Vandernoot, Isabelle
  • Goffard, Jean-Christope
  • Smits, Guillaume|||0000-0003-2845-6758
  • Migeotte, Isabelle
  • Haerynck, Filomeen|||0000-0001-9161-7361
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Martín Nalda, Andrea|||0000-0002-1715-153X
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
  • Morange, Pierre-Emmanuel|||0000-0002-9065-722X
  • Keles, Sevgi|||0000-0001-7344-8947
  • Ozcelik, Tayfun|||0000-0001-5937-1082
  • Kadriye, Kart Yaşar|||0000-0003-2963-4894
  • Senoglu, Sevtap|||0000-0003-4796-9583
  • Karabela, Şemsi Nur|||0000-0003-2562-3004
  • Rodríguez-Gallego, Carlos|||0000-0002-4344-8644
  • Novelli, Giuseppe|||0000-0002-7781-602X
  • Hraiech, Sami
  • Tandjaoui-Lambiotte redondo, Yacine|||0000-0003-1123-4788
  • Duval, Xavier
  • Laouénan, Cédric|||0000-0002-3681-6314
  • Foti, Giuseppe
  • Bellani, Giacomo
  • Citerio, Giuseppe|||0000-0002-5374-3161
  • Contro, Ernesto
  • Pesci, Alberto
  • Valsecchi, Maria Grazia
  • Cazzaniga, Marina
  • Abad Capa, Jorge|||0000-0002-8129-7859
  • Aguilera-Albesa, Sergio|||0000-0003-3540-1448
  • Akcan, Ozge Metin
  • Darazam, Ilad Alavi
  • Aldave, Juan C.
  • Ramos, Miquel Alfonso
  • Nadji, Seyed Alireza
  • Alkan, Gulsum
  • Allardet-Servent, Jerome
  • Allende-Martinez, Luis M.
  • Alsina Manrique, Laia|||0000-0002-3559-0018
  • Alyanakian, Marie-Alexandra
  • Amador Borrero, Blanca|||0000-0001-6170-8721
  • Amoura, Zahir
  • Antolí, Arnau
  • Arslan, Sevket
  • Assant, Sophie
  • Auguet, Teresa
  • Azot, Axelle
  • Bajolle, Fanny
  • Baldolli, Aurélie
  • Ballester, Maite
  • Feldman, Hagit Baris
  • Barrou, Benoit
  • Beurton, Alexandra
  • Bilbao, Agurtzane
  • Blanchard-Rohner, Geraldine
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Blandinières, Adeline
  • Blázquez-Gamero, Daniel|||0000-0001-6483-8329
  • Bloomfield, Marketa
  • Bolivar-Prados, Mireia|||0000-0002-8896-1150
  • Borie, Raphael
  • Bosteels, Cédric
  • Bousfiha, Ahmed A.
  • Bouvattier, Claire
  • Boyarchuk, Oksana|||0000-0002-1234-0040
  • Bueno, Maria Rita P.
  • Cáceres Agra, Juan José|||0000-0001-9003-261X
  • Calimli, Semra
  • Capra, Ruggero
  • Carrabba, Maria
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Caseris, Marion
  • Castelle, Martin
  • Castelli, Francesco|||0000-0001-9161-7804
  • Castillo de Vera, Martín
  • Castro, Mateus V.
  • Catherinot, Emilie
  • Chalumeau, Martin
  • Charbit, Bruno
  • Cheng, Matthew P.
  • Clavé i Civit, Pere|||0000-0002-0696-8560
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Codina, Anna
  • Colkesen, Fatih
  • Çölkesen, Fatma|||0000-0001-9545-5179
  • Comarmond, Cloé
  • Dalmau, David|||0000-0003-1936-478X
  • Darley, David Ross|||0000-0002-9721-101X
  • Dauby, Nicolas
  • Dauger, Stéphane
  • de Pontual, Loic
  • Dehban, Amin
  • Delplancq, Geoffroy
  • Demoule, Alexandre
  • Diehl, Jean-Luc
  • Dobbelaere, Stephanie
  • Durand, Sophie
  • Eldars, Waleed
  • Elgamal, Mohamed
  • Elnagdy, Marwa H.
  • Emiroglu, Melike|||0000-0003-1307-0246
  • Erdeniz, Emine Hafize
  • Erol Aytekin, Selma
  • Euvrard, Romain
  • Evcen, Recep
  • Fabio, Giovanna
  • Faivre, Laurence
  • Falck, Antonin
  • Fartoukh, Muriel
  • Faure, Morgane
  • Fernández Arquero, Miguel
  • Flores, Carlos|||0000-0001-5352-069X
  • Francois, Bruno
  • Fumadó, Victoria
  • Fusco, Francesca
  • García Solis, Blanca|||0000-0002-3718-2560
  • Gaussem, Pascale
  • Gil-Herrera, Juana|||0000-0002-2297-9665
  • Gilardin, Laurent|||0000-0001-9212-0859
  • Girona-Alarcón, Mònica|||0000-0002-2752-7481
  • Gok, Funda
  • González Montelongo, Rafaela|||0000-0001-9022-8663
  • Guerder, Antoine
  • Gul, Yahya
  • Guner, Sukru Nail
  • Gut, Marta|||0000-0002-4063-7159
  • Hadjadj, Jérôme
  • Halwani, Rabih|||0000-0002-6516-7771
  • Hammarström, Lennart|||0000-0002-8635-9609
  • Nevin, Hatipoglu
  • Hernandez-Brito, Elisa|||0000-0002-8435-6885
  • Heijmans, Cathérine
  • Holanda-Peña, María Soledad
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
  • Hoste, Levi
  • Hoste, Eric
  • Humbert, Linda
  • Iglesias, Alejandro D.
  • Íñigo-Campos, Antonio|||0000-0003-1571-0454
  • Jamme, Matthieu
  • Arranz, María Jesús|||0000-0002-6757-9198
  • Jordán García, Iolanda|||0000-0002-2041-4425
  • Jorens, Philippe
  • Kanat, Fikret
  • Kapakli, Hasan
  • Kara, Iskender
  • Karbuz, Adem
  • Kendir Demirkol, Yasemin
  • Klocperk, Adam
  • Król, Zbigniew J.
  • Kuentz, Paul
  • Kwan, Mike Yat Wah|||0000-0002-1476-9625
  • Lagier, Jean-Christophe
  • Lambrecht, Bart N.
  • Lau, Yu Lung|||0000-0002-4780-0289
  • Le Bourgeois, Fleur
  • Leo, Yee-Sin
  • Leon Lopez, Rafael|||0000-0002-8102-9520
  • Leung, Daniel|||0000-0002-9360-6233
  • Levin, Michael|||0000-0003-2767-6919
  • Levy, Michael
  • Lévy, Romain
  • Li, Zhi
  • Linglart, Agnès|||0000-0003-3455-002X
  • Loeys, Bart
  • Lorenzo-Salazar, José Miguel|||0000-0002-5135-2861
  • Louapre, Céline
  • Lubetzki, Catherine
  • Luyt, Charles-Edouard|||0000-0001-7424-2705
  • Lye, David C.
  • Marjani, Majid
  • Marquez Pereira, Jesús
  • Martínez Pueyo, David
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Marzana, Iciar
  • Mathian, Alexis|||0000-0002-7653-6528
  • Matos, Larissa R. B.
  • Matthews, Gail V.
  • Mayaux, Julien
  • Mège, Jean-Louis
  • Melki, Isabelle
  • Meritet, Jean-François
  • Meyts, Isabelle|||0000-0003-1214-0302
  • Mezidi, Mehdi
  • Millereux, Maude
  • Mirault, Tristan
  • Mircher, Clotilde
  • Mirsaeidi, Mehdi
  • Montesdeoca Melián, Abián|||0000-0002-9158-2127
  • Morales Martínez, Antonio
  • Mordacq, Clémence
  • Morelle, Guillaume|||0000-0001-6511-1674
  • Mouly, Stéphane
  • Muñoz-Barrera, Adrián|||0000-0002-1561-5898
  • Naesens, Leslie
  • Nafati, Cyril
  • Farela Neves, João
  • FP. Ng, Lisa|||0000-0003-4071-5222
  • Novoa Medina, Yeray|||0000-0002-9564-0654
  • Nuñez Cuadros, Esmeralda|||0000-0003-1938-1678
  • Ocejo-Vinyals, J. Gonzalo|||0000-0003-2245-4639
  • Orbak, Zerrin
  • Oualha, Mehdi
  • Pan-Hammarström, Qiang|||0000-0003-1990-8804
  • Parizot, Christophe
  • Pascreau, Tiffany
  • Paz-Artal, Estela|||0000-0002-0646-2375
  • Pellegrini, Sandra
  • Perez de Diego, Rebeca|||0000-0001-8426-8765
  • Philippe, Aurélien
  • Planas-Serra, Laura|||0000-0002-2586-0897
  • Ploin, Dominique
  • Poissy, Julien|||0000-0001-6017-5353
  • Poncelet, Géraldine
  • Pouletty, Marie
  • Quentric, Paul
  • Raoult, Didier
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Reisli, Ismail
  • Ricart, Pilar|||0000-0003-0067-9132
  • Richard, Jean-Christophe
  • Rivet, Nadia
  • Rivière, Jacques G.|||0000-0003-1055-2063
  • Rocamora Blanch, Gemma|||0000-0003-4427-9384
  • Rodrigo Gonzalo de Líria, Carlos|||0000-0003-1140-2585
  • Rodríguez-Palmero, Agustí|||0000-0002-4141-5515
  • Romero, Carolina Soledad|||0000-0002-2325-4463
  • Rothenbuhler, Anya
  • Rozenberg, Flore|||0000-0001-7212-2021
  • Ruiz del Prado, María Yolanda
  • Sabater-Riera, Joan|||0000-0003-1246-5537
  • Sánchez, Oliver
  • Sánchez Ramón, Silvia|||0000-0001-9585-6167
  • Schmidt, Matthieu|||0000-0002-2931-4412
  • Schweitzer, Cyril E.
  • Scolari, Francesco
  • Sediva, Anna
  • Seijo, Luis M.
  • Sene, Damien
  • Seppänen, Mikko R. J.|||0000-0001-9733-3650
  • Serra Ilovich, Alex
  • Shahrooei, Mohammed
  • Slabbynck, Hans
  • Smadja, David M.
  • Sobh, Ali
  • Solanich, Xavier|||0000-0002-2572-2187
  • Dalgard, Clifton L.|||0000-0003-2025-8239
  • Milner, Joshua D.
  • Vinh, Donald C.|||0000-0003-1347-7767
  • Mogensen, Trine Hyrup|||0000-0002-1853-9704
  • Marr, Nico|||0000-0002-1927-7072
  • Spaan, András|||0000-0001-5981-7259
  • Boisson, Bertrand|||0000-0001-5240-3555
  • Boisson-Dupuis, Stephanie|||0000-0002-7115-116X
  • Bustamante, Jacinta|||0000-0002-3439-2482
  • Puel, Anne|||0000-0003-2603-0323
  • Ciancanelli, Michael J.|||0000-0002-4623-852X
  • Maniatis, Tom|||0000-0002-2722-8633
  • Soumelis, Vassili
  • Amara, Ali
  • Nussenzweig, Michel|||0000-0003-0592-8564
  • Garcia-Sastre, Adolfo|||0000-0002-6551-1827
  • Krammer, Florian|||0000-0003-4121-776X
  • Pujol, Aurora|||0000-0002-9606-0600
  • Duffy, Darragh|||0000-0002-8875-2308
  • Lifton, Richard P.
  • Zhang, Shen-Ying|||0000-0002-9449-3672
  • Gorochov, Guy|||0000-0003-2097-9677
  • Béziat, Vivien|||0000-0002-4020-824X
  • Jouanguy, Emmanuelle|||0000-0002-7358-9157
  • Sancho Shimizu, Vanessa|||0000-0002-3519-0727
  • Rice, Charles M.|||0000-0003-3087-8079
  • Abel, Laurent|||0000-0001-7016-6493
  • Notarangelo, Luigi|||0000-0002-8335-0262
  • Cobat, Aurélie|||0000-0001-7209-6257
  • Su, Helen C.|||0000-0002-5582-9110
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
  • Zhang, S. Y.
  • Blanch, G. R.
  • Riera, J. S.
  • Ballester Devis, Maria|||0000-0002-5413-4640
  • van Braeckel, E.
  • Vincent, Amy|||0000-0002-0360-6644
  • Zatz, Mayana|||0000-0003-3970-8025
  • Vélez-Santamaria, V.
  • Toubiana, J.
  • Vilaire, M. E.
  • Ursini, Matilde Valeria
  • Perez de Diego, Rebeca|||0000-0001-8426-8765
  • Van Den Rym, Ana
  • Yosunkaya, A.
  • Thy, M.
  • van Agtmael, Michiel
  • Bomers, Marije
  • Chouchane, Osoul
  • Geerlings, Suzanne
  • Goorhuis, Bram
  • Grobusch, Martin P.
  • Harris, Vanessa
  • Hermans, Sabine M.
  • Hovius, Joppe W.
  • Nellen, Jeaninne
  • Peters, Edgar
  • van der Poll, Tom
  • Prins, Jan M.
  • Reijnders, Tom
  • Schinkel, Michiel
  • Sigaloff, Kim
  • Stijnis, Cornelis S.
  • van der Valk, Marc
  • van Vugt, Michèle
  • Joost Wiersinga, W.
  • Algera, Anna Geke
  • van Baarle, Frank
  • Bos, Lieuwe D.|||0000-0003-2911-4549
  • Botta, Michela
  • de Bruin, Sanne
  • Bulle, Esther
  • Elbers, Paul
  • Fleuren, Lucas
  • Girbes, Armand
  • Hagens, Laura
  • Heunks, Leo
  • Horn, Janneke
  • van Mourik, Niels
  • Paulus, Frederique
  • Raasveld, Jorinde
  • Schultz, Marcus J.|||0000-0003-3969-7792
  • Smit, Marry
  • Stilma, Willemke|||0000-0002-7581-1321
  • Thoral, Patrick
  • Tsonas, Anissa M.
  • de Vries, Heder
  • Bax, Diane
  • Cloherty, Alex
  • Beudel, Martijn
  • Brouwer, Matthijs C.
  • Koning, Rutger|||0000-0003-3128-5072
  • Bogaard, H. J.
  • de Brabander, J.
  • de Bree, G.
  • Bugiani, Marianna
  • Geerts, Bart
  • Hollmann, Markus W.
  • Preckel, Benedikt
  • Veelo, Denise
  • Geijtenbeek, Theo
  • Hafkamp, Florianne
  • Hamann, Jorg
  • Hemke, Robert
  • de Jong, Menno D.
  • Schuurman, Alex
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Vlaar, Alexander P. J.
  • Wouters, Dorien
  • Zwinderman, Aeilko Having Koos
  • Aiuti, Alessandro|||0000-0002-5398-1717
  • Muhsen, Saleh Al
  • Anderson, Mark S.
  • Bogunovic, Dusan|||0000-0002-9277-3232
  • Itan, Yuval
  • Cirulli, Elizabeth
  • Barrett, Kelly Schiabor
  • Washington, Nicole
  • Bondarenko, Anastasiia
  • Brodin, Petter|||0000-0002-8103-0046
  • Bryceson, Yenan
  • Bustamante, Carlos D.|||0000-0002-4187-7920
  • Butte, Manish J.
  • Casari, Giorgio|||0000-0002-0115-8980
  • Chakravorty, Samya|||0000-0002-0236-3281
  • Christodoulou, John
  • Le Mestre, S.
  • Condino-Neto, Antonio|||0000-0002-1069-3117
  • Cooper, Megan A.
  • David, Alessia
  • DeRisi, Joseph L.
  • Desai, Murkesh
  • Drolet, Beth A.
  • Espinosa, Sara
  • Franco, Jose Luis
  • Gregersen, Peter K.|||0000-0003-1613-1518
  • Hagin, David|||0000-0003-2702-1031
  • Heath, Jim
  • Henrickson, Sarah E.
  • Hsieh, Elena
  • Imai, Kohsuke
  • Karamitros, Timokratis
  • Kisand, Kai|||0000-0002-5426-4648
  • Ku, Cheng-Lung
  • Ling, Yun
  • Lucas, Carrie L.
  • Marodi, Laszlo
  • Mironska, Kristina
  • Morio, Tomohiro
  • Novelli, Antonio
  • O'Farrelly, Cliona
  • Okada, Satoshi|||0000-0002-4622-5657
  • Planas, Anna Maria|||0000-0002-6147-1880
  • Prando, Carolina|||0000-0002-9570-9770
  • Quintana-Murci, Lluis|||0000-0003-2429-6320
  • Renia, Laurent
  • Renieri, Alessandra|||0000-0002-0846-9220
  • Sankaran, Vijay
  • Snow, Andrew|||0000-0002-8728-6691
  • Tangye, Stuart|||0000-0002-5360-5180
  • Turvey, Stuart
  • Uddin, Furkan
  • Uddin, Mohammed J.
  • Vazquez, Sara E.
  • von Bernuth, Horst
  • Zawadzki, Pawel
  • Jing, Huie|||0000-0001-6283-3452
  • Tung, W.
  • Meguro, K.
  • Shaw, E.
  • Tung, Wesley|||0000-0002-4577-3926
  • Shafer, S.
  • Zheng, L.
  • Zhang, Z.
  • Kubo, S.
  • Chauvin, S. D.
  • Shaw, Elana|||0000-0001-9265-8026
  • Lenardo, M.
  • Luthers, Christopher R.
  • Bauman, Bradly M.
  • Shafer, Samantha
  • Zheng, Lixin
  • Zhang, Zinan
  • Kubo, Satoshi
  • Chauvin, Samuel D.
  • Lenardo, Michael
  • Lack, Justin
  • Karlins, Eric
  • Hupalo, Daniel M.
  • Rosenberger, John
  • Sukumar, Gauthaman
  • Wilkerson, Matthew D.
  • Zhang, Xijun
Clinical outcome upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ranges from silent infection to lethal coronavirus disease 2019 (COVID-19). We have found an enrichment in rare variants predicted to be loss-of-function (LOF) at the 13 human loci known to govern Toll-like receptor 3 (TLR3)- and interferon regulatory factor 7 (IRF7)-dependent type I interferon (IFN) immunity to influenza virus in 659 patients with life-threatening COVID-19 pneumonia relative to 534 subjects with asymptomatic or benign infection. By testing these and other rare variants at these 13 loci, we experimentally defined LOF variants underlying autosomal-recessive or autosomal-dominant deficiencies in 23 patients (3.5%) 17 to 77 years of age. We show that human fibroblasts with mutations affecting this circuit are vulnerable to SARS-CoV-2. Inborn errors of TLR3- and IRF7-dependent type I IFN immunity can underlie life-threatening COVID-19 pneumonia in patients with no prior severe infection.
Dipòsit Digital de Documents de la UAB
Publicación

Severe manifestations of SARS-CoV-2 in children and adolescents, from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain

  • García-Salido, Alberto
  • de Carlos Vicente, Juan Carlos
  • Belda Hofheinz, Sylvia
  • Balcells Ramírez, Joan|||0000-0002-8341-6508
  • Slocker Barrio, Maria
  • Leóz Gordillo, Inés
  • Hernández Yuste, Alexandra
  • Guitart Pardellans, Carmina
  • Cuervas-Mons Tejedor, Maite
  • Huidobro Labarga, Beatriz
  • Vázquez Martínez, José Luís
  • Gutiérrez Jimeno, Míriam
  • Oulego-Erróz, Ignacio
  • Trastoy Quintela, Javier
  • Medina Monzón, Carmen
  • Medina Ramos, Laura
  • Holanda Peña, María Soledad
  • Gil-Antón, Javier
  • Sorribes Ortí, Clara
  • Flores González, José Carlos
  • Hernández Palomo, Rosa María
  • Sánchez Ganfornina, Inma
  • Fernández Romero, Emilia
  • García-Besteiro, María
  • López Herce, Jesús|||0000-0001-6105-9178
  • González Cortés, Rafael|||0000-0002-3259-7898
BACKGROUND: Multisystem inflammatory syndrome temporally associated with COVID-19 (MIS-C) has been described as a novel and often severe presentation of SARS-CoV-2 infection in children. We aimed to describe the characteristics of children admitted to Pediatric Intensive Care Units (PICUs) presenting with MIS-C in comparison with those admitted with SARS-CoV-2 infection with other features such as COVID-19 pneumonia. METHODS: A multicentric prospective national registry including 47 PICUs was carried out. Data from children admitted with confirmed SARS-CoV-2 infection or fulfilling MIS-C criteria (with or without SARS-CoV-2 PCR confirmation) were collected. Clinical, laboratory and therapeutic features between MIS-C and non-MIS-C patients were compared. RESULTS: Seventy-four children were recruited. Sixty-one percent met MIS-C definition. MIS-C patients were older than non-MIS-C patients (p = 0.002): 9.4 years (IQR 5.5-11.8) vs 3.4 years (IQR 0.4-9.4). A higher proportion of them had no previous medical history of interest (88.2% vs 51.7%, p = 0.005). Non-MIS-C patients presented more frequently with respiratory distress (60.7% vs 13.3%, p < 0.001). MIS-C patients showed higher prevalence of fever (95.6% vs 64.3%, p < 0.001), diarrhea (66.7% vs 11.5%, p < 0.001), vomits (71.1% vs 23.1%, p = 0.001), fatigue (65.9% vs 36%, p = 0.016), shock (84.4% vs 13.8%, p < 0.001) and cardiac dysfunction (53.3% vs 10.3%, p = 0.001). MIS-C group had a lower lymphocyte count (p < 0.001) and LDH (p = 0.001) but higher neutrophil count (p = 0.045), neutrophil/lymphocyte ratio (p < 0.001), C-reactive protein (p < 0.001) and procalcitonin (p < 0.001). Patients in the MIS-C group were less likely to receive invasive ventilation (13.3% vs 41.4%, p = 0.005) but were more often treated with vasoactive drugs (66.7% vs 24.1%, p < 0.001), corticosteroids (80% vs 44.8%, p = 0.003) and immunoglobulins (51.1% vs 6.9%, p < 0.001). Most patients were discharged from PICU by the end of data collection with a median length of stay of 5 days (IQR 2.5-8 days) in the MIS-C group. Three patients died, none of them belonged to the MIS-C group. CONCLUSIONS: MIS-C seems to be the most frequent presentation among critically ill children with SARS-CoV-2 infection. MIS-C patients are older and usually healthy. They show a higher prevalence of gastrointestinal symptoms and shock and are more likely to receive vasoactive drugs and immunomodulators and less likely to need mechanical ventilation than non-MIS-C patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg), A structured summary of a study protocol for a randomised placebo controlled trial

  • González, Raquel|||0000-0001-5487-801X
  • García-Otero, Laura
  • Pons-Duran, Clara|||0000-0002-9840-7559
  • Marbán-Castro, E.
  • Goncé, Anna|||0000-0002-0859-4750
  • Llurba, Elisa|||0000-0003-4048-6407
  • Del Mar Gil, M.
  • Rodríguez-Zambrano, Miguel Ángel
  • Chen, Haily
  • Ramírez, Máximo
  • Bardají, Azucena
  • Menendez, Clara
Objectives: The primary objectives of the study are: 1. To assess the effect of hydroxychloroquine (HCQ) in reducing SARS-CoV-2 viral shedding by PCR in infected pregnant women with mild symptoms. 2. To assess the efficacy of HCQ to prevent SARS-CoV-2 infection in pregnant women in contact with an infected or suspected case. 3. To evaluate the effect of HCQ in preventing the development of the COVID-19 disease in asymptomatic SARS-CoV-2-infected pregnant women. The secondary objectives are: 1. To determine the effect of HCQ on the clinical course and duration of the COVID-19 disease in SARS-CoV-2-infected pregnant women. 2. To determine the impact of HCQ on the risk of hospitalization and mortality of SARS-CoV-2-infected pregnant women. 3. To assess the safety and tolerability of HCQ in pregnant women. 4. To describe the clinical presentation of SARS-CoV-2 infection during pregnancy. 5. To describe the effects of maternal SARS-CoV-2 infection on pregnancy and perinatal outcomes by treatment group. 6. To determine the risk of vertical transmission (intra-utero and intra-partum) of SARS-CoV-2. Trial design: Randomized double-blind placebo-controlled two-arm multicentre clinical trial to evaluate the safety and efficacy of HCQ to prevent and/or minimize SARS-CoV-2 infection during pregnancy. Participants will be randomized to receive a 14-day oral treatment course of HCQ or placebo, ratio 1:1. Participants: Study population: pregnant women undergoing routine prenatal follow up or attending emergency units at the participating hospitals who report either symptoms/signs suggestive of COVID-19 disease or close contact with a suspected or confirmed COVID-19 case. Inclusion criteria Women will be invited to participate in the trial and sign an informed consent if they meet the following inclusion criteria. •Presenting with fever (≥37.5°C) and/or one mild symptom suggestive of COVID-19 disease (cough, dyspnoea, chills, odynophagia, diarrhoea, muscle pain, anosmia, dysgeusia, headache) OR being contact*of a SARS-CoV-2 confirmed or suspected case in the past 14 days •More than 12 weeks of gestation (dated by ultrasonography) •Agreement to deliver in the study hospitals Exclusion criteria •Known hypersensitivity to HCQ or other 4-amonoquinoline compounds •History of retinopathy of any aetiology •Concomitant use of digoxin, cyclosporine, cimetidine •Known liver disease •Clinical history of cardiac pathology including known long QT syndrome •Unable to cooperate with the requirements of the study •Participating in other intervention studies •Delivery onset (characterized by painful uterine contractions and variable changes of the cervix, including some degree of effacement and slower progression of dilatation up to 5 cm for first and subsequent labours) The study participants will be stratified by clinical presentation and SARS-CoV-2 PCR results. Assignment of participants to study groups will be as follows: •SARS-CoV-2-PCR confirmed, infected pregnant women: a. symptomatic (n=100) b. asymptomatic (n=100) •SARS-CoV-2 PCR negative pregnant women in contact*with a SARS-CoV-2-infected confirmed or suspected case (n=514).*The ECDC definition of close contact will be followed. The trial will be conducted in five hospitals in Spain: Hospital Clínic of Barcelona, Hospital Sant Joan de Déu and Hospital de la Santa Creu i Sant Pau, in Barcelona, and HM Puerta del Sur and Hospital Universitario de Torrejón, in Madrid. Intervention and comparator: Participants will be randomized to HCQ (400 mg/day for three days, followed by 200 mg/day for 11 days) or placebo (2 tablets for three days, followed by one tablet for 11 days). Main outcomes: The primary outcome is the number of PCR-confirmed infected pregnant women assessed from collected nasopharyngeal and oropharyngeal swabs at day 21 after treatment start (one week after treatment is completed). Randomisation: Allocation of participants to study arms will be done centrally by the trial's Sponsor (the Barcelona Institute for Global Health, ISGlobal) by block randomization. This method will ensure balanced allocation to both arms. The electronic CRF will automatically assign a study number to each participant, depending on her study group and recruitment site. Each number will be related to a treatment number, which assigns them to one of the study arms. Blinding (masking): Participants, caregivers, investigators and those assessing the outcomes will be blinded to group assignment. Study tablets (HCQ and placebo) will be identically packaged in small opaque bottles. Numbers to be randomised (sample size): This study requires 200 SARS-CoV-2 infected and 514 contact pregnant women, randomised 1:1 with 100 and 227 respectively in each study arm. Trial Status: Protocol version 1.0, from May 8th, 2020. Recruitment is ongoing (first patient recruited the 19th May 2020 and recruitment end anticipated by December 2020). Trial registration: EudraCT number: 2020-001587-29, registered 2 April 2020. Clinicaltrials.gov identifier: NCT04410562, retrospectively registered 1 June 2020. Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ICU-Acquired Pneumonia Is Associated with Poor Health Post-COVID-19 Syndrome

  • Martin-Loeches, Ignacio|||0000-0002-5834-4063
  • Motos, Ana|||0000-0002-3757-1232
  • Menéndez, Rosario
  • Gabarrús, Albert|||0000-0003-3492-1310
  • González Gutiérrez, Jessica|||0000-0002-6847-5315
  • Fernández Barat, Laia|||0000-0001-7528-9636
  • Ceccato, Adrian|||0000-0001-9454-062X
  • Pérez-Arnal, Raquel|||0000-0002-0041-8146
  • Garcia-Gasulla, Dario|||0000-0001-6732-5641
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Riera del Brio, Jordi|||0000-0002-1738-4448
  • Lorente, José Ángel
  • Peñuelas, Óscar
  • Bermejo Martín, Jesús F.|||0000-0002-7998-6268
  • Díaz Santos, Emilio|||0000-0003-3637-3821
  • Rodríguez, Alejandro
  • Barbé, Ferran|||0000-0002-2340-8928
  • Aguilera, Luciano
  • Amaya-Villar, Rosario
  • Barberà, Carme
  • Barberán, José
  • Blandino Ortiz, Aaron|||0000-0002-3184-6418
  • Bustamante-Munguira, Elena
  • Caballero, Jesús|||0000-0001-9005-9687
  • Carbajales, Cristina|||0000-0002-4496-5336
  • Carbonell, Nieves|||0000-0002-9149-0310
  • Catalán-González, Mercedes
  • Galbán, Cristóbal
  • Gumucio-Sanguino, Víctor D.
  • de la Torre, Maria Del Carmen
  • Díaz-Aparicio, Efren
  • Gallego, Elena
  • García Garmendia, José Luis|||0000-0003-1443-9236
  • Garnacho Montero, José|||0000-0003-2542-7601
  • Gómez García, José Manuel|||0009-0002-2154-8043
  • Jorge García, Ruth Noemí
  • Loza-Vázquez, Ana
  • Marín Corral, Judith|||0000-0003-1320-4427
  • Martínez de la Gándara, Amalia
  • Martínez Varela, Ignacio Y.|||0000-0002-2419-3914
  • Lopez Messa, Juan
  • Albaiceta, Guillermo M.|||0000-0002-9276-3253
  • Novo, Mariana Andrea
  • Peñasco, Yhivian
  • Ricart, Pilar|||0000-0003-0067-9132
  • Urrelo-Cerrón, Luis
  • Sánchez Miralles, Ángel
  • Sancho Chinesta, Susana
  • Socias, Lorenzo
  • Sole-Violan, Jordi|||0000-0002-0483-4470
  • Tamayo Lomas, Luis
  • Vidal-Cortés, Pablo|||0000-0003-0225-9975
  • Torres, Antoni|||0000-0002-8643-2167
Background. Some patients previously presenting with COVID-19 have been reported to develop persistent COVID-19 symptoms. While this information has been adequately recognised and extensively published with respect to non-critically ill patients, less is known about the incidence and factors associated with the characteristics of persistent COVID-19. On the other hand, these patients very often have intensive care unit-acquired pneumonia (ICUAP). A second infectious hit after COVID increases the length of ICU stay and mechanical ventilation and could have an influence on poor health post-COVID 19 syndrome in ICU-discharged patients. Methods: This prospective, multicentre, and observational study was carrid out across 40 selected ICUs in Spain. Consecutive patients with COVID-19 requiring ICU admission were recruited and evaluated three months after hospital discharge. Results: A total of 1255 ICU patients were scheduled to be followed up at 3 months; however, the final cohort comprised 991 (78.9%) patients. A total of 315 patients developed ICUAP (97% of them had ventilated ICUAP). Patients requiring invasive mechanical ventilation had more persistent post-COVID-19 symptoms than those who did not require mechanical ventilation. Female sex, duration of ICU stay, development of ICUAP, and ARDS were independent factors for persistent poor health post-COVID-19. Conclusions: Persistent post-COVID-19 symptoms occurred in more than two-thirds of patients. Female sex, duration of ICU stay, development of ICUAP, and ARDS all comprised independent factors for persistent poor health post-COVID-19. Prevention of ICUAP could have beneficial effects in poor health post-COVID-19.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells

  • Grau Expósito, Judith|||0000-0001-9350-2429
  • Perea, David|||0000-0003-1562-4740
  • Suppi, Marina|||0000-0002-9042-6659
  • Massana, Núria|||0000-0002-5403-3161
  • Vergara, Ander|||0000-0003-1926-0147
  • Soler, María José|||0000-0003-3621-0766
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Blanco, Julià|||0000-0002-2225-0217
  • García-Pérez, Javier|||0000-0003-0300-1810
  • Alcami, Jose|||0000-0003-0023-7377
  • Serrano-Mollar, Anna|||0000-0002-4990-8162
  • Rosado Rodríguez, Joel|||0000-0001-9308-7827
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
  • Buzón, Maria José|||0000-0003-4427-9413
The development of physiological models that reproduce SARS-CoV-2 infection in primary human cells will be instrumental to identify host-pathogen interactions and potential therapeutics. Here, using cell suspensions directly from primary human lung tissues (HLT), we have developed a rapid platform for the identification of viral targets and the expression of viral entry factors, as well as for the screening of viral entry inhibitors and anti-inflammatory compounds. The direct use of HLT cells, without long-term cell culture and in vitro differentiation approaches, preserves main immune and structural cell populations, including the most susceptible cell targets for SARS-CoV-2; alveolar type II (AT-II) cells, while maintaining the expression of proteins involved in viral infection, such as ACE2, TMPRSS2, CD147 and AXL. Further, antiviral testing of 39 drug candidates reveals a highly reproducible method, suitable for different SARS-CoV-2 variants, and provides the identification of new compounds missed by conventional systems, such as VeroE6. Using this method, we also show that interferons do not modulate ACE2 expression, and that stimulation of local inflammatory responses can be modulated by different compounds with antiviral activity. Overall, we present a relevant and rapid method for the study of SARS-CoV-2. The early stages of laboratory identification of therapeutics against pathogens is usually based on the use of immortalized cell lines, as exemplified by many studies screening antivirals against SARS-CoV-2. Cell lines are manipulated for their continuous growth which offers several advantages, however they do not fully reproduce the behavior of primary cells nor the complexity of heterogeneous populations. In this study, we overcome this limitation by using surgical resections to establish human lung tissue (HLT) cell cultures ready for drug evaluation. First, we show that HLT preserves lung cell composition, including the main SARS-CoV-2 cellular target, namely alveolar type-2 cells, as well as the proteins required for viral entry into the cells: ACE2, CD147, TMPRSS2 and AXL. Moreover, using HLT cells we identified new antiviral drug candidates missed by conventional systems, and anti-inflammatory compounds that module molecules associated with SARS-CoV-2 infection. In summary, we have established a physiological model that can be used for the identification of novel anti-SARS-CoV-2 therapeutics and other respiratory pathogens.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nationwide COVID-19-EII Study, Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

  • Zabana, Yamile|||0000-0003-4023-8868
  • Marín Jiménez, Ignacio|||0000-0001-5424-2484
  • Rodríguez-Lago, Iago|||0000-0003-1133-4578
  • Vera-Mendoza, Isabel
  • Martín-Arranz, María Dolores|||0000-0002-1872-0917
  • Guerra, Iván|||0000-0002-5175-2515
  • P. Gisbert, Javier|||0000-0003-2090-3445
  • Mesonero, Francisco|||0000-0002-7864-8187
  • Benítez-Leiva, Olga|||0000-0003-1748-7751
  • Taxonera, Carlos|||0000-0001-9166-7350
  • Ponferrada Díaz, Ángel|||0000-0002-1176-276X
  • Piqueras, Marta|||0000-0002-3874-2638
  • Lucendo, Alfredo J.|||0000-0003-1183-1072
  • Caballol, Berta|||0000-0002-7921-6730
  • Mañosa i Ciria, Míriam|||0000-0002-9051-2581
  • Martínez Montiel, Pilar|||0000-0002-8688-8244
  • Bosca-Watts, Marta Maia|||0000-0001-7495-8797
  • Gordillo, Jordi|||0000-0001-6418-0715
  • Bujanda, Luis|||0000-0002-4353-9968
  • Manceñido, Noemí|||0000-0002-8089-9858
  • Martínez-Pérez, Teresa
  • López, Alicia
  • Rodríguez Gutiérrez, Cristina|||0000-0003-3954-0736
  • García-López, Santiago|||0000-0003-3970-5457
  • Vega Villaamil, Pablo|||0000-0001-7545-6297
  • Rivero, Montserrat|||0000-0002-5834-1559
  • Melcarne, Luigi|||0000-0002-9718-9692
  • Calvo Iñiguez, María|||0000-0002-9862-2427
  • Iborra, Marisa|||0000-0001-7360-7581
  • Barreiro de-Acosta, Manuel|||0000-0001-5915-1477
  • Sicilia Aladrén, Beatriz|||0000-0002-4495-9358
  • Barrio, Jesús|||0000-0001-7087-3921
  • Pérez-Calle, José Lázaro|||0000-0002-8724-2760
  • Busquets, David|||0000-0002-9385-1415
  • Pérez-Martínez, Isabel|||0000-0002-2535-1929
  • Navarro-Llavat, Mercè|||0000-0002-1132-0427
  • Hernández, Vicent|||0000-0003-1607-0831
  • Argüelles-Arias, Federico|||0000-0003-3646-8919
  • Ramírez Esteso, Fernando|||0000-0003-4728-5253
  • Meijide, Susana
  • Ramos López, Laura|||0000-0001-7015-1742
  • Gomollón, Fernando|||0000-0003-0076-3529
  • Muñoz, Fernando
  • Suris, Gerard
  • de Zarate, Jone Ortiz
  • Huguet, José María|||0000-0001-6486-1262
  • Llaó, Jordina
  • García-Sepulcre, Mariana Fe|||0000-0002-1329-9529
  • Sierra Ausín, Mónica|||0000-0003-3342-8209
  • Durà, Miguel
  • Estrecha, Sandra
  • Fuentes Coronel, Ana María|||0000-0001-8862-0922
  • Hinojosa, Esther
  • Olivan, Lorenzo|||0000-0002-7215-6907
  • Iglesias-Flores, Eva
  • Gutiérrez Casbas, Ana|||0000-0002-5460-4139
  • Varela, Pilar|||0000-0003-1737-3236
  • Rull, Núria
  • Gilabert, Pau
  • Hernández Camba, Alejandro|||0000-0002-8653-207X
  • Brotons, Alicia|||0000-0003-3017-1671
  • Ginard, Daniel
  • Sesé Abizanda, Eva
  • Carpio, Daniel|||0000-0001-7929-1151
  • Aceituno, Montserrat|||0000-0003-0352-9527
  • Cabriada, José Luis|||0000-0002-3068-5659
  • González-Lama, Yago|||0000-0003-3896-7914
  • Jiménez, Laura
  • Chaparro, María|||0000-0002-9275-4242
  • López San Román, Antonio|||0000-0003-0236-4118
  • Alba, Cristina
  • Plaza-Santos, Rocío|||0000-0003-0893-4599
  • Mena, Raquel
  • Tamarit-Sebastián, Sonsoles|||0000-0001-5309-8310
  • Ricart, Elena
  • Calafat, Margalida|||0000-0003-2335-3792
  • Olivares, Sonsoles
  • Navarro, Pablo|||0000-0001-6228-3462
  • Bertoletti, Federico|||0000-0002-1484-3952
  • Alonso-Galán, Horacio
  • Pajares, Ramón|||0000-0003-0549-6036
  • Olcina, Pablo|||0000-0001-8898-0231
  • Manzano, Pamela
  • Domènech, Eugeni|||0000-0002-2315-7196
  • Esteve, Maria|||0000-0001-7716-0027
We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged ≥ 60 years (OR 7.1, 95% CI: 1.8-27 and 4.5, 95% CI: 1.3-15.9), while having ≥2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3-11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Estimating the real burden of disease under a pandemic situation, The SARS-CoV2 case

  • Fernández-Fontelo, Amanda|||0000-0002-0822-6915
  • Moriña, David|||0000-0001-5949-7443
  • Cabaña, Alejandra|||0000-0002-1289-967X
  • Arratia, Argimiro|||0000-0003-1551-420X
  • Puig, Pedro|||0000-0002-6607-9642
The present paper introduces a new model used to study and analyse the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) epidemic-reported-data from Spain. This is a Hidden Markov Model whose hidden layer is a regeneration process with Poisson immigration, Po-INAR(1), together with a mechanism that allows the estimation of the under-reporting in non-stationary count time series. A novelty of the model is that the expectation of the unobserved process's innovations is a time-dependent function defined in such a way that information about the spread of an epidemic, as modelled through a Susceptible-Infectious-Removed dynamical system, is incorporated into the model. In addition, the parameter controlling the intensity of the under-reporting is also made to vary with time to adjust to possible seasonality or trend in the data. Maximum likelihood methods are used to estimate the parameters of the model.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

On a Discrete SEIR Epidemic Model with Two-Doses Delayed Feedback Vaccination Control on the Susceptible

  • De la Sen, Manuel|||0000-0001-9320-9433
  • Alonso-Quesada, Santiago|||0000-0002-4724-7583
  • Ibeas, Asier|||0000-0001-5094-3152
  • Nistal, Raul|||0000-0003-2196-1989
A new discrete susceptible-exposed-infectious-recovered (SEIR) epidemic model is presented subject to a feedback vaccination effort involving two doses. Both vaccination doses, which are subject to a non-necessarily identical effectiveness, are administrated by respecting a certain mutual delay interval, and their immunity effect is registered after a certain delay since the second dose. The delays and the efficacies of the doses are parameters, which can be fixed in the model for each concrete experimentation. The disease-free equilibrium point is characterized as well as its stability properties, while it is seen that no endemic equilibrium point exists. The exposed subpopulation is supposed to be infective eventually, under a distinct transmission rate of that of the infectious subpopulation. Some simulation examples are presented by using disease parameterizations of the COVID-19 pandemic under vaccination efforts requiring two doses.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 transmission in students of public schools of Catalonia (Spain) after a month of reopening

  • Llupià, Anna|||0000-0001-8284-7560
  • Borrás Santos, Alícia|||0000-0003-1831-7965
  • Guinovart, Caterina
  • Utzet, Mireia|||0000-0001-5948-3914
  • Moriña, David|||0000-0001-5949-7443
  • Puig, Joaquim|||0000-0003-0600-1023
SARS-CoV-2 transmission within schools and its contribution to community transmission are still a matter of debate. A retrospective cohort study in all public schools in Catalonia was conducted using publicly available data assessing the association between the number of reported SARS-CoV-2 cases among students and staff in weeks 1-2 (Sept 14-27th, 2020) of the academic year with school SARS-CoV-2 incidence among students in weeks 4-5. A multilevel Poisson regression model adjusted for the community incidence in the corresponding basic health area (BHA) and the type of school (primary or secondary), with random effects at the sanitary region and BHA levels, was performed. A total of 2184 public schools opened on September 14th with 778,715 students. Multivariate analysis showed a significant association between the total number of SARS-CoV-2 cases in a centre in weeks 1-2 and the SARS-CoV-2 school incidence among students in weeks 4-5 (Risk Ratio (RR) 1.074, 95% CI 1.044-1.105, p-value <0.001). The adjusted BHA incidence in the first two weeks was associated with school incidence in weeks 4-5 (RR 1.002, 95% CI 1.002-1.003, p-value <0.001). Secondary schools showed an increased incidence in weeks 4 and 5 (RR primary vs secondary 1.709 95% CI 1.599-1.897, p-value <0.001). Safety measures adopted by schools were not enough to stop related-to-school transmission in students and could be improved. The safest way to keep schools open is to reduce community transmission down to a minimum.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Peripheral and lung resident memory T cell responses against SARS-CoV-2

  • Grau Expósito, Judith|||0000-0001-9350-2429
  • Sánchez Gaona, Nerea|||0000-0003-1977-8691
  • Massana, Núria|||0000-0002-5403-3161
  • Suppi, Marina|||0000-0002-9042-6659
  • Astorga-Gamaza, Antonio|||0000-0002-1276-5276
  • Perea, David|||0000-0003-1562-4740
  • Rosado Rodríguez, Joel|||0000-0001-9308-7827
  • Falcó Roget, Anna
  • Kirkegaard, Cristina|||0000-0001-9035-1450
  • Torrella Domingo, Adriana|||0000-0003-1848-5096
  • Planas, Bibiana|||0000-0002-1490-7127
  • Navarro, Jordi|||0000-0002-7187-0367
  • Suanzes, Paula|||0000-0002-6871-0098
  • Álvarez-Sierra, Daniel|||0000-0001-8221-5117
  • Ayora, Alfonso
  • Sansano, Irene|||0000-0003-0188-5210
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Andrés, Cristina|||0000-0002-3200-0895
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • Almirante Gragera, Benito|||0000-0002-1189-2361
  • Pujol-Borrell, Ricardo|||0000-0001-7833-675X
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Buzón, Maria José|||0000-0003-4427-9413
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
Resident memory T cells (T) positioned within the respiratory tract are probably required to limit SARS-CoV-2 spread and COVID-19. Importantly, T are mostly non-recirculating, which reduces the window of opportunity to examine these cells in the blood as they move to the lung parenchyma. Here, we identify circulating virus-specific T cell responses during acute infection with functional, migratory and apoptotic patterns modulated by viral proteins and associated with clinical outcome. Disease severity is associated predominantly with IFNγ and IL-4 responses, increased responses against S peptides and apoptosis, whereas non-hospitalized patients have increased IL-12p70 levels, degranulation in response to N peptides and SARS-CoV-2-specific CCR7 + T cells secreting IL-10. In convalescent patients, lung-T are frequently detected even 10 months after initial infection, in which contemporaneous blood does not reflect tissue-resident profiles. Our study highlights a balanced anti-inflammatory antiviral response associated with a better outcome and persisting T cells as important for future protection against SARS-CoV-2 infection. Lung resident memory T (T) cells are important for protection from viral infection in the lungs. Here the authors use paired lung biopsy material and blood to characterize T cell responses in patients with COVID-19 over time and find persistence of antiviral lung T cells that might be important to limit reinfection.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Thirty-day suicidal thoughts and behaviours in the Spanish adult general population during the first wave of the Spain COVID-19 pandemic

  • Mortier, Philippe|||0000-0003-2113-6241
  • Vilagut, Gemma|||0000-0002-3714-226X
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Alayo, Itxaso|||0000-0002-7333-3450
  • Bruffaerts, Ronny|||0000-0002-0330-3694
  • del Cura-González, Isabel
  • Domènech-Abella, Joan|||0000-0001-7605-3887
  • Felez-Nobrega, M.
  • Olaya, Beatriz|||0000-0003-2046-3929
  • Pijoan, J. I.
  • Vieta, Eduard|||0000-0002-0548-0053
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Kessler, R. C.
  • Haro Abad, Josep Maria|||0000-0002-3984-277X
  • Alonso, Jordi|||0000-0001-8627-9636
To investigate the prevalence of suicidal thoughts and behaviours (STB; i.e. suicidal ideation, plans or attempts) in the Spanish adult general population during the first wave of the Spain coronavirus disease 2019 (COVID-19) pandemic (March-July, 2020), and to investigate the individual- and population-level impact of relevant distal and proximal STB risk factor domains. Cross-sectional study design using data from the baseline assessment of an observational cohort study (MIND/COVID project). A nationally representative sample of 3500 non-institutionalised Spanish adults (51.5% female; mean age = 49.6 [ = 17.0]) was taken using dual-frame random digit dialing, stratified for age, sex and geographical area. Professional interviewers carried out computer-assisted telephone interviews (1-30 June 2020). Thirty-day STB was assessed using modified items from the Columbia Suicide Severity Rating Scale. Distal (i.e. pre-pandemic) risk factors included sociodemographic variables, number of physical health conditions and pre-pandemic lifetime mental disorders; proximal (i.e. pandemic) risk factors included current mental disorders and a range of adverse events-experiences related to the pandemic. Logistic regression was used to investigate individual-level associations (odds ratios [OR]) and population-level associations (population attributable risk proportions [PARP]) between risk factors and 30-day STB. All data were weighted using post-stratification survey weights. Estimated prevalence of 30-day STB was 4.5% (1.8% active suicidal ideation; n = 5 [0.1%] suicide attempts). STB was 9.7% among the 34.3% of respondents with pre-pandemic lifetime mental disorders, and 1.8% among the 65.7% without any pre-pandemic lifetime mental disorder. Factors significantly associated with STB were pre-pandemic lifetime mental disorders (total PARP = 49.1%) and current mental disorders (total PARP = 58.4%), i.e. major depressive disorder (OR = 6.0; PARP = 39.2%), generalised anxiety disorder (OR = 5.6; PARP = 36.3%), post-traumatic stress disorder (OR = 4.6; PARP = 26.6%), panic attacks (OR = 6.7; PARP = 36.6%) and alcohol/substance use disorder (OR = 3.3; PARP = 5.9%). Pandemic-related adverse events-experiences associated with STB were lack of social support, interpersonal stress, stress about personal health and about the health of loved ones (PARPs 32.7-42.6%%), and having loved ones infected with COVID-19 (OR = 1.7; PARP = 18.8%). Up to 74.1% of STB is potentially attributable to the joint effects of mental disorders and adverse events-experiences related to the pandemic. STB at the end of the first wave of the Spain COVID-19 pandemic was high, and large proportions of STB are potentially attributable to mental disorders and adverse events-experiences related to the pandemic, including health-related stress, lack of social support and interpersonal stress. There is an urgent need to allocate resources to increase access to adequate mental healthcare, even in times of healthcare system overload. NCT04556565.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Air trapping in COVID-19 patients following hospital discharge, retrospective evaluation with paired inspiratory/expiratory thin-section CT

  • Franquet, Tomas|||0000-0002-7443-1730
  • Giménez Palleiro, Ana|||0000-0002-3898-0652
  • Ketai, Loren
  • Mazzini, Sandra|||0000-0002-2619-2253
  • Rial, Andrea
  • Pomar, Virginia|||0000-0002-8473-5834
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
The study reports our experience with paired inspiration/expiration thin-section computed tomographic (CT) scans in the follow-up of COVID-19 patients with persistent respiratory symptoms. From August 13, 2020, to May 31, 2021, 48 long-COVID patients with respiratory symptoms (27 men and 21 women; median age, 62.0 years; interquartile range: 54.0-69.0 years) underwent follow-up paired inspiration-expiration thin-section CT scans. Patient demographics, length of hospital stay, intensive care unit admission rate, and clinical and laboratory features of acute infection were also included. The scans were obtained on a median of 72.5 days after onset of symptoms (interquartile range: 58.5-86.5) and at least 30 days after hospital discharge. Thin-section CT findings included ground-glass opacity, mosaic attenuation pattern, consolidation, traction bronchiectasis, reticulation, parenchymal bands, bronchial wall thickening, and air trapping. We used a quantitative score to determine the degree of air trapping in the expiratory scans. Parenchymal abnormality was found in 50% (24/48) of patients and included air trapping (37/48, 77%), ground-glass opacities (19/48, 40%), reticulation (18/48, 38%), parenchymal bands (15/48, 31%), traction bronchiectasis (9/48, 19%), mosaic attenuation pattern (9/48, 19%), bronchial wall thickening (6/48, 13%), and consolidation (2/48, 4%). The absence of air trapping was observed in 11/48 (23%), mild air trapping in 20/48 (42%), moderate in 13/48 (27%), and severe in 4/48 (8%). Independent predictors of air trapping were, in decreasing order of importance, gender (p = 0.0085), and age (p = 0.0182). Our results, in a limited number of patients, suggest that follow-up with paired inspiratory/expiratory CT in long-COVID patients with persistent respiratory symptoms commonly displays air trapping. • Our experience indicates that paired inspiratory/expiratory CT in long-COVID patients with persistent respiratory symptoms commonly displays air trapping. • Iterative reconstruction and dose-reduction options are recommended for demonstrating air trapping in long-COVID patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Neurocognitive Profile of the Post-COVID Condition in Adults in Catalonia-A Mixed Method Prospective Cohort and Nested Case-Control Study, Study Protocol

  • Dacosta Aguayo, Rosalia|||0000-0003-1861-365X
  • Lamonja-Vicente, Noemí|||0000-0003-1342-1130
  • Chacón, Carla|||0000-0001-8524-6189
  • Carrasco-Ribelles, Lucía Amalia|||0000-0001-9263-1747
  • Montero-Alía, Pilar|||0000-0002-9823-1485
  • Costa-Garrido, Anna|||0000-0001-5428-1408
  • García-Sierra, Rosa|||0000-0001-9220-610X
  • López-Lifante, Víctor-Miguel|||0000-0002-0919-9998
  • Moreno Gabriel, Eduard|||0000-0001-8184-6232
  • Massanella, Marta|||0000-0002-3326-151X
  • Puig, Josep|||0000-0003-2791-6599
  • Muñoz-Moreno, José Antonio|||0000-0002-7239-5422
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Prats, Anna|||0000-0002-3586-4525
  • Rodríguez, Carmina
  • Mataró, Maria|||0000-0002-9946-2656
  • Prado, Julia G.|||0000-0002-5439-4645
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
  • Violán, Concepció|||0000-0003-3309-5360
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
The diagnosis of the post-COVID condition is usually achieved by excluding other diseases; however, cognitive changes are often found in the post-COVID disorder. Therefore, monitoring and treating the recovery from the post-COVID condition is necessary to establish biomarkers to guide the diagnosis of symptoms, including cognitive impairment. Our study employs a prospected cohort and nested case-control design with mixed methods, including statistical analyses, interviews, and focus groups. Our main aim is to identify biomarkers (functional and structural neural changes, inflammatory and immune status, vascular and vestibular signs and symptoms) easily applied in primary care to detect cognitive changes in post-COVID cases. The results will open up a new line of research to inform diagnostic and therapeutic decisions with special considerations for cognitive impairment in the post-COVID condition.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Novel genes and sex differences in COVID-19 severity

  • Cruz, Raquel|||0000-0002-6964-8898
  • Diz-de Almeida, Silvia|||0000-0003-2813-8928
  • López de Heredia, Miguel|||0000-0003-2826-9565
  • Quintela, Inés|||0000-0002-0239-7975
  • Ceballos, Francisco C.
  • Pita, Guillermo|||0000-0003-2393-0510
  • Lorenzo-Salazar, José M.
  • González-Montelongo, Rafaela
  • Gago-Dominguez, Manuela
  • Sevilla Porras, Marta
  • Tenorio Castaño, Jair Antonio|||0000-0002-5308-2316
  • Nevado, Julián|||0000-0001-5611-2659
  • Aguado, José María|||0000-0002-9520-8255
  • Aguilar Franco, Carlos
  • Aguilera-Albesa, Sergio|||0000-0003-3540-1448
  • Almadana, Virginia
  • Almoguera, Berta|||0000-0002-5599-2954
  • Alvarez, Nuria
  • Andreu-Bernabeu, Álvaro
  • Arana-Arri, Eunate|||0000-0001-9759-333X
  • Arango, Celso|||0000-0003-3382-4754
  • Arranz, María Jesús|||0000-0002-6757-9198
  • Artiga, Maria-Jesus
  • Baptista-Rosas, Raúl C.|||0000-0002-0273-4740
  • Barreda Sánchez, María
  • Belhassen-Garcia, Moncef
  • Bezerra, Joao F.
  • Bezerra, Marcos A C.
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Brion, María|||0000-0001-7463-2148
  • Brugada, Ramon|||0000-0001-6607-3032
  • Bustos, Matilde
  • Calderón, Enrique J.|||0000-0002-3166-5086
  • Carbonell, Cristina|||0000-0002-6271-5111
  • Castaño, Luis|||0000-0003-0437-9401
  • Castelao, Jose E.
  • Conde-Vicente, Rosa
  • Cordero-Lorenzana, M Lourdes
  • Cortes-Sanchez, Jose L.
  • Corton, Marta|||0000-0003-0087-1626
  • Darnaude, M Teresa
  • De Martino-Rodríguez, Alba|||0000-0002-2436-9852
  • Campo Pérez, Víctor del|||0000-0002-9424-9653
  • Diaz de Bustamante, Aranzazu
  • Domínguez-Garrido, Elena|||0000-0002-2066-0511
  • Luchessi, Andre D.
  • Eiros, Rocío
  • Estigarribia Sanabria, Gladys Mercedes
  • Carmen Fariñas, María
  • Fernández-Robelo, Uxía
  • Fernández-Rodríguez, Amanda|||0000-0002-5110-2213
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Gil-Fournier, Belén
  • Gómez-Arrue, Javier
  • González Álvarez, Beatriz
  • Gonzalez Bernaldo de Quirós, Fernan
  • González-Peñas, Javier|||0000-0002-3850-3012
  • Gutiérrez-Bautista, Juan F.|||0000-0003-1374-0756
  • Herrero, María José
  • Herrero-Gonzalez, Antonio
  • Jimenez-Sousa, María A.
  • Lattig, María Claudia|||0000-0003-2113-9266
  • Liger Borja, Anabel
  • Lopez-Rodriguez, Rosario
  • Mancebo, Esther
  • Martín-López, Caridad
  • Martín, Vicente|||0000-0003-0552-2804
  • Martinez-Nieto, Oscar
  • Martinez-Lopez, Iciar
  • Martinez-Resendez, Michel F.
  • Martinez-Perez, Angel|||0000-0002-5934-1454
  • Mazzeu, Juliana F.
  • Merayo Macías, Eleuterio
  • Minguez, Pablo|||0000-0003-4099-9421
  • Moreno Cuerda, Victor
  • Silbiger, Vivian N.
  • Oliveira, Silviene F.|||0000-0002-7741-0257
  • Ortega-Paino, Eva
  • Parellada, Mara|||0000-0001-7977-3601
  • Paz-Artal, Estela|||0000-0002-0646-2375
  • Santos, Ney P C.
  • Pérez-Matute, Patricia
  • Perez, Patricia
  • Pérez-Tomás, M. Elena|||0000-0002-5429-3414
  • Perucho, Teresa
  • Pinsach-Abuin, Mel Lina
  • Pompa-Mera, Ericka N.
  • Porras-Hurtado, Gloria L.
  • Pujol, Aurora|||0000-0002-9606-0600
  • Ramiro-León, Soraya
  • Resino, Salvador|||0000-0001-8783-0450
  • Fernandes, Marianne R.
  • Rodríguez-Ruiz, Emilio
  • Rodriguez-Artalejo, Fernando
  • Rodriguez-Garcia, José A.
  • Ruiz Cabello, Francisco
  • Ruiz-Hornillos, Javier
  • Ryan, Pablo|||0000-0002-4212-7419
  • Soria Fernández, José Manuel|||0000-0002-6226-4293
  • Souto, Juan Carlos|||0000-0003-2092-5142
  • Tamayo, Eduardo
  • Tamayo-Velasco, Alvaro
  • Taracido-Fernandez, Juan Carlos
  • Teper, Alejandro
  • Torres-Tobar, Lilian
  • Urioste, Miguel|||0000-0001-7583-7305
  • Valencia-Ramos, Juan
  • Yáñez, Zuleima
  • Zarate, Ruth N.
  • Nakanishi, Tomoko|||0000-0001-9510-5646
  • Pigazzini, Sara
  • Degenhardt, Frauke|||0000-0001-7516-3179
  • Butler-Laporte, Guillaume|||0000-0001-5388-0396
  • Maya-Miles, Douglas|||0000-0002-0669-6526
  • Bujanda, Luis|||0000-0002-4353-9968
  • Bouysran, Youssef|||0000-0003-1368-6550
  • Palom, Adriana|||0000-0002-0130-1302
  • Ellinghaus, David|||0000-0002-4332-6110
  • Martínez-Bueno, Manuel
  • Rolker, Selina
  • Amitrano, Sara
  • Roade, Luisa|||0000-0002-8160-9613
  • Fava, Francesca
  • Spinner, Christoph D.|||0000-0002-3875-5367
  • Prati, Daniele|||0000-0002-2281-7498
  • Bernardo, D.|||0000-0002-2843-6696
  • Garcia, Federico
  • Darcis, Gilles|||0000-0001-8192-1351
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Holter, Jan Cato
  • Banales, Jesus|||0000-0002-5224-2373
  • Frithiof, Robert
  • Duga, Stefano
  • Asselta, Rosanna
  • Pereira, Alexandre C.
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
  • Nafria-Jimenez, Beatriz|||0000-0002-4698-5680
  • Hov, Johannes R.|||0000-0002-5900-8096
  • Migeotte, Isabelle
  • Renieri, Alessandra|||0000-0002-0846-9220
  • Planas, Anna Maria|||0000-0002-6147-1880
  • Ludwig, Kerstin U.|||0000-0002-8541-2519
  • Buti, Maria|||0000-0002-0732-3078
  • Rahmouni, Souad
  • Alarcón-Riquelme, Marta E.|||0000-0002-7632-4154
  • Schulte, Eva C.|||0000-0003-3105-5672
  • Franke, Andre|||0000-0003-1530-5811
  • Karlsen, Tom H.
  • Valenti, Luca|||0000-0001-8909-0345
  • Zeberg, Hugo
  • Richards, Brent
  • Ganna, Andrea|||0000-0002-8147-240X
  • Boada, Mercè|||0000-0003-2617-3009
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Real, Luis M.|||0000-0003-4932-7429
  • Guillén-Navarro, Encarna|||0000-0002-2915-7381
  • Ayuso, Carmen|||0000-0002-9606-6957
  • González-Neira, Anna
  • Riancho, José A.|||0000-0003-0691-8755
  • Rojas-Martinez, Augusto|||0000-0003-3765-6778
  • Flores, Carlos|||0000-0001-5352-069X
  • Lapunzina, Pablo|||0000-0002-6324-4825
  • Carracedo, Ángel|||0000-0003-1085-8986
Here, we describe the results of a genome-wide study conducted in 11 939 coronavirus disease 2019 (COVID-19) positive cases with an extensive clinical information that were recruited from 34 hospitals across Spain (SCOURGE consortium). In sex-disaggregated genome-wide association studies for COVID-19 hospitalization, genome-wide significance (P < 5 × 10 -8) was crossed for variants in 3p21.31 and 21q22.11 loci only among males (P = 1.3 × 10 -22 and P = 8.1 × 10 -12, respectively), and for variants in 9q21.32 near TLE1 only among females (P = 4.4 × 10 -8). In a second phase, results were combined with an independent Spanish cohort (1598 COVID-19 cases and 1068 population controls), revealing in the overall analysis two novel risk loci in 9p13.3 and 19q13.12, with fine-mapping prioritized variants functionally associated with AQP3 (P = 2.7 × 10 -8) and ARHGAP33 (P = 1.3 × 10 -8), respectively. The meta-analysis of both phases with four European studies stratified by sex from the Host Genetics Initiative (HGI) confirmed the association of the 3p21.31 and 21q22.11 loci predominantly in males and replicated a recently reported variant in 11p13 (ELF5, P = 4.1 × 10 -8). Six of the COVID-19 HGI discovered loci were replicated and an HGI-based genetic risk score predicted the severity strata in SCOURGE. We also found more SNP-heritability and larger heritability differences by age (<60 or ≥60 years) among males than among females. Parallel genome-wide screening of inbreeding depression in SCOURGE also showed an effect of homozygosity in COVID-19 hospitalization and severity and this effect was stronger among older males. In summary, new candidate genes for COVID-19 severity and evidence supporting genetic disparities among sexes are provided.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effects of intubation timing in patients with COVID-19 throughout the four waves of the pandemic, a matched analysis

  • Riera del Brio, Jordi|||0000-0002-1738-4448
  • Barbeta, Enric|||0000-0001-9725-4100
  • Tormos, Adrián
  • Mellado Artigas, Ricard|||0000-0003-2815-6819
  • Ceccato, Adrian|||0000-0001-9454-062X
  • Motos, Ana|||0000-0002-3757-1232
  • Fernández Barat, Laia|||0000-0001-7528-9636
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Garcia-Gasulla, Dario|||0000-0001-6732-5641
  • Peñuelas, Oscar|||0000-0003-1484-3933
  • Lorente, José Ángel
  • Menéndez, Rosario
  • Roca Gas, Oriol|||0000-0003-3841-4551
  • Palomeque, Andrea
  • Ferrando, Carlos|||0000-0002-1907-5323
  • Sole-Violan, Jordi|||0000-0002-0483-4470
  • Novo, Mariana
  • Boado Varela, Maria Victoria
  • Tamayo, Luis
  • Estella, Ángel|||0000-0003-0665-557X
  • Galbán, Cristóbal
  • Trenado Álvarez, José|||0000-0002-2930-0766
  • Huerta, Arturo|||0000-0002-6191-4143
  • Loza, Ana
  • Aguilera, Luciano
  • Garmendia, José Luís García
  • Barberà, Carme
  • Gumucio, Víctor
  • Socias, Lorenzo
  • Franco, Nieves
  • Valdivia, Luis Jorge
  • Vidal-Cortés, Pablo|||0000-0003-0225-9975
  • Sagredo, Victor
  • Ruiz-García, Ángela Leonor
  • Varela, Ignacio Martínez
  • López, Juan
  • Pozo, Juan Carlos
  • Nieto, Maite
  • Gómez García, José Manuel|||0009-0002-2154-8043
  • Blandino Ortiz, Aaron|||0000-0002-3184-6418
  • Valledor, Manuel
  • Bustamante-Munguira, Elena
  • Sánchez Miralles, Ángel
  • Peñasco, Yhivian
  • Barberán, José
  • Úbeda, Alejandro
  • Amaya-Villar, Rosario
  • Martín, María Cruz
  • Jorge García, Ruth Noemí
  • Caballero, Jesús|||0000-0001-9005-9687
  • Marín Corral, Judith|||0000-0003-1320-4427
  • Añón, José Manuel
  • Sipmann, Fernando Suárez
  • Muñiz, Guillermo
  • Castellanos Ortega, Álvaro|||0000-0002-8315-2485
  • Adell-Serrano, Berta
  • Catalán-González, Mercedes
  • de la Gándara, Amalia Martínez
  • Ricart, Pilar|||0000-0003-0067-9132
  • Carbajales, Cristina|||0000-0002-4496-5336
  • Rodríguez, Alejandro
  • Díaz Santos, Emilio|||0000-0003-3637-3821
  • de la Torre, Maria Del Carmen
  • Gallego, Elena
  • Cantón-Bulnes, Luisa
  • Carbonell, Nieves|||0000-0002-9149-0310
  • González Gutiérrez, Jessica|||0000-0002-6847-5315
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Barbé, Ferran|||0000-0002-2340-8928
  • Torres, Antoni|||0000-0002-8643-2167
The primary aim of our study was to investigate the association between intubation timing and hospital mortality in critically ill patients with COVID-19-associated respiratory failure. We also analysed both the impact of such timing throughout the first four pandemic waves and the influence of prior non-invasive respiratory support on outcomes. This is a secondary analysis of a multicentre, observational and prospective cohort study that included all consecutive patients undergoing invasive mechanical ventilation due to COVID-19 from across 58 Spanish intensive care units (ICU) participating in the CIBERESUCICOVID project. The study period was between 29 February 2020 and 31 August 2021. Early intubation was defined as that occurring within the first 24 h of intensive care unit (ICU) admission. Propensity score (PS) matching was used to achieve balance across baseline variables between the early intubation cohort and those patients who were intubated after the first 24 h of ICU admission. Differences in outcomes between early and delayed intubation were also assessed. We performed sensitivity analyses to consider a different timepoint (48 h from ICU admission) for early and delayed intubation. Of the 2725 patients who received invasive mechanical ventilation, a total of 614 matched patients were included in the analysis (307 for each group). In the unmatched population, there were no differences in mortality between the early and delayed groups. After PS matching, patients with delayed intubation presented higher hospital mortality (27.3% versus 37.1%, p =0.01), ICU mortality (25.7% versus 36.1%, p=0.007) and 90-day mortality (30.9% versus 40.2%, p=0.02) when compared to the early intubation group. Very similar findings were observed when we used a 48-hour timepoint for early or delayed intubation. The use of early intubation decreased after the first wave of the pandemic (72%, 49%, 46% and 45% in the first, second, third and fourth wave, respectively; first versus second, third and fourth waves p<0.001). In both the main and sensitivity analyses, hospital mortality was lower in patients receiving high-flow nasal cannula (n=294) who were intubated earlier. The subgroup of patients undergoing NIV (n=214) before intubation showed higher mortality when delayed intubation was set as that occurring after 48 h from ICU admission, but not when after 24 h. In patients with COVID-19 requiring invasive mechanical ventilation, delayed intubation was associated with a higher risk of hospital mortality. The use of early intubation significantly decreased throughout the course of the pandemic. Benefits of such an approach occurred more notably in patients who had received high-flow nasal cannula.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Not all COVID-19 pandemic waves are alike

  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Pomar, Virginia|||0000-0002-8473-5834
  • Mur, Isabel|||0000-0001-7660-8483
  • Castellvi, Ivan|||0000-0002-5410-5807
  • Corominas, Hèctor|||0000-0002-7738-6787
  • Benito, Natividad|||0000-0001-6410-013X
Objective: We aimed to assess differences in patients' profiles in the first two surges of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in Barcelona, Spain. Methods: We prospectively collected data from all adult patients with SARS-CoV-2 infection diagnosed at the Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. All the patients were diagnosed through nasopharyngeal swab PCR. The first surge spanned from 1st March to 13th August 2020, while surge two spanned from 14th August to 8th December 2020. Results: There were 2479 and 852 patients with microbiologically proven SARS-CoV-2 infection in surges one and two, respectively. Patients from surge two were significantly younger (median age 52 (IQR 35) versus 59 (40) years, respectively, p < 0.001), had fewer comorbidities (379/852, 44.5% versus 1237/2479, 49.9%, p 0.007), and there was a shorter interval between onset of symptoms and diagnosis (median 3 (5) versus 4 (5) days, p < 0.001). All-cause in-hospital mortality significantly decreased for both the whole population (24/852, 2.8% versus 218/2479, 8.8%, p < 0.001) and hospitalized patients (20/302, 6.6% versus 206/1570, 13.1%, p 0.012). At adjusted logistic regression analysis, predictors of in-hospital mortality were older age (per year, adjusted odds ratio (aOR) 1.079, 95%CI 1.063-1.094), male sex (aOR 1.476, 95%CI 1.079-2.018), having comorbidities (aOR 1.414, 95%CI 0.934-2.141), ICU admission (aOR 3.812, 95%CI 1.875-7.751), mechanical ventilation (aOR 2.076, 95%CI 0.968-4.454), and coronavirus disease 2019 (COVID-19) during surge one (with respect to surge two) (aOR 2.176, 95%CI 1.286-3.680). Conclusions: First-wave SARS-CoV-2-infected patients had a more than two-fold higher in-hospital mortality than second-wave patients. The causes are likely multifactorial.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)

  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Mur, Isabel|||0000-0001-7660-8483
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Vidal, Francesc|||0000-0002-6692-6186
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
Introduction: When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed. Areas covered: Data from observational studies suggest similar incidence attacks of SARS-CoV-2 infection in people living with HIV (PLWH) and HIV-uninfected populations. The mortality rate of COVID-19 is similar in both populations too. The authors discuss the role of combination antiretroviral therapy (cART) in preventing infection or reducing COVID-19 severity. They also discuss the pharmacological interventions for COVID-19 in PLWH. Expert opinion: Management of COVID-19 in PLWH is no different from the general population. It should be based on careful supportive care, emphasizing lung-protective ventilation, and wise pharmacological interventions. The antiviral drug remdesivir and dexamethasone are the only pharmacological interventions with clinical benefit for COVID-19, whereas anticoagulation may prevent thrombotic complications. The experience with using these drugs in PLWH is limited, which prevents from rendering well-founded conclusions. Until more data on COVID-19 in PLWH become available, the best weapons within our reach are sound supportive care and sensible use of RDV and dexamethasone, bearing in mind the potential for drug-drug interactions of most corticosteroids and antiretroviral drugs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Obstetric outcomes of sars-cov-2 infection in asymptomatic pregnant women

  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Ferriols Pérez, Elena|||0000-0002-8003-0335
  • De La Cruz Conty, Maria Luisa
  • Caño Aguilar, Africa
  • Encinas Pardilla, Maria Begoña
  • Prats Rodriguez, Pilar|||0000-0001-9216-9118
  • Mune Hernando, Marta
  • Forcen Acebal, Laura
  • Pintado Recarte, Pilar
  • Medina Mallen, Maria del Carmen|||0000-0002-1219-5947
  • Perez Perez, Noelia
  • Canet Rodriguez, Judit|||0000-0001-7387-1462
  • Villazlba Yarza, Ana
  • Nieto Velasco, Olga|||0000-0001-8311-9442
  • Del Barrio Fernandez, Pablo Guillermo
  • Orizales Lago, Carmen María|||0000-0001-7184-2799
  • Marcos Puig, Beatriz
  • Muñoz Abellana, Begoña
  • Fuentes Ricoy, Laura
  • Rodriguez Vicente, Agueda
  • Janeiro Freire, Maria Jesus
  • Alferez Alvarez-Mallo, Macarena
  • Casanova Pedraz, Cristina
  • Alomar Mateu, Onofre
  • Lesmes Heredia, Cristina|||0000-0002-6857-3935
  • Wizner de Alva, Juan Carlos
  • Posadas San Juan, Alma
  • Macia Badia, Montserrat
  • Alvarez Colomo, Cristina
  • Sanchez Muñoz, Antonio
  • Pratcorona Alicart, Laia|||0000-0002-3805-1589
  • Alonso Saiz, Ruben
  • Lopez Rodriguez, Monica|||0000-0001-8134-9682
  • Barbancho Lopez, Maria Carmen
  • Meca Casbas, Marta Ruth
  • Vaquerizo Ruiz, Oscar
  • Moran Antolin, Eva
  • Nuñez Valera, Maria Jose
  • fernandez Fernandez, Camino
  • Tubau Navarra, Albert|||0000-0001-5460-0763
  • Cano Garcia, Alejandra Maria
  • Soldevilla Perez, Susana
  • Gattaca Abasolo, Irene
  • Adanez Garcia, Jose
  • Puertas Prieto, Alberto
  • Ostos Serna, Rosa
  • Guadix Martin, Maria del Pilar
  • Catalina Coello, Monica
  • Espuelas Malon, Silvia
  • Sainz Bueno, Jose Antonio
  • Granell Escobar, Maria Reyes|||0000-0002-7553-1688
  • Cruz Melguizo, Sara
  • Martinez Perez, Oscar|||0000-0002-1457-3446
Around two percent of asymptomatic women in labor test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Spain. Families and care providers face childbirth with uncertainty. We determined if SARS-CoV-2 infection at delivery among asymptomatic mothers had different obstetric outcomes compared to negative patients. This was a multicenter prospective study based on universal antenatal screening for SARS-CoV-2 infection. A total of 42 hospitals tested women admitted for delivery using polymerase chain reaction, from March to May 2020. We included positive mothers and a sample of negative mothers asymptomatic throughout the antenatal period, with 6-week postpartum follow-up. Association between SARS-CoV-2 and obstetric outcomes was evaluated by multivariate logistic regression analyses. In total, 174 asymptomatic SARS-CoV-2 positive pregnancies were compared with 430 asymptomatic negative pregnancies. No differences were observed between both groups in key maternal and neonatal outcomes at delivery and follow-up, with the exception of prelabor rupture of membranes at term (adjusted odds ratio 1.88, 95% confidence interval 1.13-3.11; p = 0.015). Asymptomatic SARS-CoV-2 positive mothers have higher odds of prelabor rupture of membranes at term, without an increase in perinatal complications, compared to negative mothers. Pregnant women testing positive for SARS-CoV-2 at admission for delivery should be reassured by their healthcare workers in the absence of symptoms.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long-term survival of mechanically ventilated patients with severe COVID-19, an observational cohort study

  • Peñuelas, Oscar|||0000-0003-1484-3933
  • del Campo-Albendea, Laura|||0000-0002-1940-4932
  • Lesmes González de Aledo, Amanda|||0000-0001-8397-4844
  • Añón, José Manuel
  • Rodríguez-Solís, Carmen
  • Mancebo Cortes, Jordi|||0000-0003-3308-5410
  • Vera Artazcoz, Paula|||0000-0003-3346-5093
  • Ballesteros Orozco, Daniel
  • Jiménez, Jorge
  • Maseda, Emilio|||0000-0003-2898-7073
  • Figueira, Juan Carlos
  • Franco, Nieves
  • Algaba, Ángela
  • Avilés, Juan Pablo
  • Díaz, Ricardo
  • Abad, Beatriz
  • Canabal, Alfonso|||0000-0001-7021-3456
  • Abella, Ana
  • Gordo Vidal, Federico|||0000-0001-9605-1918
  • García, Javier
  • García Suarez, Jessica
  • Cedeño, Jamil
  • Martínez-Palacios, Basilia
  • Manteiga, Eva
  • Martínez, Óscar|||0000-0003-0263-4333
  • Blancas, Rafael|||0000-0002-7559-710X
  • Bardi, Tommaso
  • Pestaña, David
  • Lorente, Jose Ángel
  • Muriel, Alfonso|||0000-0002-4805-4011
  • Esteban, Andrés|||0000-0002-0146-3328
  • Frutos-Vivar, Fernando
Background: Information is lacking regarding long-term survival and predictive factors for mortality in patients with acute hypoxemic respiratory failure due to coronavirus disease 2019 (COVID-19) and undergoing invasive mechanical ventilation. We aimed to estimate 180-day mortality of patients with COVID-19 requiring invasive ventilation, and to develop a predictive model for long-term mortality. Methods: Retrospective, multicentre, national cohort study between March 8 and April 30, 2020 in 16 intensive care units (ICU) in Spain. Participants were consecutive adults who received invasive mechanical ventilation for COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection detected in positive testing of a nasopharyngeal sample and confirmed by real time reverse-transcriptase polymerase chain reaction (rt-PCR). The primary outcomes was 180-day survival after hospital admission. Secondary outcomes were length of ICU and hospital stay, and ICU and in-hospital mortality. A predictive model was developed to estimate the probability of 180-day mortality. Results: 868 patients were included (median age, 64 years [interquartile range [IQR], 56-71 years]; 72% male). Severity at ICU admission, estimated by SAPS3, was 56 points [IQR 50-63]. Prior to intubation, 26% received some type of noninvasive respiratory support. The unadjusted overall 180-day survival rates was 59% (95% CI 56-62%). The predictive factors measured during ICU stay, and associated with 180-day mortality were: age [Odds Ratio [OR] per 1-year increase 1.051, 95% CI 1.033-1.068)), SAPS3 (OR per 1-point increase 1.027, 95% CI 1.011-1.044), diabetes (OR 1.546, 95% CI 1.085-2.204), neutrophils to lymphocytes ratio (OR per 1-unit increase 1.008, 95% CI 1.001-1.016), failed attempt of noninvasive positive pressure ventilation prior to orotracheal intubation (OR 1.878 (95% CI 1.124-3.140), use of selective digestive decontamination strategy during ICU stay (OR 0.590 (95% CI 0.358-0.972) and administration of low dosage of corticosteroids (methylprednisolone 1 mg/kg) (OR 2.042 (95% CI 1.205-3.460). Conclusion: The long-term survival of mechanically ventilated patients with severe COVID-19 reaches more than 50% and may help to provide individualized risk stratification and potential treatments. Trial registration: ClinicalTrials.gov Identifier: NCT04379258. Registered 10 April 2020 (retrospectively registered).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

On a discrete SEIR epidemic model with exposed infectivity, feedback vaccination and partial delayed re-susceptibility

  • De la Sen, Manuel|||0000-0001-9320-9433
  • Alonso-Quesada, Santiago|||0000-0002-4724-7583
  • Ibeas, Asier|||0000-0001-5094-3152
A new discrete Susceptible-Exposed-Infectious-Recovered (SEIR) epidemic model is proposed, and its properties of non-negativity and (both local and global) asymptotic stability of the solution sequence vector on the first orthant of the state-space are discussed. The calculation of the disease-free and the endemic equilibrium points is also performed. The model has the follow-ing main characteristics: (a) the exposed subpopulation is infective, as it is the infectious one, but their respective transmission rates may be distinct; (b) a feedback vaccination control law on the Susceptible is incorporated; and (c) the model is subject to delayed partial re-susceptibility in the sense that a partial immunity loss in the recovered individuals happens after a certain delay. In this way, a portion of formerly recovered individuals along a range of previous samples is incorporated again to the susceptible subpopulation. The rate of loss of partial immunity of the considered range of previous samples may be, in general, distinct for the various samples. It is found that the endemic equilibrium point is not reachable in the transmission rate range of values, which makes the disease-free one to be globally asymptotically stable. The critical transmission rate which confers to only one of the equilibrium points the property of being asymptotically stable (respectively below or beyond its value) is linked to the unity basic reproduction number and makes both equilibrium points to be coincident. In parallel, the endemic equilibrium point is reachable and globally asymptotically stable in the range for which the disease-free equilibrium point is unstable. It is also discussed the relevance of both the vaccination effort and the re-susceptibility level in the modifi-cation of the disease-free equilibrium point compared to its reached component values in their absence. The influences of the limit control gain and equilibrium re-susceptibility level in the reached endemic state are also explicitly made viewable for their interpretation from the endemic equilibrium components. Some simulation examples are tested and discussed by using disease parameterizations of COVID-19.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Objective and subjective cognition in survivors of COVID-19 one year after ICU discharge, the role of demographic, clinical, and emotional factors

  • Godoy-González, Marta|||0000-0002-1374-918X
  • Navarra-Ventura, Guillem|||0000-0001-9839-7357
  • Gomà, Gemma|||0000-0002-1890-4855
  • Haro López, Candelaria de|||0000-0002-2668-1030
  • Espinal, Cristina|||0000-0001-8701-9983
  • Ridao, Natalia
  • Miguel Rebanal, Nuria
  • Oliveras-Furriols, Laia
  • Subirà, Carles|||0000-0003-2285-2311
  • Jódar Vicente, Mercè|||0000-0002-8913-5977
  • Santos-Pulpon, Verónica|||0000-0003-2685-9377
  • Sarlabous, Leonardo|||0000-0002-0495-8422
  • Fernández, Rafael
  • Ochagavía Calvo, Ana|||0000-0002-0564-2913
  • Blanch, Lluís|||0000-0002-4158-7464
  • Roca Gas, Oriol|||0000-0003-3841-4551
  • López-Aguilar, Josefina|||0000-0003-2359-3980
  • Fernández-Gonzalo, Sol|||0000-0003-0267-0617
Intensive Care Unit (ICU) COVID-19 survivors may present long-term cognitive and emotional difficulties after hospital discharge. This study aims to characterize the neuropsychological dysfunction of COVID-19 survivors 12 months after ICU discharge, and to study whether the use of a measure of perceived cognitive deficit allows the detection of objective cognitive impairment. We also explore the relationship between demographic, clinical and emotional factors, and both objective and subjective cognitive deficits. Critically ill COVID-19 survivors from two medical ICUs underwent cognitive and emotional assessment one year after discharge. The perception of cognitive deficit and emotional state was screened through self-rated questionnaires (Perceived Deficits Questionnaire, Hospital Anxiety and Depression Scale and Davidson Trauma Scale), and a comprehensive neuropsychological evaluation was carried out. Demographic and clinical data from ICU admission were collected retrospectively. Out of eighty participants included in the final analysis, 31.3% were women, 61.3% received mechanical ventilation and the median age of patients was 60.73 years. Objective cognitive impairment was observed in 30% of COVID-19 survivors. The worst performance was detected in executive functions, processing speed and recognition memory. Almost one in three patients manifested cognitive complaints, and 22.5%, 26.3% and 27.5% reported anxiety, depression and post-traumatic stress disorder (PTSD) symptoms, respectively. No significant differences were found in the perception of cognitive deficit between patients with and without objective cognitive impairment. Gender and PTSD symptomatology were significantly associated with perceived cognitive deficit, and cognitive reserve with objective cognitive impairment. One-third of COVID-19 survivors suffered objective cognitive impairment with a frontal-subcortical dysfunction 12 months after ICU discharge. Emotional disturbances and perceived cognitive deficits were common. Female gender and PTSD symptoms emerged as predictive factors for perceiving worse cognitive performance. Cognitive reserve emerged as a protective factor for objective cognitive functioning. Trial registration : ClinicalTrials.gov Identifier: NCT04422444; June 9, 2021. The online version contains supplementary material available at 10.1186/s13054-023-04478-7.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mental impact of Covid-19 among Spanish healthcare workers. A large longitudinal survey

  • Alonso, Jordi|||0000-0001-8627-9636
  • Vilagut, Gemma|||0000-0002-3714-226X
  • Alayo, Itxaso|||0000-0002-7333-3450
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Amigo, Franco|||0000-0002-3602-5168
  • Aragón-Peña, Andrés
  • Aragonès, Enric|||0000-0002-5245-4667
  • Campos Martorell, Mireia
  • del Cura-González, Isabel
  • Urreta-Barallobre, Iratxe|||0000-0003-0498-6033
  • Espuga Jordana, Meritxell|||0000-0003-2723-2699
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Haro Abad, Josep Maria|||0000-0002-3984-277X
  • López Fresneña, Nieves
  • Martínez De Salázar, Alma
  • Molina, Juan De Dios
  • Ortí-Lucas, Rafael M.|||0000-0003-2211-7413
  • Parellada, Mara|||0000-0001-7977-3601
  • Pelayo-Terán, José María
  • Pérez Zapata, Aurora
  • Pijoan, Jose Ignacio
  • Plana, Maria Nieves|||0000-0003-0921-7954
  • Puig Reixach, Maria Teresa|||0000-0003-1402-7653
  • Rius i Gibert, Maria Cristina|||0000-0001-5189-6503
  • Rodriguez-Blazquez, Carmen|||0000-0003-3829-0675
  • Sanz, Ferran|||0000-0002-7534-7661
  • Serra, Consol|||0000-0001-8337-8356
  • Kessler, Ronald|||0000-0003-4831-2305
  • Bruffaerts, Ronny|||0000-0002-0330-3694
  • Vieta, Eduard|||0000-0002-0548-0053
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Mortier, Philippe|||0000-0003-2113-6241
Aims Longitudinal data on the mental health impact of the coronavirus disease 2019 (Covid-19) pandemic in healthcare workers is limited. We estimated prevalence, incidence and persistence of probable mental disorders in a cohort of Spanish healthcare workers (Covid-19 waves 1 and 2) -and identified associated risk factors. Methods 8996 healthcare workers evaluated on 5 May-7 September 2020 (baseline) were invited to a second web-based survey (October-December 2020). Major depressive disorder (PHQ-8 ≥ 10), generalised anxiety disorder (GAD-7 ≥ 10), panic attacks, post-traumatic stress disorder (PCL-5 ≥ 7), and alcohol use disorder (CAGE-AID ≥ 2) were assessed. Distal (pre-pandemic) and proximal (pandemic) risk factors were included. We estimated the incidence of probable mental disorders (among those without disorders at baseline) and persistence (among those with disorders at baseline). Logistic regression of individual-level [odds ratios (OR)] and population-level (population attributable risk proportions) associations were estimated, adjusting by all distal risk factors, health care centre and time of baseline interview. Results 4809 healthcare workers participated at four months follow-up (cooperation rate = 65.7%; mean = 120 days s.d. = 22 days from baseline assessment). Follow-up prevalence of any disorder was 41.5%, (v. 45.4% at baseline, p < 0.001); incidence, 19.7% (s.e. = 1.6) and persistence, 67.7% (s.e. = 2.3). Proximal factors showing significant bivariate-adjusted associations with incidence included: work-related factors [prioritising Covid-19 patients (OR = 1.62)], stress factors [personal health-related stress (OR = 1.61)], interpersonal stress (OR = 1.53) and financial factors [significant income loss (OR = 1.37)]. Risk factors associated with persistence were largely similar. Conclusions Our study indicates that the prevalence of probable mental disorders among Spanish healthcare workers during the second wave of the Covid-19 pandemic was similarly high to that after the first wave. This was in good part due to the persistence of mental disorders detected at the baseline, but with a relevant incidence of about 1 in 5 of HCWs without mental disorders during the first wave of the Covid-19 pandemic. Health-related factors, work-related factors and interpersonal stress are important risks of persistence of mental disorders and of incidence of mental disorders. Adequately addressing these factors might have prevented a considerable amount of mental health impact of the pandemic among this vulnerable population. Addressing health-related stress, work-related factors and interpersonal stress might reduce the prevalence of these disorders substantially. Study registration number: NCT04556565.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Krebs von den Lungen-6 glycoprotein circulating levels are not useful as prognostic marker in COVID-19 pneumonia, A large prospective cohort study

  • Castellvi, Ivan|||0000-0002-5410-5807
  • Castillo, Diego|||0000-0002-4862-3595
  • Corominas, Hèctor|||0000-0002-7738-6787
  • Mariscal, Anaís|||0000-0003-1013-4793
  • Orozco, Sandra
  • Benito, Natividad|||0000-0001-6410-013X
  • Pomar, Virginia|||0000-0002-8473-5834
  • Baucells, Andrés|||0000-0002-4567-8486
  • Mur, Isabel|||0000-0001-7660-8483
  • de la Rosa Carrillo, David|||0000-0003-0753-1771
  • Lobo-Prat, David|||0000-0002-4649-1904
  • Millan, Ana Milena
  • Hernández de Sosa, Nerea|||0000-0001-9935-0390
  • Filella, David
  • Matas, Laia
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Juárez Rubio, Cándido|||0000-0003-2235-9893
  • Casademont i Pou, Jordi|||0000-0002-8100-1827
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
Coronavirus disease 2019 (COVID-19) has rapidly expanded worldwide. Currently, there are no biomarkers to predict respiratory worsening in patients with mild to moderate COVID-19 pneumonia. Small studies explored the use of Krebs von de Lungen-6 circulating serum levels (sKL-6) as a prognostic biomarker of the worsening of COVID-19 pneumonia. We aimed at a large study to determine the prognostic value of sKL-6 in predicting evolving trends in COVID-19. We prospectively analyzed the characteristics of 836 patients with COVID-19 with mild lung disease on admission. sKL-6 was obtained in all patients at least at baseline and compared among patients with or without respiratory worsening. The receiver operating characteristic curve was used to find the optimal cutoff level. A total of 159 (19%) patients developed respiratory worsening during hospitalization. Baseline sKL-6 levels were not higher in patients who had respiratory worsening (median {IQR} 315.5 {209-469} vs. 306 {214-423} U/ml p = 0.38). The last sKL-6 and the change between baseline and last sKL-6 were higher in the respiratory worsening group (p = 0.02 and p < 0.0001, respectively). The best sKL-6 cutoff point for respiratory worsening was 497 U/ml (area under the curve 0.52; 23% sensitivity and 85% specificity). sKL-6 was not found to be an independent predictor of respiratory worsening. A conditional inference tree (CTREE) was not useful to discriminate patients at risk of worsening. We found that sKL-6 had a low sensibility to predict respiratory worsening in patients with mild-moderate COVID-19 pneumonia and may not be of use to assess the risk of present respiratory worsening in inpatients with COVID-19 pneumonia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells

  • Garreta, Elena|||0000-0002-1071-9794
  • Prado, Patricia|||0000-0003-2225-9948
  • Stanifer, Megan|||0000-0002-5606-1297
  • Monteil, Vanessa|||0000-0002-2652-5695
  • Marco Giménez, Andrés|||0000-0002-9831-8433
  • Ullate-Agote, Asier|||0000-0002-8595-7703
  • Moya Rull, Daniel|||0000-0002-3555-6477
  • Vilas-Zornoza, Amaia|||0000-0001-6693-0989
  • Tarantino, Carolina|||0000-0003-2470-3803
  • Romero, Juan Pablo|||0000-0002-0441-4791
  • Jonsson, Gustav|||0000-0001-6692-8395
  • Oria, Roger
  • Leopoldi, Alexandra
  • Hagelkruys, Astrid
  • Gallo, Maria|||0000-0001-9099-7235
  • González Grassi, Federico|||0000-0002-7147-2246
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Gavaldà i Navarro, Aleix|||0000-0001-8421-3174
  • Hurtado del Pozo, Carmen
  • Hasan Ali, Omar|||0000-0001-5185-7520
  • Ventura-Aguiar, Pedro|||0000-0003-3381-7503
  • Campistol Plana, Josep M.|||0000-0002-6841-1119
  • Prosper, Felipe|||0000-0001-6115-8790
  • Mirazimi, Ali|||0000-0003-2371-6055
  • Boulant, Steeve|||0000-0001-8614-4993
  • Penninger, Josef|||0000-0002-8194-3777
  • Montserrat, Nuria
It is not well understood why diabetic individuals are more prone to develop severe COVID-19. To this, we here established a human kidney organoid model promoting early hallmarks of diabetic kidney disease development. Upon SARS-CoV-2 infection, diabetic-like kidney organoids exhibited higher viral loads compared with their control counterparts. Genetic deletion of the angiotensin-converting enzyme 2 (ACE2) in kidney organoids under control or diabetic-like conditions prevented viral detection. Moreover, cells isolated from kidney biopsies from diabetic patients exhibited altered mitochondrial respiration and enhanced glycolysis, resulting in higher SARS-CoV-2 infections compared with non-diabetic cells. Conversely, the exposure of patient cells to dichloroacetate (DCA), an inhibitor of aerobic glycolysis, resulted in reduced SARS-CoV-2 infections. Our results provide insights into the identification of diabetic-induced metabolic programming in the kidney as a critical event increasing SARS-CoV-2 infection susceptibility, opening the door to the identification of new interventions in COVID-19 pathogenesis targeting energy metabolism.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection

  • Moga, Esther|||0000-0003-4264-6910
  • Lynton-Pons, Elionor|||0000-0001-5375-7195
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
Two years after the appearance of the SARS-CoV-2 virus, the causal agent of the current global pandemic, it is time to analyze the evolution of the immune protection that infection and vaccination provide. Cellular immunity plays an important role in limiting disease severity and the resolution of infection. The early appearance, breadth and magnitude of SARS-CoV-2 specific T cell response has been correlated with disease severity and it has been thought that T cell responses may be sufficient to clear infection with minimal disease in COVID-19 patients with X-linked or autosomal recessive agammaglobulinemia. However, our knowledge of the phenotypic and functional diversity of CD8+ cytotoxic lymphocytes, CD4+ T helper cells, mucosal-associated invariant T (MAIT) cells and CD4+ T follicular helper (Tfh), which play a critical role in infection control as well as long-term protection, is still evolving. It has been described how CD8+ cytotoxic lymphocytes interrupt viral replication by secreting antiviral cytokines (IFN-γ and TNF-α) and directly killing infected cells, negatively correlating with stages of disease progression. In addition, CD4+ T helper cells have been reported to be key pieces, leading, coordinating and ultimately regulating antiviral immunity. For instance, in some more severe COVID-19 cases a dysregulated CD4+ T cell signature may contribute to the greater production of pro-inflammatory cytokines responsible for pathogenic inflammation. Here we discuss how cellular immunity is the axis around which the rest of the immune system components revolve, since it orchestrates and leads antiviral response by regulating the inflammatory cascade and, as a consequence, the innate immune system, as well as promoting a correct humoral response through CD4+ Tfh cells. This review also analyses the critical role of cellular immunity in modulating the development of high-affinity neutralizing antibodies and germinal center B cell differentiation in memory and long-lived antibody secreting cells. Finally, since there is currently a high percentage of vaccinated population and, in some cases, vaccine booster doses are even being administered in certain countries, we have also summarized newer approaches to long-lasting protective immunity and the cross-protection of cellular immune response against SARS-CoV-2.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

COVID-19 in hospitalized HIV-positive and HIV-negative patients, A matched study

  • Diez, Cristina
  • Del Romero-Raposo, Jorge|||0000-0003-1635-3444
  • Micán-Rivera, R.|||0000-0002-6626-4266
  • López, Juan Carlos
  • Blanco, José Ramón|||0000-0002-4268-0150
  • Calzado, Sonia|||0000-0002-2975-6448
  • Sampériz, Gloria|||0000-0003-0693-2266
  • García-Fraile Fraile, Lucio|||0000-0002-2512-6107
  • Gutiérrez, Félix|||0000-0002-9485-6867
  • Gómez-Sirvent, Juan L.
  • Suárez-García, Inés|||0000-0002-7016-716X
  • Amador, Concha|||0000-0003-0843-8624
  • Novella Mena, María
  • Arribas, José Ramón
  • Moreno, Santiago|||0000-0002-2843-1094
  • González García, Juan|||0000-0002-3652-002X
  • Jarrin, Inmaculada
  • Berenguer, Juan|||0000-0001-8541-8200
  • Navarro, Maria Luisa
  • González, Maria Isabel
  • García, Federico
  • Poveda, Eva|||0000-0003-4835-9875
  • Iribarren, José Antonio
  • Rubio, Rafael
  • Alejos, Belén
  • Moreno, Cristina
  • Iniesta, Carlos|||0000-0002-0928-2679
  • Rava, Marta|||0000-0003-2260-9370
  • Izquierdo, Rebeca
  • Muñoz Fernández, María Ángeles
  • Consuegra Fernández, Irene
  • Merino, Esperanza
  • García, Gema
  • Portilla, Irene
  • Agea, Iván
  • Portilla, Joaquín|||0000-0002-3676-9511
  • Sánchez Payá, José
  • Rodríguez, Juan Carlos
  • Gimeno, Lina
  • Giner, Livia|||0000-0002-1885-3736
  • Díez, Marcos
  • Carreres, Melissa
  • Reus, Sergio|||0000-0002-3320-9754
  • Boix, Vicente|||0000-0002-7015-3948
  • Torrús-Tendero, Diego
  • López Lirola, Ana
  • García, Dácil
  • Díaz-Flores, Felicitas
  • Alonso, María del Mar
  • Pelazas, Ricardo
  • Hernández, Jehovana
  • Alemán, María Remedios
  • Hernández, María Inmaculada
  • Asensi, Víctor
  • Valle, Eulalia
  • Rivas Carmenado, María Eugenia
  • Suárez-Zarracina, Tomás
  • Pérez Is, Laura
  • Pulido, Federico|||0000-0002-7414-8812
  • Bisbal, Otilia|||0000-0003-3746-3378
  • Hernando, Asunción|||0000-0002-1901-1119
  • Domínguez-Domínguez, Lourdes|||0000-0001-6018-9026
  • Rial, David
  • Bermejo, Laura
  • Santacreu, Mireia
  • Arrizabalaga, Julio
  • Aramburu, María José
  • Camino, Xabier
  • Rodríguez-Arrondo, Francisco
  • Von Wichmann, Miguel Ángel
  • Pascual Tomé, Lidia
  • Goenaga, Miguel Ángel
  • Bustinduy, Maria Jesús
  • Azkune, Harkaitz
  • Ibarguren, Maialen
  • Lizardi, Aitziber
  • Kortajarena, Xabier
  • Carmona Oyaga, Maria Pilar
  • Umerez Igartua, Maitane
  • Masiá, Mar|||0000-0001-9878-2458
  • Padilla Urrea, Sergio|||0000-0002-8420-7310
  • Robledano, Catalina
  • Colomé, Joan Gregori
  • Adsuar, Araceli
  • Pascual, Rafael
  • Fernández, Marta
  • García, José Alberto
  • Barber, Xavier|||0000-0003-3079-5855
  • Re, Vanessa
  • Garcia Abellán, Javier
  • Pascual Pérez, Reyes
  • Roca, María
  • Muga, Roberto|||0000-0001-6301-431X
  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Fuster, Daniel|||0000-0003-1262-5860
  • Gutiérrez, Isabel
  • Ramírez, Margarita
  • Padilla Ortega, Belén
  • Gijon, Paloma|||0000-0002-5011-1927
  • Aldámiz-Echevarría Lois, Maria Teresa|||0000-0002-4374-6940
  • Tejerina, Francisco|||0000-0002-4136-3575
  • Parras, Francisco José
  • Balsalobre, Pascual
  • Pérez Latorre, Leire|||0000-0001-9919-3778
  • Fanciulli, Chiara|||0000-0003-2175-9027
  • Vidal, Francesc|||0000-0002-6692-6186
  • Peraire, Joaquín
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Veloso, Sergio
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Olona, Montserrat|||0000-0001-5303-9361
  • Rull, Anna|||0000-0002-8907-7754
  • Alba, Verónica|||0000-0002-5925-9573
  • Yeregui, Elena|||0000-0003-2994-4219
  • Masip, Jenifer|||0000-0002-9233-5195
  • Reverté Calvet, Laia|||0000-0003-4690-2387
  • Montero, Marta|||0000-0002-3432-5394
  • López-Aldeguer, José
  • Blanes, Marino
  • Tasias Pitarch, María
  • Castro Hernández, Iván
  • Calabuig, Eva|||0000-0002-0177-0037
  • Cuéllar, Sandra
  • Salavert, Miguel|||0000-0002-8571-2124
  • Fernández Navarro, Juan
  • Arnalich Fernandez, Francisco|||0000-0003-2943-0373
  • Bernardino, José Ignacio|||0000-0003-3501-8529
  • Busca, Carmen
  • Cano, Joanna
  • Cardiñanos, Julen
  • Castro, Juan Miguel
  • Delgado Hierro, Ana
  • Escosa García, Luis|||0000-0003-0730-4026
  • Herranz Pinto, Pedro|||0000-0002-9840-6628
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • García Bujalance, Silvia
  • García López-Hortelano, Milagros
  • González Baeza, Alicia
  • Miguel, Rosa de
  • Martín Carbonero, Luz|||0000-0001-8102-4079
  • Mayoral, Mario
  • Mellado Peña, María José|||0000-0003-2251-9666
  • Montejano Sanchez, Rocio|||0000-0002-3446-0545
  • Montes, María Luisa|||0000-0003-1748-813X
  • Moreno, Victoria
  • Pérez Valero, Ignacio|||0000-0002-3488-7135
  • Rúa Cebrián, Guadalupe
  • Rodés, Berta
  • Sainz, Talia|||0000-0002-5301-0945
  • Sendagorta, Elena
  • Valencia, Eulalia|||0000-0001-6902-0120
  • Oteo, José A.|||0000-0001-7080-6542
  • Ibarra, Valvanera
  • Metola, Luis
  • Sanz, Mercedes
  • Pérez-Martínez, Laura|||0000-0002-1384-024X
  • Arazo, Piedad
  • Dalmau, David|||0000-0003-1936-478X
  • Jaén, Angels
  • Sanmartí, Montse
  • Cairó, Mireia|||0000-0003-2386-2765
  • Martinez-Lacasa, Javier
  • Velli, Pablo
  • Font, Roser
  • Martinez, Marina
  • Aiello, Tommaso Francesco|||0000-0003-4441-6318
  • Rivero Marcotegui, Maria
  • Repáraz, Jesús
  • Ruiz de Alda, María Gracia
  • De León Cano, María Teresa
  • Pierola, Beatriz
  • Amengual Guedan, Maria Jose|||0000-0002-5385-3061
  • Navarro Rubio, Gemma|||0000-0002-7195-9046
  • Cervantes Garcia, Manuel|||0000-0001-6073-1110
  • Navarro Vilasaro, Marta|||0000-0002-3784-4405
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Sanz Sanz, Jesús
  • Salas, Ana
  • Sarriá, Cristina
  • Martín Gayo, Enrique|||0000-0002-2619-6086
  • Casado, José Luis|||0000-0002-7639-8591
  • Dronda, Fernando|||0000-0002-0443-5816
  • Moreno, Ana
  • Pérez Elías, Mª Jesus|||0000-0001-5700-5257
  • Gutiérrez, Carolina
  • Madrid, Nadia
  • del Campo, Santos|||0000-0003-2234-5432
  • Serrano-Villar, Sergio|||0000-0002-5447-3554
  • Vivancos-Gallego, María J.|||0000-0002-9373-6011
  • Martínez Sanz, Javier|||0000-0003-2020-3908
  • Anxa Urroz, Usua
  • Velasco, Tamara
  • Vallejo, Alejandro
  • Bernal, Enrique|||0000-0002-4041-0579
  • Cano Sánchez, Alfredo
  • Alcaráz, Antonia
  • Bravo Urbieta, Joaquín|||0000-0003-2079-0305
  • Muñoz Perez, Ángeles
  • Alcaraz, Maria Jose
  • Villalba, Maria del Carmen
  • Hernández Quero, José
  • Muñoz Medina, Leopoldo|||0000-0001-8995-8271
  • Álvarez, Marta
  • Chueca, Natalia|||0000-0002-3420-3290
  • Vinuesa, David|||0000-0002-5663-8447
  • Martinez-Montes, Clara
  • Guerrero, Carlos
  • de Salazar, Adolfo|||0000-0002-4318-858X
  • Fuentes, Ana
  • Raposo Utrilla, Montserrat
  • Del Romero Guerrero, Jorge|||0000-0001-8922-5182
  • Rodríguez, Carmen
  • Puerta, Teresa
  • Carrió, Juan Carlos
  • Vera, Mar|||0000-0002-3841-7747
  • Ballesteros, Juan
  • Ayerdi, Oskar|||0000-0002-9441-8031
  • Antela, Antonio
  • Losada, Elena
  • Riera, Melchor
  • Peñaranda, María|||0000-0001-6290-3457
  • Ribas, Maria Àngels
  • Campins, Antoni A.
  • Vidal Lampurdanés, Carmen|||0000-0001-5843-8038
  • Fanjul, Francisco
  • Murillas, Javier|||0000-0003-2169-7110
  • Homar, Francisco|||0000-0003-0116-3277
  • Vilchez, Helem H.
  • Martin, Maria Luisa
  • Payeras, Antoni
  • Santos, Jesús
  • Gómez Ayerbe, Cristina
  • Viciana, Isabel
  • Palacios, Rosario
  • Pérez López, Carmen
  • González Domenec, Carmen María
  • Viciana, Pompeyo|||0000-0001-5606-0166
  • Espinosa, Nuria|||0000-0003-2249-2352
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Podzamczer, Daniel|||0000-0001-7090-3561
  • Imaz, Arkaitz|||0000-0001-8411-1952
  • Tiraboschi, Juan Manuel|||0000-0002-0073-873X
  • Silva, Ana
  • Saumoy, Maria|||0000-0002-0047-1991
  • Prieto, Paula
  • Ribera, Esteban|||0000-0002-3752-8808
  • Curran, Adrian|||0000-0002-1263-0814
  • Olalla, Julian|||0000-0002-8577-3891
  • Pérez Stachowski, Javier|||0000-0002-5189-1953
  • del Arco, Alfonso
  • de la Torre Lima, Javier|||0000-0003-4718-0320
  • Prada, José Luis
  • García de Lomas Guerrero, José María|||0000-0001-8160-8488
  • Martínez, Onofre Juan
  • Vera, Francisco J.
  • Martínez, Lorena
  • García, Josefina
  • Alcaraz, Begoña
  • Jimeno, Amaya
  • Castro, Ángeles
  • Pernas, Berta
  • Mena, Álvaro
  • Muñoz, Josefa
  • Zubero, Miren
  • Baraia-Etxaburu, Josu Mirena
  • Ibarra, Sofia
  • Ferrero, Oscar Luis
  • López de Munain, Josefina
  • Cámara López, Maria Mar
  • De La Peña, Mireia
  • Lopez, Miriam
  • López Azkarreta, Iñigo
  • Galera, Carlos
  • Albendin, Helena
  • Pérez, Aurora
  • Iborra, Asunción
  • Moreno, Antonio
  • Merlos, Maria Angustias
  • Vidal, Asunción
  • Meca, Marisa
  • Pasquau, Francisco
  • Ena, Javier|||0000-0002-1181-7396
  • Benito, Concha
  • Fenoll, Vicenta
  • Gil Anguita, Concepción
  • Algado, José Tomás
  • Malmierca Corral, Eduardo|||0000-0002-4071-7247
  • González-Ruano, Patricia|||0000-0003-0395-7740
  • Martín Rodrigo, Dolores
  • Ruiz Seco, Maria Pilar
  • Omar, Mohamed
  • Gómez Vidal, María Amparo
  • De Zarraga, Miguel Alberto
  • Estrada, Vicente|||0000-0002-7795-5986
  • Téllez, Maria Jesús
  • Vergas, Jorge
  • Pérez-Somarriba, Juncal
  • Górgolas, Miguel
  • Cabello-Ubeda, Alfonso|||0000-0001-8429-8358
  • Álvarez, Beatriz
  • Prieto, Laura
  • Sanz Moreno, José
  • Arranz, Alberto
  • Hernández Gutiérrez, Cristina
  • Galindo Puerto, María José
  • Vilalta, Ramon Fernando
  • Ferrer, Ana Maria|||0000-0002-3381-9472
  • Rivero Román, Antonio|||0000-0002-8643-4250
  • Rivero-Juarez, Antonio|||0000-0002-5813-6889
  • López, Pedro
  • Machuca, Isabel
  • Frias, Mario
  • Camacho, Angela
  • Cervero Jiménez, Miguel|||0000-0001-9387-7917
  • Torres, Rafael
  • Pineda, Juan A.|||0000-0002-3751-0296
  • Rincón, Pilar
  • Macías, Juan|||0000-0002-4778-790X
  • Merchante, Nicolás|||0000-0003-1120-8942
  • Real, Luis M.|||0000-0003-4932-7429
  • Corma Gómez, Anaïs|||0000-0002-1078-0237
  • Fernández Fuertes, Marta
  • Gonzalez-Serna, Alejandro|||0000-0002-0239-8417
  • Pérez González, Alexandre|||0000-0003-4836-6768
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Morano, Luis
  • Miralles, Celia
  • Ocampo Hermida, Antonio|||0000-0002-3176-9758
  • Pousada, Guillermo|||0000-0002-2466-8094
Objectives: We compared the characteristics and clinical outcomes of hospitalized individuals with COVID-19 with [people with HIV (PWH)] and without (non-PWH) HIV co-infection in Spain during the first wave of the pandemic. Methods: This was a retrospective matched cohort study. People with HIV were identified by reviewing clinical records and laboratory registries of 10 922 patients in active-follow-up within the Spanish HIV Research Network (CoRIS) up to 30 June 2020. Each hospitalized PWH was matched with five non-PWH of the same age and sex randomly selected from COVID-19@Spain, a multicentre cohort of 4035 patients hospitalized with confirmed COVID-19. The main outcome was all-cause in-hospital mortality. Results: Forty-five PWH with PCR-confirmed COVID-19 were identified in CoRIS, 21 of whom were hospitalized. A total of 105 age/sex-matched controls were selected from the COVID-19@Spain cohort. The median age in both groups was 53 (Q1-Q3, 46-56) years, and 90.5% were men. In PWH, 19.1% were injecting drug users, 95.2% were on antiretroviral therapy, 94.4% had HIV-RNA < 50 copies/mL, and the median (Q1-Q3) CD4 count was 595 (349-798) cells/μL. No statistically significant differences were found between PWH and non-PWH in number of comorbidities, presenting signs and symptoms, laboratory parameters, radiology findings and severity scores on admission. Corticosteroids were administered to 33.3% and 27.4% of PWH and non-PWH, respectively (P = 0.580). Deaths during admission were documented in two (9.5%) PWH and 12 (11.4%) non-PWH (P = 0.800). Conclusions: Our findings suggest that well-controlled HIV infection does not modify the clinical presentation or worsen clinical outcomes of COVID-19 hospitalization.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Health service and psychotropic medication use for mental health conditions among healthcare workers active during the Spain Covid-19 Pandemic, A prospective cohort study using web-based surveys

  • Mortier, Philippe|||0000-0003-2113-6241
  • Vilagut, Gemma|||0000-0002-3714-226X
  • García-Mieres, Helena|||0000-0002-2813-1737
  • Alayo, Itxaso|||0000-0002-7333-3450
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Amigo, Franco|||0000-0002-3602-5168
  • Aragonès, Enric|||0000-0002-5245-4667
  • Aragón-Peña, Andrés
  • Asúnsolo del Barco, Ángel
  • Campos Martorell, Mireia
  • Espuga Jordana, Meritxell|||0000-0003-2723-2699
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Haro Abad, Josep Maria|||0000-0002-3984-277X
  • López Fresneña, Nieves
  • Martínez de Salázar, Alma D.
  • Molina, Juan D.|||0000-0001-8561-8130
  • Ortí-Lucas, Rafael M.|||0000-0003-2211-7413
  • Parellada, Mara|||0000-0001-7977-3601
  • Pelayo-Terán, José Maria|||0000-0001-9711-2874
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Pérez-Zapata, Aurora
  • Pijoan, José Ignacio
  • Plana, Nieves
  • Polentinos-Castro, Elena|||0000-0001-9460-2966
  • Portillo-Van Diest, Ana|||0000-0001-7199-8339
  • Puig Reixach, Maria Teresa|||0000-0003-1402-7653
  • Rius i Gibert, Maria Cristina|||0000-0001-5189-6503
  • Sanz, Ferran|||0000-0002-7534-7661
  • Serra, Consol|||0000-0001-8337-8356
  • Urreta-Barallobre, Iratxe|||0000-0003-0498-6033
  • Kessler, Ronald|||0000-0003-4831-2305
  • Bruffaerts, Ronny|||0000-0002-0330-3694
  • Vieta, Eduard|||0000-0002-0548-0053
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Alonso, Jordi|||0000-0001-8627-9636
Little is known about healthcare workers' (HCW) use of healthcare services for mental disorders. This study presents data from a 16-month prospective cohort study of Spanish HCW (n = 4,809), recruited shortly after the COVID-19 pandemic onset, and assessed at four timepoints using web-based surveys. Use of health services among HCW with mental health conditions (i.e., those having a positive screen for mental disorders and/or suicidal thoughts and behaviours [STB]) was initially low (i.e., 18.2 %) but increased to 29.6 % at 16-month follow-up. Service use was positively associated with pre-pandemic mental health treatment (OR=1.99), a positive screen for major depressive disorder (OR=1.50), panic attacks (OR=1.74), suicidal thoughts and behaviours (OR=1.22), and experiencing severe role impairment (OR=1.33), and negatively associated with being female (OR = 0.69) and a higher daily number of work hours (OR=0.95). Around 30 % of HCW with mental health conditions used anxiolytics (benzodiazepines), especially medical doctors. Four out of ten HCW (39.0 %) with mental health conditions indicated a need for (additional) help, with most important barriers for service use being too ashamed, long waiting lists, and professional treatment not being available. Our findings delineate a clear mental health treatment gap among Spanish HCW.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Impact of COVID-19 disease on placental histopathology. PLAXAVID study

  • Montáns Araújo, José
  • García Ruiz, Itziar
  • Garcia Aguilar, E.
  • Hidalgo Bermejo, F. J.
  • Suy Franch, Anna
  • Maiz, Nerea
COVID-19 disease; Placental histopathology, Malaltia COVID-19; Histopatologia placentària, Enfermedad COVID-19; Histopatología placentaria, Background: The impact of COVID-19 on pregnancy has been analyzed suggesting an increased risk of placental lesions that might lead to maternal and neonatal complications. However, the current published evidence is not conclusive because contradictory results. Methods: PLAXAVID is an observational, retrospective, histopathological, single-center study that aimed to evaluate the prevalence of vascular and inflammatory lesions in placental and umbilical cord samples of one hundred women infected by SARS-CoV-2 during pregnancy. Results: The histopathological analysis showed that in most of the placentas (77.8%) there were signs of maternal vascular malperfusion (MVM; primary endpoint). The most common MVM features were an accelerated villous maturation (37.4%), central villous infarcts (33.3%), and villous agglutination (46.5%). Fetal vascular malperfusion (FVM) was identified in 57.6% of samples, and the most frequent features were hyalinized avascular villi (38.4%), fetal vascular thrombi (20.2%) and umbilical cord at risk of partial obstruction (14.1%). Acute and chronic inflammatory pathology were noticed in 22.2% and 49.5% of placentas, respectively. No significant correlations were found between MVM presence and the time, duration, and severity of infection, nor with the duration of pregnancy. However, in critically ill patients, the pregnancy duration (p=0.008), newborn weight (p=0.003), and APGAR test scores (p<0.001) were significantly lower. The same trend was observed considering the presence of infection at the time of delivery and in preterm births. Conclusion: A very high percentage of placentas with vascular and/or inflammatory lesions was found in the analyzed cohort. Therefore, PLAXAVID study results supported that COVID-19 should be considered a risk factor during gestation and requires close monitoring of pregnancy., The study has been founded by ITF Research Pharma S.L.U. The Gesta-COVID19 was supported by a grant from Instituto de Salud Carlos III (ISCIII) (COV20/00188).
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Shaping current European mitochondrial haplogroup frequency in response to infection: the case ofSARS-CoV-2severity

  • Cabrera Alarcón, José Luis
  • Cruz, Raquel
  • Rosa Moreno, Marina
  • Latorre Pellicer, Ana
  • Diz de Almeida, Silvia
  • Scourge Cohort Group
  • Riancho, José A.
  • Rojas Martínez, Augusto
  • Flores, Carlos
  • Lapunzina, Pablo
  • Sánchez Cabo, Fátima
  • Carracedo, Ángel
  • Enriquez, José Antonio
Scourge Cohort Group: Javier Abellán, René Acosta-Isaac, Jose María Aguado, Carlos Aguilar, Sergio Aguilera-Albesa, Abdolah Ahmadi Sabbagh, Jorge Alba, Sergiu Albu, Karla A M Alcalá-Gallardo, Julia Alcoba-Florez, Sergio Alcolea Batres, Holmes Rafael Algarin-Lara, Virginia Almadana, Kelliane A Medeiros, Julia Almeida, Berta Almoguera, María R Alonso, Nuria Álvarez, Rodolfo Álvarez-Sala Walther, Yady Álvarez-Benítez, Felipe Álvarez-Navia, Katiusse A Dos Santos, Álvaro Andreu-Bernabeu, Maria Rosa Antonijoan, Eleno Martínez-Aquino, Eunate Arana-Arri, Carlos Aranda, Celso Arango, Carolina Araque, Nathalia K Araujo, Ana C Arcanjo, Ana Arnaiz, Francisco Arnalich Fernández, María J Arranz, José Ramón Arribas López, Maria-Jesús Artiga, Yubelly Avello-Malaver, Carmen Ayuso, Belén Ballina Martín, Raúl C Baptista-Rosas, Ana María Baldion, Andrea Barranco-Díaz, María Barreda-Sánchez, Viviana Barrera-Penagos, Moncef Belhassen-Garcia, David Bernal-Bello, Enrique Bernal, Joao F Bezerra, Marcos A C Bezerra, Natalia Blanca-López, Rafael Blancas, Lucía Boix-Palop, Alberto Borobia, Elsa Bravo, María Brion, Óscar Brochado-Kith, Ramón Brugada, Matilde Bustos, Alfonso Cabello, Alejandro Cáceres, Juan J Cáceres-Agra, Esther Calbo, Enrique J Calderón, Shirley Camacho, Francisco C Ceballos, Yolanda Cañadas, Cristina Carbonell, Servando Cardona-Huerta, María Sánchez-Carpintero Abad, Carlos Carpio-Segura, José Antonio Carrillo-Avila, Marcela C Campos, Carlos Casasnovas, Luis Castaño, Carlos F Castaño, Jose E Castelao, Aranzazu Castellano Candalija, María A Castillo, Walter G Chaves-Santiago, Sylena Chiquillo-Gómez, Marco A Cid-López, Óscar Cienfuegos-Jiménez, Rosa Conde-Vicente, Gabriela C R Cunha, M Lourdes Cordero-Lorenzana, Dolores Corella, Almudena Corrales, Jose L Cortés-Sánchez, Marta Corton, Karla S C Souza, Fabiola T C Silva, Raquel Cruz, Luisa Cuesta, Nathali A C Tavares, Maria C C Carvalho, David Dalmau, Raquel C S Dantas-Komatsu, M Teresa Darnaude, Raimundo de Andrés, Carmen de Juan, Juan J de la Cruz Troca, Carmen de la Horra, Ana B de la Hoz, Alba De Martino-Rodríguez, Marina S Cruz, Julianna Lys de Sousa Alves Neri, Victor Del Campo-Pérez, Juan Delgado-Cuesta, Aranzazu Diaz de Bustamante, Anderson Díaz-Pérez, Beatriz Dietl, Silvia Diz-de Almeida, Manoella do Monte Alves, Elena Domínguez-Garrido, Lidia S Rosa, Andre D Luchessi, Jose Echave-Sustaeta, Rocío Eiros, César O Enciso-Olivera, Gabriela Escudero, Pedro Pablo España, Gladys Estigarribia Sanabria, María Carmen Fariñas, Ramón Fernández, Lidia Fernández-Caballero, Ana Fernández-Cruz, Silvia Fernández-Ferrero, Yolanda Fernández Martínez, María J Fernandez-Nestosa, Uxía Fernández-Robelo, Amanda Fernández-Rodríguez, Marta Fernández-Sampedro, Ruth Fernández, Tania Fernández-Villa, Carmen Fernández-Capitán, Antonio Augusto F Carioca, Patricia Flores-Pérez, Lácides Fuenmayor-Hernández, Marta Fuertes-Núñez, Victoria Fumadó, Ignacio Gadea, Lidia Gagliardi, Manuela Gago-Domínguez, Natalia Gallego, Cristina Galoppo, Ana García-Soidán, Carlos García-Cerrada, Aitor García-de-Vicuña, Josefina Garcia-García, Irene García-García, Carmen García-Ibarbia, Andrés C García-Montero, Leticia García, Mercedes García, María Carmen García Torrejón, Inés García, Elisa García-Vázquez, Emiliano Garza-Frias, Angela Gentile, Belén Gil-Fournier, Jéssica N G de Araújo, Mario Gómez-Duque, Javier Gómez-Arrue, Luis Gómez Carrera, María Gómez García, Ángela Gómez Sacristán, Juan R González, Anna González-Neira, Beatriz González Álvarez, Fernán González Bernaldo de Quirós, Rafaela González-Montelongo, Javier González-Peñas, Manuel Gonzalez-Sagrado, Hugo Gonzalo-Benito, Oscar Gorgojo-Galindo, Miguel Górgolas, Florencia Guaragna, Jessica G Chaux, Encarna Guillén-Navarro, Beatriz Guillén-Guío, Pablo Guisado-Vasco, Luz D Gutiérrez-Castañeda, Juan F Gutiérrez-Bautista, Sara Heili-Frades, Rafael H Jacomo, Estefania Hernández, Cristina Hernández-Moro, Luis D Hernández-Ortega, Guillermo Hernández-Pérez, Rebeca Hernández-Vaquero, Belén Herráez, M Teresa Herranz, María Herrera, María José Herrero, Antonio Herrero-González, Juan P Horcajada, Natale Imaz-Ayo, Maider Intxausti-Urrutibeaskoa, Antonio Íñigo-Campos, María Íñiguez, Rubén Jara, Ángel Jiménez, Pilar Jiménez, María A Jiménez-Sousa, Iolanda Jordan, Ignacio Jiménez-Alfaro, Rocío Laguna-Goya, Daniel Laorden, María Lasa-Lázaro, María Claudia Lattig, Ailen Lauriente, Anabel Liger Borja, Lucía Llanos, Amparo López-Bernús, Miguel López de Heredia, Esther Lopez-Garcia, Eduardo López-Granados, Rosario Lopez-Rodriguez, Miguel A López-Ruz, Leonardo Lorente, José M Lorenzo-Salazar, José E Lozano, María Lozano-Espinosa, Ignacio Mahillo, Esther Mancebo, Carmen Mar, Cristina Marcelo Calvo, Alba Marcos-Delgado, Miguel Marcos, Alicia Marín-Candón, Pablo Mariscal-Aguilar, Laura Martin-Pedraza, Marta Martin-Fernandez, Caridad Martín-López, José-Ángel Martín-Oterino, María Dolores Martín, Vicente Martín, María M Martín, María Martín-Vicente, Amalia Martinez, Óscar Martínez-González, Ricardo Martínez, Pedro Martinez-Paz, Covadonga M Díaz-Caneja, Óscar Martínez-Nieto, Iciar Martínez-López, Michel F Martínez-Reséndez, Silvia Martínez, Juan José Martínez, Ángel Martínez-Pérez, Andrea Martínez-Ramas, Violeta Martínez-Robles, Laura Marzal, Juliana F Mazzeu, Francisco J Medrano, Xose M Meijome, Natalia Mejuto-Montero, Ingrid Mendes, Alice L Duarte, Ana Méndez-Echevarría, Humberto Mendoza Charris, Eleuterio Merayo Macías, Fátima Mercadillo, Arieh R Mercado-Sesma, Pablo Mínguez, Elena Molina-Roldán, Antonio J J Molina, Juan José Montoya, Susana M T Pinho, Patricia Moreira-Escriche, Xenia Morelos-Arnedo, Rocío Moreno, Víctor Moreno Cuerda, Antonio Moreno-Docón, Junior Moreno-Escalante, Alberto Moreno Fernández, Patricia Muñoz García, Pablo Neira, Julián Nevado, Israel Nieto-Gañán, Vivian N Silbiger, Rocío Nuñez-Torres, Antònia Obrador-Hevia, J Gonzalo Ocejo-Vinyals, Virginia Olivar, Silviene F Oliveira, Lorena Ondo, Alberto Orfao, Eva Ortega-Paino, Luis Ortega, Rocío Ortiz-López, Fernando Ortiz-Flores, José A Oteo, Manuel Pacheco, Fredy Javier Pacheco-Miranda, Irene Padilla-Conejo, Sonia Panadero-Fajardo, Mara Parellada, Roberto Pariente-Rodríguez, Vicente Friaza, Estela Paz-Artal, Germán Peces-Barba, Miguel S Pedromingo Kus, Celia Perales, Ney P C Santos, Genilson P Guegel, María Jazmín Pérez, Alexandra Pérez, Patricia Pérez-Matute, César Pérez, Gustavo Pérez-de-Nanclares, Felipe Pérez-García, Patricia Pérez, Luis A Pérez-Jurado, M Elena Pérez-Tomás, Teresa Perucho, Lisbeth A Pichardo, Adriana P Ribeiro, Mel Lina Pinsach-Abuin, Luz Adriana Pinzón, Jeane F P Medeiros, Guillermo Pita, Francesc Pla-Juncà, Laura Planas-Serra, Ericka N Pompa-Mera, Gloria L Porras-Hurtado, Aurora Pujol, María Eugenia Quevedo-Chávez, Maria Angeles Quijada, Inés Quintela, Soraya Ramiro-León, Pedro Rascado Sedes, Joana F R Nunes, Delia Recalde, Emma Recio-Fernández, Salvador Resino, Renata R Sousa, Carlos S Rivadeneira-Chamorro, Diana Roa-Agudelo, Montserrat Robelo Pardo, Marianne R Fernandes, María A Rodríguez-Hernández, Agustí Rodriguez-Palmero, Emilio Rodríguez-Ruiz, Marilyn Johanna Rodriguez, Fernando Rodríguez-Artalejo, Marena Rodríguez-Ferrer, Carlos Rodríguez-Gallego, José A Rodríguez-García, Belén Rodríguez Maya, Antonio Rodriguez-Nicolas, German Ezequiel Rodríguez-Novoa, Paula A Rodriguez-Urrego, Federico Rojo, Andrea Romero-Coronado, Rubén Morilla, Filomeno Rondón-García, Antonio Rosales-Castillo, Cladelis Rubio, María Rubio Olivera, Francisco Ruiz-Cabello, Eva Ruiz-Casares, Juan J Ruiz-Cubillan, Javier Ruiz-Hornillos, Montserrat Ruiz, Pablo Ryan, Hector D Salamanca, Lorena Salazar-García, Giorgina Gabriela Salgueiro-Origlia, Anna Sangil, Olga Sánchez-Pernaute, Pedro-Luis Sánchez, Antonio J Sánchez López, Clara Sánchez-Pablo, María Concepción Sánchez-Prados, Javier Sánchez-Real, Jorge Sánchez-Redondo, Cristina Sancho-Sainz, Esther Sande, Arnoldo Santos, Agatha Schlüter, Sonia Segovia, Alex Serra-Llovich, Fernando Sevil-Puras, Marta Sevilla-Porras, Miguel A Sicolo, Cristina Silván-Fuentes, Vitor M S Moraes, Vanessa S Souza, Jordi Solé-Violán, José Manuel Soria, Jose V Sorlí, Nayara S Silva, Juan Carlos Souto, John J Sprockel, José Javier Suárez-Rama, David A Suárez-Zamora, Xiana Taboada-Fraga, Eduardo Tamayo, Alvaro Tamayo-Velasco, Juan Carlos Taracido-Fernández, Romero H T Vasconcelos, Carlos Tellería, Thássia M T Carratto, Jair Antonio Tenorio-Castaño, Alejandro Teper, Izabel M T Araujo, Juan Torres-Macho, Lilian Torres-Tobar, Ronald P Torres-Gutiérrez, Jesús Troya, Miguel Urioste, Juan Valencia-Ramos, Agustín Valido, Juan Pablo Vargas-Gallo, Belén Varón, Tomas Vega, Santiago Velasco-Quirce, Valentina Vélez-Santamaría, Virginia Víctor, Julia Vidán-Estévez, Gabriela V Silva, Miriam Vieitez-Santiago, Carlos Vilches, Lavinia Villalobos, Felipe Villar, Judit Villar-Garcia, Cristina Villaverde, Pablo Villoslada-Blanco, Ana Virseda-Berdices, Tatiana X Costa, Zuleima Yáñez, Antonio Zapatero-Gaviria, Ruth Zarate, Sandra Zazo, Carlos Flores, José A Riancho, Augusto Rojas-Martinez, Pablo Lapunzina, Ángel Carracedo, The frequency of mitochondrial DNA haplogroups (mtDNA-HG) in humans is known to be shaped by migration and repopulation. Mounting evidence indicates that mtDNA-HG are not phenotypically neutral, and selection may contribute to its distribution. Haplogroup H, the most abundant in Europe, improved survival in sepsis. Here we developed a random forest trained model for mitochondrial haplogroup calling using data procured from GWAS arrays. Our results reveal that in the context of the SARS-CoV-2 pandemic, HV branch were found to represent protective factors against the development of critical SARS-CoV-2 in an analysis of 14,349 patients. These results highlight the role of mtDNA in the response to infectious diseases and support the proposal that its expansion and population proportion has been influenced by selection through successive pandemics., Agencia Estatal de Investigación, Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Fundación Amancio Ortega Gaona, Banco de Santander S.A., Human Frontier Science Program, Leducq Foundation, European Regional Development Fund
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study

  • Abajo Iglesias, Francisco José de|||0000-0001-9119-8646
  • Rodríguez Miguel, Antonio
  • Rodríguez Martín, Sara|||0000-0003-3539-1470
  • Lerma Hambleton, Victoria Beatriz
  • García Lledó, José Alberto|||0000-0002-8986-2584
  • MED-ACE2-COVID19 Study Group
Additional commentary on: Vidal-Petiot and Gault, "BMC Medicine" (2021) 19:136: https://doi.org/10.1186/s12916-021-02012-6, Background: In the first wave of the COVID-19 pandemic, the hypothesis that angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) increased the risk and/or severity of the disease was widely spread. Consequently, in many hospitals, these drugs were discontinued as a “precautionary measure”. We aimed to assess whether the in-hospital discontinuation of ARBs or ACEIs, in real-life conditions, was associated with a reduced risk of death as compared to their continuation and also to compare head-to-head the continuation of ARBs with the continuation of ACEIs. Methods: Adult patients with a PCR-confirmed diagnosis of COVID-19 requiring admission during March 2020 were consecutively selected from 7 hospitals in Madrid, Spain. Among them, we identified outpatient users of ACEIs/ARBs and divided them in two cohorts depending on treatment discontinuation/continuation at admission. Then, they were followed-up until discharge or in-hospital death. An intention-to-treat survival analysis was carried out and hazard ratios (HRs), and their 95%CIs were computed through a Cox regression model adjusted for propensity scores of discontinuation and controlled by potential mediators. Results: Out of 625 ACEI/ARB users, 340 (54.4%) discontinued treatment. The in-hospital mortality rates were 27.6% and 27.7% in discontinuation and continuation cohorts, respectively (HR=1.01; 95%CI 0.70–1.46). No difference in mortality was observed between ARB and ACEI discontinuation (28.6% vs. 27.1%, respectively), while a significantly lower mortality rate was found among patients who continued with ARBs (20.8%, N=125) as compared to those who continued with ACEIs (33.1%, N=136; p=0.03). The head-to-head comparison (ARB vs. ACEI continuation) yielded an adjusted HR of 0.52 (95%CI 0.29–0.93), being especially notorious among males (HR=0.34; 95%CI 0.12– 0.93), subjects older than 74 years (HR=0.46; 95%CI 0.25–0.85), and patients with obesity (HR=0.22; 95%CI 0.05–0.94), diabetes (HR=0.36; 95%CI 0.13–0.97), and heart failure (HR=0.12; 95%CI 0.03–0.97). Conclusions: The discontinuation of ACEIs/ARBs at admission did not improve the in-hospital survival. On the contrary, the continuation with ARBs was associated with a trend to a reduced mortality as compared to their discontinuation and to a significantly lower mortality risk as compared to the continuation with ACEIs, particularly in high-risk patients., Instituto de Salud Carlos III, Universidad de Alcalá, Biomedical Research Foundation from the University Hospital Príncipe de Asturias
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

  • Pérez Jurado, Luis A.
  • Cáceres, Alejandro
  • Balagué Dobón, Laura
  • Esko, Tonu
  • López de Heredia, Miguel
  • Quintela, Inés
  • Cruz, Raquel
  • Lapunzina, Pablo
  • Carracedo, Ángel
  • Scourge Cohort Group
  • González, Juan R.
SCOURGE Cohort Group: Javier Abellán, René Acosta-Isaac, Jose María Aguado, Carlos Aguilar, Sergio Aguilera-Albesa, Abdolah Ahmadi Sabbagh, Jorge Alba, Sergiu Albu, Karla A M Alcalá-Gallardo, Julia Alcoba-Florez, Sergio Alcolea Batres, Holmes Rafael Algarin-Lara, Virginia Almadana, Kelliane A Medeiros, Julia Almeida, Berta Almoguera, María R Alonso, Nuria Álvarez, Rodolfo Álvarez-Sala Walther, Yady Álvarez-Benítez, Felipe Álvarez-Navia, Katiusse A Dos Santos, Álvaro Andreu-Bernabeu, Maria Rosa Antonijoan, Eleno Martínez-Aquino, Eunate Arana-Arri, Carlos Aranda, Celso Arango, Carolina Araque, Nathalia K Araujo, Ana C Arcanjo, Ana Arnaiz, Francisco Arnalich Fernández, María J Arranz, José Ramón Arribas López, Maria-Jesús Artiga, Yubelly Avello-Malaver, Carmen Ayuso, Belén Ballina Martín, Raúl C Baptista-Rosas, Ana María Baldion, Andrea Barranco-Díaz, María Barreda-Sánchez, Viviana Barrera-Penagos, Moncef Belhassen-Garcia, David Bernal-Bello, Enrique Bernal, Joao F Bezerra, Marcos A C Bezerra, Natalia Blanca-López, Rafael Blancas, Lucía Boix-Palop, Alberto Borobia, Elsa Bravo, María Brion, Óscar Brochado-Kith, Ramón Brugada, Matilde Bustos, Alfonso Cabello, Juan J Cáceres-Agra, Esther Calbo, Enrique J Calderón, Shirley Camacho, Francisco C Ceballos, Yolanda Cañadas, Cristina Carbonell, Servando Cardona-Huerta, María Sánchez-Carpintero Abad, Carlos Carpio Segura, José Antonio Carrillo-Avila, Marcela C Campos, Carlos Casasnovas, Luis Castaño, Carlos F Castaño, Jose E Castelao, Aranzazu Castellano Candalija, María A Castillo, Walter G Chaves-Santiago, Sylena Chiquillo-Gómez, Marco A Cid-López, Óscar Cienfuegos-Jiménez, Rosa Conde-Vicente, Gabriela C R Cunha, M Lourdes Cordero-Lorenzana, Dolores Corella, Almudena Corrales, Jose L Cortés-Sánchez, Marta Corton, Karla S C Souza, Fabiola T C Silva, Luisa Cuesta, Nathali A C Tavares, Maria C C Carvalho, David Dalmau, Raquel C S Dantas-Komatsu, M Teresa Darnaude, Raimundo de Andrés, Carmen de Juan, Juan J de la Cruz Troca, Carmen de la Horra, Ana B de la Hoz, Alba De Martino-Rodríguez, Marina S Cruz, Julianna Lys de Sousa Alves Neri, Victor Del Campo-Pérez, Juan Delgado-Cuesta, Aranzazu Diaz de Bustamante, Anderson Díaz-Pérez, Beatriz Dietl, Silvia Diz-de Almeida, Manoella do Monte Alves, Elena Domínguez-Garrido, Lidia S Rosa, Andre D Luchessi, Jose Echave-Sustaeta, Rocío Eiros, César O Enciso-Olivera, Gabriela Escudero, Pedro Pablo España, Gladys Estigarribia Sanabria, María Carmen Fariñas, Ramón Fernández, Lidia Fernández-Caballero, Ana Fernández-Cruz, Silvia Fernández-Ferrero, Yolanda Fernández Martínez, María J Fernandez-Nestosa, Uxía Fernández-Robelo, Amanda Fernández-Rodríguez, Marta Fernández-Sampedro, Ruth Fernández, Tania Fernández-Villa, Carmen Fernández-Capitán, Antonio Augusto F Carioca, Patricia Flores-Pérez, Lácides Fuenmayor-Hernández, Marta Fuertes-Núñez, Victoria Fumadó, Ignacio Gadea, Lidia Gagliardi, Manuela Gago-Domínguez, Natalia Gallego, Cristina Galoppo, Ana García-Soidán, Carlos García-Cerrada, Aitor García-de-Vicuña, Josefina Garcia-García, Irene García-García, Carmen García-Ibarbia, Andrés C García-Montero, Leticia García, Mercedes García, María Carmen García Torrejón, Inés García, Elisa García-Vázquez, Emiliano Garza-Frias, Angela Gentile, Belén Gil-Fournier, Jéssica N G de Araújo, Mario Gómez-Duque, Javier Gómez-Arrue, Luis Gómez Carrera, María Gómez García, Ángela Gómez Sacristán, Juan R González, Anna González-Neira, Beatriz González Álvarez, Fernán González Bernaldo de Quirós, Rafaela González-Montelongo, Javier González-Peñas, Manuel Gonzalez-Sagrado, Hugo Gonzalo-Benito, Oscar Gorgojo-Galindo, Miguel Górgolas, Florencia Guaragna, Jessica G Chaux, Encarna Guillén-Navarro, Beatriz Guillén-Guío, Pablo Guisado-Vasco, Luz D Gutiérrez-Castañeda, Juan F Gutiérrez-Bautista, Sara Heili-Frades, Rafael H Jacomo, Estefania Hernández, Cristina Hernández-Moro, Luis D Hernández-Ortega, Guillermo Hernández-Pérez, Rebeca Hernández-Vaquero, Belén Herráez, M Teresa Herranz, María Herrera, María José Herrero, Antonio Herrero-González, Juan P Horcajada, Natale Imaz-Ayo, Maider Intxausti-Urrutibeaskoa, Antonio Íñigo-Campos, María Íñiguez, Rubén Jara, Ángel Jiménez, Ignacio Jiménez-Alfaro, Pilar Jiménez, María A Jiménez-Sousa, Iolanda Jordan, Rocío Laguna-Goya, Daniel Laorden, María Lasa-Lázaro, María Claudia Lattig, Ailen Lauriente, Anabel Liger Borja, Lucía Llanos, Amparo López-Bernús, Miguel López de Heredia, Esther Lopez-Garcia, Eduardo López-Granados, Rosario Lopez-Rodriguez, Miguel A López-Ruz, Leonardo Lorente, José M Lorenzo-Salazar, José E Lozano, María Lozano-Espinosa, Ignacio Mahillo, Esther Mancebo, Carmen Mar, Cristina Marcelo Calvo, Alba Marcos-Delgado, Miguel Marcos, Alicia Marín-Candón, Pablo Mariscal-Aguilar, Laura Martin-Pedraza, Marta Martin-Fernandez, Caridad Martín-López, José-Ángel Martín-Oterino, María Dolores Martín, Vicente Martín, María M Martín, María Martín-Vicente, Amalia Martinez, Óscar Martínez-González, Ricardo Martínez, Pedro Martinez-Paz, Covadonga M Díaz-Caneja, Óscar Martínez-Nieto, Iciar Martínez-López, Michel F Martínez-Reséndez, Silvia Martínez, Juan José Martínez, Ángel Martínez-Pérez, Andrea Martínez-Ramas, Violeta Martínez-Robles, Laura Marzal, Juliana F Mazzeu, Francisco J Medrano, Xose M Meijome, Natalia Mejuto-Montero, Ingrid Mendes, Alice L Duarte, Ana Méndez-Echevarría, Humberto Mendoza Charris, Eleuterio Merayo Macías, Fátima Mercadillo, Arieh R Mercado-Sesma, Pablo Mínguez, Elena Molina-Roldán, Antonio J J Molina, Juan José Montoya, Susana M T Pinho, Patricia Moreira-Escriche, Xenia Morelos-Arnedo, Rocío Moreno, Víctor Moreno Cuerda, Antonio Moreno-Docón, Junior Moreno-Escalante, Alberto Moreno Fernández, Patricia Muñoz García, Pablo Neira, Julián Nevado, Israel Nieto-Gañán, Vivian N Silbiger, Rocío Nuñez-Torres, Antònia Obrador-Hevia, J Gonzalo Ocejo-Vinyals, Virginia Olivar, Silviene F Oliveira, Lorena Ondo, Alberto Orfao, Eva Ortega-Paino, Luis Ortega, Rocío Ortiz-López, Fernando Ortiz-Flores, José A Oteo, Manuel Pacheco, Fredy Javier Pacheco-Miranda, Irene Padilla-Conejo, Sonia Panadero-Fajardo, Mara Parellada, Roberto Pariente-Rodríguez, Vicente Friaza, Estela Paz-Artal, Germán Peces-Barba, Miguel S Pedromingo Kus, Celia Perales, Ney P C Santos, Genilson P Guegel, María Jazmín Pérez, Alexandra Pérez, Patricia Pérez-Matute, César Pérez, Gustavo Pérez-de-Nanclares, Felipe Pérez-García, Patricia Pérez, M Elena Pérez-Tomás, Teresa Perucho, Lisbeth A Pichardo, Adriana P Ribeiro, Mel Lina Pinsach-Abuin, Luz Adriana Pinzón, Jeane F P Medeiros, Guillermo Pita, Francesc Pla-Juncà, Laura Planas-Serra, Ericka N Pompa-Mera, Gloria L Porras-Hurtado, Aurora Pujol, María Eugenia Quevedo-Chávez, Maria Angeles Quijada, Inés Quintela, Soraya Ramiro-León, Pedro Rascado Sedes, Joana F R Nunes, Delia Recalde, Emma Recio-Fernández, Salvador Resino, Renata R Sousa, Carlos S Rivadeneira-Chamorro, Diana Roa-Agudelo, Montserrat Robelo Pardo, Marianne R Fernandes, María A Rodríguez-Hernández, Agustí Rodriguez-Palmero, Emilio Rodríguez-Ruiz, Marilyn Johanna Rodriguez, Fernando Rodríguez-Artalejo, Marena Rodríguez-Ferrer, Carlos Rodríguez-Gallego, José A Rodríguez-García, Belén Rodríguez Maya, Antonio Rodriguez-Nicolas, German Ezequiel Rodríguez-Novoa, Paula A Rodriguez-Urrego, Federico Rojo, Andrea Romero-Coronado, Rubén Morilla, Filomeno Rondón-García, Antonio Rosales-Castillo, Cladelis Rubio, María Rubio Olivera, Francisco Ruiz-Cabello, Eva Ruiz-Casares, Juan J Ruiz-Cubillan, Javier Ruiz-Hornillos, Montserrat Ruiz, Pablo Ryan, Hector D Salamanca, Lorena Salazar-García, Giorgina Gabriela Salgueiro-Origlia, Anna Sangil, Olga Sánchez-Pernaute, Pedro-Luis Sánchez, Antonio J Sánchez López, Clara Sánchez-Pablo, María Concepción Sánchez-Prados, Javier Sánchez-Real, Jorge Sánchez-Redondo, Cristina Sancho-Sainz, Esther Sande, Arnoldo Santos, Agatha Schlüter, Sonia Segovia, Alex Serra-Llovich, Fernando Sevil-Puras, Marta Sevilla-Porras, Miguel A Sicolo, Cristina Silván-Fuentes, Vitor M S Moraes, Vanessa S Souza, Jordi Solé-Violán, José Manuel Soria, Jose V Sorlí, Nayara S Silva, Juan Carlos Souto, John J Sprockel, José Javier Suárez-Rama, David A Suárez-Zamora, Xiana Taboada-Fraga, Eduardo Tamayo, Alvaro Tamayo-Velasco, Juan Carlos Taracido-Fernández, Romero H T Vasconcelos, Carlos Tellería, Thássia M T Carratto, Jair Antonio Tenorio-Castaño, Alejandro Teper, Izabel M T Araujo, Juan Torres-Macho, Lilian Torres-Tobar, Ronald P Torres-Gutiérrez, Jesús Troya, Miguel Urioste, Juan Valencia-Ramos, Agustín Valido, Juan Pablo Vargas-Gallo, Belén Varón, Tomas Vega, Santiago Velasco-Quirce, Valentina Vélez-Santamaría, Virginia Víctor, Julia Vidán-Estévez, Gabriela V Silva, Miriam Vieitez-Santiago, Carlos Vilches, Lavinia Villalobos, Felipe Villar, Judit Villar-Garcia, Cristina Villaverde, Pablo Villoslada-Blanco, Ana Virseda-Berdices, Tatiana X Costa, Zuleima Yáñez, Antonio Zapatero-Gaviria, Ruth Zarate, Sandra Zazo, Carlos Flores, José A Riancho, Augusto Rojas-Martinez, The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people., Generalitat de Catalunya, Agencia Estatal de Investigación, Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional, Fundación Amancio Ortega, Banco de Santander, Estonian Research Council
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Machine-learning analysis identifies "elite" viral controllers with increased survival and homeostatic responses in critical COVID-19

  • García Mateo, Nadia
  • Álvaro Meca, Alejandro
  • Postigo, Tamara
  • Ortega, Alicia
  • Fuente, Amanda de La
  • Almansa, Raquel
  • Jorge, Noelia
  • González González, Laura
  • Sánchez Recio, Lara
  • Martínez, Isidoro
  • Martín Vicente, María Dolores
  • Muñoz Gómez, María José
  • Más, Vicente
  • Vázquez, Mónica
  • Cano, Olga
  • Vélez Serrano, Daniel
  • Tamayo, Luis
  • Berezo, José Ángel
  • Herrán Monge, Rubén
  • Blanco, Jesús
  • Enríquez, Pedro
  • Ryan Murúa, Pablo
  • Martínez de la Gándara, Amalia de la
  • Rodríguez, Covadonga
  • Andrade, Gloria
  • Bustamante Munguira, Elena
  • Renedo Sánchez Girón, Gloria
  • Cicuéndez Ávila, Ramón
  • Bustamante Munguira, Juan
  • Trapiello, Wysali
  • Gallego Curto, Elena
  • Úbeda Iglesias, Alejandro
  • Salgado Villén, María
  • Berruguilla Pérez, Enrique
  • Torre, María del Carmen de la
  • Güel, Estel
  • Casadiego, Fernando
  • Estella, Ángel
  • Recuerda Núñez, María
  • Sánchez Calvo, Juan Manuel
  • Campos Fernández, Sandra
  • Peñasco Martín, Yhivian
  • García Unzueta, María Teresa
  • Martínez Varela, Ignacio
  • Bouza Vieiro, María Teresa
  • Pérez García, Felipe|||0000-0002-4885-4334
  • Moreno Romero, Ana
  • Socias Crespí, Lorenzo
  • López Messa, Juan
  • Pérez Bastida, Leire
  • Vidal Cortés, Pablo
  • Río Carbajo, Lorena del
  • Nieto del Olmo, Jorge del
  • Prol Silva, Estefanía
  • Sagredo Meneses, Víctor
  • Albalá Martínez, Noelia
  • González Rivera, Milagros
  • Gómez, José Manuel
  • Carbonell, Nieves
  • Blasco, María Luisa
  • Gonzalo Calvo, David de
  • González, Jessica
  • Caballero, Jesús
  • Barberà, Carme
  • Martín Delgado, María Cruz
  • Valdivia, Luis Jorge
  • Martín López, Caridad
  • Nieto, María Teresa
  • Jorge García, Ruth Noemí
  • Maseda, Emilio
  • Loza Vázquez, Ana
  • Eiros, José María
  • Motos, Anna
  • Fernández Barat, Laia
  • Casenco Ribas, Joan
  • Ceccato, Adrián
  • Barbé, Ferran
  • Kelvin, David J.
  • Bermejo Martín, Jesús Francisco
  • Tedim, Ana P.
  • Resino, Salvador
  • Torres, Antoni
9 p., Instituto de Salud Carlos III, Canadian Institutes of Health Research, Fondo Europeo de Desarrollo Regional, European Social Fund, European Society of Clinical Microbiology and Infectious Diseases
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Longitudinal recovery trajectories and ventilatory modalities in COVID-19 acute respiratory distress syndrome survivors

  • González, Jessica
  • Benítez, Iván D.
  • Santisteve, Sally
  • Vila, Anna
  • Aguilà, Maria
  • Torres, Gerard
  • Sánchez Cucó, Anna
  • Malla Bañeres, Mar
  • Moncusí Moix, Anna
  • Batlle, Jordi de
  • Gracia Lavedan, Esther
  • Ceccato, Adrián
  • Ferrer, Ricard
  • Motos, Anna
  • Riera, Jordi
  • Fernández, Laia
  • Menéndez, Rosario
  • Lorente, José Ángel
  • Peñuelas, Oscar
  • García, Darío
  • Roca, Oriol
  • Peñasco, Yhivian
  • Ricart, Pilar
  • Martín Delgado, María Cruz
  • Aguilera, Luciano
  • Rodriguez, Alejandro
  • Boado Varela, María Victoria
  • Pérez García, Felipe|||0000-0002-4885-4334
  • Pozo Laderas, Juan Carlos
  • Solé Violan, Jordi
  • Adell Serrano, Berta
  • Andrea Novo, Mariana
  • Barberán, José
  • Amaya Villar, Rosario
  • Gonzalo Calvo, David de
  • Torres, Antoni
  • Barbé, Ferran
  • Roche Campo, Ferrán
CIBERESUCICOVID Group: José Garnacho-Montero, Jose M. Gómez, Aaron Blandino Ortiz, Luis Tamayo Lomas, Alejandro Úbeda, Mercedes Catalán-González, Angel Sánchez-Miralles, Ignacio Martinez Varela, Ruth Noemí Jorge García, Nieves Franco, Victor D. Gumucio-Sanguino, Elena Bustamante-Munguira, Luis Jorge Valdivia, Jesús Caballero, Elena Gallego, Amalia Martínez de la Gándara, Alvaro Castellanos-Ortega, Josep Trenado, Judith Marin-Corral, Guillermo M. Albaiceta, Maria del Carmen de la Torre, Ana Loza-Vázquez, Pablo Vidal, Jose M. Añón, Cristina Carbajales Pérez, Victor Sagredo, Nieves Carbonell, Lorenzo Socias, Carme Barberà, Angel Estella, Emili Diaz, Fatty Seck, Adriano D.S. Targa, Inmaculada Salvador-Adell, Luis Urrelo-Cerrón, Mireia Serra-Fortuny and Esther Sauras-Colón., Background The impact of different ventilatory support modalities and timing of intubation on longitudinal lung recovery trajectories in patients with severe coronavirus disease 2019 (COVID-19) is unknown. Methods This was a multicentre, prospective observational study conducted in 52 Spanish intensive care units (ICUs) involving critically ill COVID-19 patients admitted between 25 February 2020 and 8 February 2021. 1854 COVID-19 patients were followed after hospital discharge at 3, 6 and 12 months with diffusing capacity of the lung for carbon monoxide (DLCO) measurements and chest imaging. Patients were classified regarding the ventilatory support received during the ICU stay: noninvasive mechanical ventilation (NIMV), high-flow nasal cannula (HFNC) and invasive mechanical ventilation (IMV), divided into early IMV (intubation within 24 h) and late IMV (intubation after 24 h). The primary objective was to evaluate the impact of the different respiratory support modalities during the ICU stay and the time of intubation on DLCO measurements and their recovery trajectories over a 1-year follow-up. Secondary outcomes included other pulmonary function parameters and chest imaging findings. Results A total of 360 (19.4%) and 290 (15.6%) patients received HFNC and NIMV, respectively. 1204 (64.9%) patients underwent IMV; 966 received early IMV and 238 received late IMV. The latter exhibited a significantly worse percentage predicted DLCO during the 1-year follow-up with adjusted differences of 6.9 (95% CI 3.9-10; p<0.001), 4.2 (95% CI 1.1-7.2; p=0.007) and 4.9 (95% CI 1.7-8.2; p=0.003) at 3, 6 and 12 months compared with early IMV. NIMV patients exhibited greater lung damage at follow-up than those under HFNC with an adjusted difference of percentage predicted DLCO of 5.2 (95% CI 1.7-8.7; p=0.003) at 6 months and greater presence of radiological abnormalities during follow-up. Matched and sensitivity analysis showed results consistent with those reported. Conclusions Delay in intubation implies the worst outcomes; however, patients with NIMV exhibited a slower lung recovery in terms of DLCO measurements and more radiological abnormalities compared with HFNC patients. These results should be used to optimise follow-up protocols for COVID-19 acute respiratory distress syndrome (ARDS) survivors., Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional, Fondo Social Europeo Plus, Centro de Investigación Biomédica en Red, Fundación Francisco Soria Melguizo
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Immunosuppressed patients with COVID-19 pneumonia in ICU: clinical characteristics and factors influencing outcomes

  • Galli, Flavia
  • Forin, Edoardo
  • Motos, Ana
  • Molina Saldarriaga, Francisco José
  • Gabarrús, Albert
  • Canseco, Joan
  • Fernández Barat, Laia
  • Barbeta, Enric
  • Calabretta, Davide
  • Ceccato, Adrián
  • Bermejo Martín, Jesús Francisco
  • Ferrer, Ricard
  • Riera, Jordi
  • Peñuelas, Oscar
  • Lorente, José Ángel
  • Gonzalo Calvo, David de
  • Menéndez, Rosario
  • González, Jessica
  • Palomeque, Andrea
  • Soler Comas, Alba
  • Amaya Villar, Rosario
  • Anon, José Manuel
  • Balan Mariño, Ana
  • Barberà, Carme
  • Barberán, José
  • Blandino Ortiz, Aaron Rolando
  • Bustamante Munguira, Elena
  • Caballero, Jesús
  • Cantón Bulnes, María Luisa
  • Carbajales Pérez, Cristina
  • Carbonell, Nieves
  • Catalán González, Mercedes
  • Frutos, Raúl de
  • Franco, Nieves
  • Galbán, Cristóbal
  • López Lago, Ana
  • Gumucio Sanguino, Víctor D.
  • Torre, María del Carmen de la
  • Díaz, Emilio
  • Estella, Ángel
  • Gallego Curto, Elena
  • García Garmendia, José Luis
  • Gómez, José Manuel
  • Huerta, Arturo
  • Jorge García, Ruth Noemí
  • Loza Vázquez, Ana
  • Marín Corral, Judith
  • Martín Delgado, María Cruz
  • Martínez de la Gándara, Amalia
  • Martínez Varela, Ignacio
  • López Messa, Juan
  • Albaiceta, Guillermo M.
  • Andrea Novo, Mariana
  • Peñasco, Yhivian
  • Pérez García, Felipe|||0000-0002-4885-4334
  • Pozo Laderas, Juan Carlos
  • Ricart, Pilar
  • Sagredo, Víctor
  • Sánchez Miralles, Ángel
  • Sancho Chinesta, Susana
  • Roche Campo, Ferran
  • Socias Crespí, Lorenzo
  • Solé Violan, Jordi
  • Suarez Sipmann, Fernando
  • Tamayo Lomas, Luis
  • Trenado, José
  • Úbeda, Alejandro
  • Valdivia, Luis Jorge
  • Vidal, Pablo
  • Boado, María Victoria
  • Rodriguez, Alejandro
  • Ferrer, Miquel
  • Barbé, Ferran
  • Torres, Antoni
  • CIBERESUCICOVID Project investigators
CIBERESUCICOVID Project investigators (COV20/00110, ISCIII): Rafael Mañez, Felipe Rodríguez de Castro, María Mora Aznar, Mateu Torres, María Martinez, Cynthia Alegre, Sofía Contreras, Javier Trujillano, Montse Vallverdú, Miguel León, Mariona Badía, Begoña Balsera, Lluís Servià, Judit Vilanova, Silvia Rodríguez, Neus Montserrat, Silvia Iglesias, Javier Prados, Sula Carvalho, Mar Miralbés, Josman Monclou, Gabriel Jiménez, Jordi Codina, Estela Val, Pablo Pagliarani, Jorge Rubio, Dulce Morales, Andrés Pujol, Àngels Furro, Beatriz García, Gerard Torres, Javier Vengoechea, Silvia Gomez, Lorena Forcelledo Espina, Emilio García Prieto, Paula Martín Vicente, Cecilia Del Busto Martínez, María Aguilar Cabello, Carmen Eulalia Martínez Fernández, María Luisa Blasco Cortés, Ainhoa Serrano Lázaro, Mar Juan Díaz, María Teresa Bouza Vieiro, Inés Esmorís Arijón, David Campi Hermoso, Rafaela Nogueras Salinas, Teresa Farre Monjo, Ramon Nogue Bou, Gregorio Marco Naya, Núria Ramon Coll, Juan Carlos Montejo-González, Gloria Renedo Sanchez-Giron, Juan Bustamante-Munguira, Ramon Cicuendez Avila, Nuria Mamolar Herrera, Alexander Agrifoglio, Lucia Cachafeiro, Emilio Maseda, Albert Figueras, Maria Teresa Janer, Laura Soliva, Marta Ocón, Luisa Clar, JIgnacio Ayestarán, Sandra Campos Fernández, Eva Forcadell-Ferreres, Immaculada Salvador-Adell, Neus Bofill, Berta Adell-Serrano, Josep Pedregosa Díaz, Núria Casacuberta-Barberà, Luis Urrelo-Cerrón, Àngels Piñol-Tena, Pablo Ryan Murúa, Covadonga Rodríguez Ruíz, Laura Carrión García, Juan ILazo Álvarez, Desire Macias Guerrero, Daniel Tognetti, Carlos García Redruello, David Mosquera Rodríguez, Eva María Menor Fernández, Sabela Vara Adrio, Vanesa Gómez Casal, Marta Segura Pensado, María Digna Rivas Vilas, Amaia García Sagastume, Raul de Pablo Sánchez, David Pestaña Laguna, Tommaso Bardi, Carmen Gómez Gonzalez, Maria Luisa Gascón Castillo, José Garnacho-Montero, Joan Ramon Masclans, Ana Salazar Degracia, Judit Bigas, Rosana Muñoz-Bermúdez, Clara Vilà-Vilardel, Francisco Parrilla, Irene Dot, Ana Zapatero, Yolanda Díaz, María Pilar Gracia, Purificación Pérez, Andrea Castellví, Cristina Climent, Lidia Serra, Laura Barbena, Iosune Cano, Alba Herraiz, Pilar Marcos, Laura Rodríguez, Maria Teresa Sariñena, Ana Sánchez, Juan Fernando Masa Jimenez, Gemma Gomà, Mercedes Ibarz, Diego De Mendoza, Victoria Alcaraz-Serrano, Joan Ramon Badia, Manuel Castella, Leticia Bueno, Catia Cillóniz, Pamela Conde, Javier Fernández, Karsa Kiarostami, Alexandre López-Gavín, Cecilia L Mantellini, Carla Speziale, Nil Vázquez, Hua Yang, Minlan Yang, Carlos Ferrando, Pedro Castro, Marta Arrieta, Jose Maria Nicolas, Rut Andrea, Marta Barroso, Sergio Álvarez, Dario Garcia-Gasulla, Adrián Tormos, Cesar Aldecoa, Rubén Herrán-Monge, José Ángel Berezo García, Pedro Enríquez Giraudo, Pablo Cardinal Fernández, Alberto Rubio López, Orville BáezPravia, Leire Pérez Bastida, Antonjo Alvarez Ruiz, Anna Parera Pous, Ana López Lago, Eva Saborido Paz, Patricia Barral Segade, Manuel Valledor Mendez, Luciano Aguilera, Esther López-Ramos, Ángela Leonor Ruiz-García, Belén Beteré, Rafael Blancas, Cristina Dólera, Gloria Perez Planelles, Enrique Marmol Peis, Maria Dolores Martinez Juan, Miriam Ruiz Miralles, Eva Perez Rubio, Maria Van der Hofstadt Martin-Montalvo, Tatiana Villada Warrington, Sara Guadalupe Moreno Cano, Federico Gordo, Basilisa Martinez Palacios, Maria Teresa Nieto, Sergio Ossa, Ana Ortega, Miguel Sanchez, Bitor Santacoloma, Introduction. COVID-19 severely impacted global health, especially older adults and those with comorbidities. Immunosuppressed patients are at high risk for severe outcomes, yet studies yield conflicting mortality rates for this group. This study examines the clinical characteristics and outcomes of immunosuppressed (IS) versus non-immunosuppressed (nIS) patients with COVID-19 in ICUs.MethodsA multicenter, observational case-control study included 5,824 ICU patients with COVID-19 from the CIBERESUCICOVID study. Patients were categorized as IS or nIS based on history of transplantation, HIV, active neoplasia, and use of immunosuppressive drugs or corticosteroids. The primary outcome was 90-day mortality; secondary outcomes included in-hospital, 15-day, 30-day and 1-year mortality, ICU-free days, ventilator-free days, and hospital length of stay. Subgroup analyses examined vaccination status and tocilizumab treatment. Propensity score (PS) matching was used to obtain balance among the baseline variables in the two groups.ResultsIS patients (n = 689, 11.8%) were older, had more comorbidities, and higher APACHE-II scores. After PS matching, IS patients had higher 90-day mortality (39 vs. 33%; HR 1.30, 95% CI 1.04 to 1.62), as well as higher in-hospital (37 vs. 29%; sHR 1.35, 95% CI 1.08 to 1.69), 30-day (28 vs 23%; HR 1.31, 95% CI 1.01 to 1.69) and 1-year mortality (45 vs. 38%; HR 1.26, 95% CI 1.02 to 1.57). Among IS patients, transplant recipients had significantly higher 90-day mortality after matching (HR 4.45, 95% CI 1.46 to 13.58). Vaccinated IS patients showed higher mortality than vaccinated nIS patients, though differences were not significant after PS matching. Tocilizumab treatment in IS patients was associated with reduced mortality; multivariable analysis confirmed a significant decrease in in-hospital mortality (sHR 0.56, 95% CI 0.42 to 0.76).ConclusionCritical immunosuppressed patients with COVID-19 have higher mortality, particularly transplant recipients. Tocilizumab shows potential benefits for IS patients. These findings highlight the need for tailored therapeutic strategies for immunosuppressed individuals with severe COVID-19. Further research is needed to confirm these results in the current clinical context., Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional, Centro de Investigación Biomédica en Red, Unión Española de Entidades Aseguradoras y Reaseguradoras, European Social Fund